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EFFECTS OF GLYCEOLLIN ON MRNA EXPRESSION IN THE FEMALE MOUSE 
BRAIN 
Sanaya F. Bamji 
August 9, 2016 
Glyceollins (Glys), produced by soy plants in response to stress, have anti-
estrogenic activity in breast and ovarian cancer cell lines in vitro and in vivo. In addition 
to known anti-estrogenic effects, Glys exhibit mechanisms of action not involving 
estrogen receptor (ER) signaling. To date, effects of Glys on brain physiology and 
function are unknown. The purpose of the experiments summarized in this dissertation 
was to gain an understanding of the effects of Gly on brain-related functions in the 
female mouse brain through the observation of changes in gene expression. For our initial 
studies, we treated ovariectomized Swiss Webster (CFW) mice with 17-β estradiol (E2) 
or placebo pellets, followed by 11 days of exposure to Glys or vehicle i.p. injections. We 
then performed microarray (Chapter 2) and RNA-sequencing analyses (Chapter 3) on 
total RNA extracted from whole brain hemispheres and identified differentially expressed 
genes (DEGs) between our treatment groups. Our results suggested that Glys, when in 
combination with E2 (E2+Gly), can oppose the E2 effects on gene expression and vice 
versa, can regulate genes similarly to E2, and can also have E2-independent effects on 
gene expression in the female brain. However, the whole brain experiments did not take 






distinct functions and can differ markedly in terms of gene expression, so we wanted to 
determine if Glys had any brain region-specific effects on gene expression. Additionally, 
as the whole brain studies only included a single time point of exposure to Glys, we 
evaluated the effects of a single acute dose of Glys (2, 24 and 48 hr) as well as chronic    
exposure to Glys (multiple doses of Glys for 7 consecutive days) on gene expression in 
distinct brain regions. Therefore, in Chapter 4, we evaluated the effects of acute vs. 
chronic doses of Glys alone and in combination with E2 on gene expression in the 
hypothalamus, hippocampus, and cortex of the female mouse brain. Our results suggest 
that Glys can rapidly upregulate the expression of genes like growth hormone (Gh) in the 
hypothalamus, hippocampus and cortex and prolactin (Prl) in the hypothalamus and 
cortex, 2h or 24h after administration of a single acute dose. Thus Glys may potentially 
affect neuronal processes like food intake, stress and cognition through its effects on Gh 
and Prl gene expression in the female mouse brain. As all of the above chapters involve a 
peripheral administration of Glys (intraperitoneal injections), it was unclear if Glys affect 
gene expression through direct action at the neuron or through some indirect peripheral 
effect. To address this issue, in Chapter 5 we screened five immortalized neural cell lines 
derived from the adult female mouse hypothalamus (mHypoA-50, 51, 55, 59 and 63) for 
the presence of our genes of interest and E2 responsiveness. Based on consistency of 
mRNA transcript detection and E2 responsivity, we selected two cell lines (mHypoA-55 
and 63) that may be suitable for future experiments to determine the direct effect of Glys 
on gene expression at the neuron. Together this work provides novel information on the 
effects of Glys in the brain, which is important in order to develop its use as a dietary 
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GLYCEOLLINS: SOYBEAN PHYTOALEXINS THAT EXHIBIT A WIDE RANGE 
OF HEALTH-PROMOTING EFFECTS 
Introduction 
In the last few decades, there has been a remarkable increase in research on 
compounds with established health benefits. Among these foods, soybeans (Glycine max) 
have been especially well studied, mainly due to their ability to produce proteins and 
isoflavones, such as genistein and daidzein, with well-known health-promoting effects 
(Dixon and Sumner 2003; Nwachukwu et al. 2013; Sacks et al. 2006). When soybean 
tissues are challenged by a microbial or physical stimulus, a special class of low 
molecular weight plant defense compounds (phytoalexins) called glyceollins (Glys) are 
synthesized de novo and accumulate in the plant’s tissues (Burden and Bailey 1975). Glys 
have received much attention due to their known antibacterial, antioxidant, antifungal, 
antitumor and insulinotropic actions both in vitro and in vivo (Kim et al. 2011a; Kim et 
al. 2010b; Ng et al. 2011; Park et al. 2010; Salvo et al. 2006). The focus of this chapter is 
to review the known health-promoting effects of Glys and to discuss potential central 
nervous system effects that have not been previously described.  
Biosynthesis of Glys in soybeans 
The biosynthesis of Glys includes enzymes that are generally dedicated to the 







to trans-cinnamic acid through the action of enzyme phenylalanine ammonia-lyase, 
followed by a hydroxylation reaction catalyzed by cinnamic acid 4-hydroxylase that 
converts the trans-cinnamic acid to p-coumaric acid (Dixon and Paiva 1995). A series of 
subsequent reactions involving enzymes 4-coumarate:coenzyme A ligase, chalcone-
synthase, chalcone reductase, chalcone isomerase and isoflavone synthase, lead to the 
formation of the isoflavonoid daidzein (Dixon and Paiva 1995). Daidzein then undergoes 
cyclization and hydroxylation reactions to give rise to glycinol, which is the non-
prenylated precursor for Glys (Dixon and Paiva 1995). Two separate prenyl transferases, 
viz. glycinol 4-dimethylallyl transferase (G4-DT) and glycinol 2-dimethylallyl 
transferase (G2-DT), then bring about the prenylation of glycinol to glyceollidins I and II, 
respectively (Akashi et al. 2009; Yazaki et al. 2009). The final step of Gly biosynthesis is 
the cyclization of glyceollidins by glyceollin synthases to convert glyceollidin I to Gly I 
and glyceollidin II to Glys II and III (Welle and Grisebach 1988) (Fig.1.1). Of 
importance is that most studies on Glys use a mixture of Glys I, II and III instead of 
isolated Gly isomers. Although these are the three main isomers of Glys, recent studies 
have also reported the existence of Glys IV, V and VI along with glyceofuran (Simons et 
al. 2011) (Not shown in Fig.1.1).  
Glys antitumor effects 
Glys have been extensively studied for their antitumor effects through estrogen 
receptor (ER)-dependent (mainly ERα and ERβ) and ER-independent mechanisms. Initial 
research on Glys focused on their anti-estrogenic effects and ability to inhibit estrogen-
responsive tumors. Glys (applied as a mixture of Glys I, II, and III) suppressed the 17-β 





(MCF-7) and ER-negative (ER-) human embryonic kidney cells (HEK 293) transiently 
transfected with either ERα or ERβ in vitro (Burow et al. 2001). Through competition 
binding assays, the study also provided evidence that Glys had a 3-fold higher affinity for 
ERα than for ERβ (Burow et al. 2001; Nikov et al. 2000). Similar to the in vitro study, 
Glys suppressed the E2-induced in vivo proliferation of both breast (MCF-7) and ovarian 
(BG-1) tumor cells implanted in ovariectomized athymic nude mice (Salvo et al. 2006). 
In addition to breast and ovarian tumors, Glys also inhibited the growth of human 
androgen-responsive prostate cancer cells (LNCaP) through the induction of cyclin-
dependent kinase inhibitors (CDKN1A and CDKN1B) involved in cell cycle arrest 
(Payton-Stewart et al. 2009). Importantly, Glys suppressed the E2-induced growth of 
LNCaP cells and not dihydrotestosterone (DHT)-induced growth, which indicated an ER-
mediated anti-estrogenic effect of Glys on prostate tumor cells (Payton-Stewart et al. 
2009). A subsequent study found that of all the Gly isomers (i.e., Glys I, II and III), Gly I 
had the highest affinity for ERα, exhibited the strongest anti-estrogenic activity compared 
to Glys II and III and also downregulated E2-responsive stromal-derived factor (SDF-1) 
and progesterone receptor (PgR) expression in both MCF-7 and BG-1 cells 
(Zimmermann et al. 2010). This finding led to further interest in determining the 
effectiveness of the Gly I isomer on tumor proliferation and overall anti-estrogenic 
activity at ERs. A comparison of naturally occurring (-) Gly I and its chemically 
synthesized enantiomer (+) Gly I showed that both had similar binding affinity to both 
ERα and ERβ (Payton-Stewart et al. 2010). The difference in their activity was that (-) 
Gly decreased the ER-induced transcriptional activation of estrogen-response element 





and ERα-transfected HEK 293 cells (Payton-Stewart et al. 2010). The natural (-) Gly I 
isomer also showed the highest growth inhibition activity against ER+ breast and ovarian 
tumors as well as androgen receptor-positive (AR+) prostate tumors in vitro, compared to 
a Gly racemic mixture and unnatural (+) Gly I isomer (Khupse et al. 2011). In contrast to 
the aforementioned anti-estrogenic effects of Glys, one study reported estrogenic effects 
of Glys, increasing the proliferation of ER+ MCF-7 cells, mainly through activity at ERβ 
(Kim et al. 2010a). The study showed Gly acting anti-estrogenically via ERα, while 
exhibiting estrogenic effects via action at ERβ (Kim et al. 2010a). These results suggest 
that Gly may not be a pure anti-estrogen but may potentially be a selective estrogen-
receptor modulator (SERM). This SERM-like activity has recently been attributed to 
differences in prenylation patterns, backbone structure and the lengths of the different 
Gly isomers, with the effects being SERM-like at ERα (Gly I) and agonistic at ERβ (Gly 
I, II and III) (van de Schans et al. 2016). 
Although all of the above studies provided evidence for ER-mediated effects of 
Glys, subsequent studies showed that Glys may act through non ER-mediated 
mechanisms as well. The very first study of this kind showed that the natural (-) Gly I 
isomer, but not the unnatural (+) Gly isomer, significantly inhibited the growth of ER- 
breast and ovarian tumors as well as androgen receptor-negative (AR-) prostate tumors in 
vitro, but to a lesser extent than its inhibition of ER+ and AR+ tumors (Khupse et al. 
2011). Further evidence for a potential ER-independent mechanism came from 
experiments that showed the ability of Glys to suppress tumorigenesis in triple-negative 
breast carcinoma cells (MDA-MB-231 and MDA-MB-468) that lack ERs, PgR and 





indicated that in addition to ERα signaling, Glys can suppress proliferation of breast 
tumors (MCF-7 and T-47D) through suppression of the mechanistic target of the 
rapamycin (mTOR) - ribosomal protein S6 kinase, 70kDa (p70S6) pathway (Bratton et al. 
2015), thus indicating a dual inhibitory mechanism of Gly action on breast cancer 
progression. Glys are also reported to affect breast, prostate, liver, lung and gastric 
carcinoma cells through the inhibition of the activity of hypoxia-inducible factor (HIF-
1α), a molecule that plays a critical role in regulation of genes involved in tumor 
metabolism, angiogenesis and metastatic ability (Lee et al. 2014). The mechanism of Gly 
inhibition of HIF-1α was through the inhibition of the phosphatidylinositol-3 
kinase/protein kinase B/mTOR (PI3K/AKT/mTOR) pathway that regulates translation of 
the HIF-1α protein and through interception of the interaction of HIF-1α-heat shock 
protein (Hsp90), which stabilizes the HIF-1α protein (Lee et al. 2014). Furthermore, a 
very recent study reported that Gly I can reverse the epithelial to mesenchymal transition 
(EMT) of letrozole-resistant breast cancer cells (LTLT-Ca) through the inhibition of zinc-
finger E-box binding homeobox 1 (ZEB1) expression (Carriere et al. 2016). Letrozole is 
an aromatase inhibitor, which is approved for treatment of ER+ breast cancer in 
postmenopausal women, and ZEB1 is a transcription factor that is known to play a role in 
EMT in breast cancer cells. Therefore, in addition to the mTOR/p70S6 or 
PI3K/AKT/mTOR pathway, Glys can also suppress tumor metastases through inhibition 
of ZEB1 gene and protein suppression. In addition to hormone-responsive tumors, Glys 
inhibited melanogenesis in B16 melanoma cells through the suppression of tyrosinase, 
tyrosinase-related protein 1 (TRP-1) and microphthalamia-associated transcription factor 





inhibited the induction of melanogenesis by alpha melanocyte-stimulating hormone (α-
MSH) by suppressing cyclic adenosine monophosphate (cAMP) levels induced by α-
MSH in melanoma cells (Lee et al. 2010). This suppression of melanin synthesis 
indicated a potential use for Glys as cosmetic skin whitening agents. A subsequent study 
also showed that Glys’ skin whitening effect may be through the inhibition of stem cell 
factor-kit receptor (SCF/c-kit) signaling in addition to tyrosinase inhibition in B16F10 
melanoma cells (Shin and Lee 2013). In addition to tumor inhibition, treatment with Glys 
also suppresses the migration and tube formation of endothelial progenitor cells (EPC), 
hematopoietic stem cells that play a role in early tumor vasculogenesis (Choi et al. 2013). 
This study also showed that Glys inhibited the expression of genes involved in EPC 
function such as SDF-1, C-X-C chemokine receptor-4 (CXCR4), angiopoietin-1 (Ang-1) 
and angiopoietin receptor (Tie-2) (Choi et al. 2013). Further, Glys also inhibited the 
activation of Akt, ERK1/2 and endothelial nitric oxide synthase (eNOS) induced by SDF-
1 or vascular endothelial growth factor (VEGF) (Choi et al. 2013). 
Thus, Glys significantly suppress several different types of tumors both in vitro in 
cancer cell lines and in vivo in xenograft mouse tumor models, directly through ER-
mediated mechanisms or pathways involving PI3K/AKT/mTOR signaling as well as 
indirectly through the suppression of tumor vasculogenesis. These studies together 
provide good evidence in support of Glys as potential chemotherapeutic agents for 
effective treatment of various cancers.  





Recently, there has been a growing interest in exploring naturally occurring 
antimicrobial agents to replace synthetically produced bactericides or fungicides in the 
food industry (Nwachukwu et al. 2013). Glys exhibit potent antibacterial and antifungal 
activity against various bacterial and fungal strains. Glys inhibited the growth of bacterial 
strains such as Pseudomonas syringae and Xanthomonas campestris and was effectively 
bactericidal towards Bacillus subtilis, Bacillus licheniformis, Staphylococcus aureus and 
Corynebacterium flaccumfaciens in three different bacterial bioassays (Fett and Osman 
1982). Subsequent studies showed that Glys potentially exhibit their antibacterial effects 
by inhibiting cellular processes and altering the structural integrity of bacterial 
membranes, thereby impeding bacterial growth (Weinstein and Albersheim 1983). 
Furthermore, Glys were not only more abundant but also the most inhibitory against the 
growth of Fusarium solani f. sp. glycines (soil-borne fungus and causative agent for 
sudden death syndrome in soybeans) in a genotype of Glycine max (PI 567374) that is 
partially resistant to fungal infections (Lozovaya et al. 2004). Glys also inhibited the 
growth of various fungal pathogens such as D. phaseolorum var. meridionales, 
Macrophomina phaseolina, Phytphthora sojae, Sclerotinia sclerotiorum, Cercospora 
sojina, Phialophora gregata, and Rhizoctonia solani in the hairy roots of non-
transformed soybean genotypes Spencer and PI 567374 (Lygin et al. 2010). Importantly, 
this Gly inhibition was much lower in soybeans transformed with isoflavone synthase or 
chalcone synthase genes, which led to markedly low levels of total isoflavones, including 
Glys (Lygin et al. 2010). This led to a study on the effects of similar isoflavone synthesis 
suppression on the susceptibility of the whole soybean plant or  the plant seeds to fungal 





lower levels of Gly production, which rendered both the whole plant and seeds 
susceptible to infection by Phytophthora sojae and Macrophomina phaseolina (Lygin et 
al. 2013). Another study showed that Glys produced by soybean seeds elicited with 
Aspergillus sojae had remarkable antifungal effects against Fusarium oxysporum, 
Phytophthora capsici, Sclerotinia sclerotiorum, and Botrytis cinerea (Kim et al. 2010c). 
Moreover, a very recent study showed that pre-treatment with calcium is beneficial for 
soybeans infected with Sclerotinia sclerotiorum and enhances the expression of defense-
related genes, including chalcone synthases, isoflavone synthase and isoflavone 
reductase, which are enzymes involved in the production of Glys (Arfaoui et al. 2016) 
(Fig.1.1). Pre-treatment with calcium, through the upregulation of these enzymes, 
improved the accumulation of daidzein, genistein and acetyl glycitin and enhanced the de 
novo synthesis of Glys, especially in soybeans inoculated with the aggressive strain of 
Sclerotinia sclerotiorum (Arfaoui et al. 2016). In combination, these studies indicate that 
rapid Gly biosynthesis during infections forms an important aspect of innate disease 
resistance in soybean. Thus, Glys hold promise in the development of natural fungicides 
and bactericides in the agriculture and food industry.    
 
Glys antioxidant properties 
Oxidative damage, especially prolonged exposure to reactive oxygen species (ROS) can 
lead to severe damage to DNA, proteins and lipids. Antioxidant defenses to minimize 
ROS accumulation and fluctuations are critical to cell survival and can be of importance 
in the treatment of cancers and age-related deterioration of functional activity. Glys along 





oxidative damage caused by stressors. A study measuring the antioxidant activity of total 
isoflavones in soybean extracts elicited by germination, wounding or exposure to 
Aspergillus sojae using 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging 
and β-carotene cooxidation in a linoleate system, found that soybean extracts exposed to 
Aspergillus sojae had the highest accumulation of total isoflavones, including Glys, and 
also displayed the highest antioxidant activity in both DPPH and β-carotene assays (Boué 
et al. 2008). This work led to further research focusing specifically on the antioxidant 
activity of Glys. One study showed that a mixture of Gly I, II and III isomers exhibited 
strong antioxidant potential in mouse brain, liver and kidney extracts treated with 
hydrogen peroxide (H2O2), measured using radical ABTS and DPPH scavenging activity, 
reduction of ferric ion (Fe3+) to ferrous ion (Fe2+), inhibition of singlet oxygen formation 
and thiobarbituric acid reactive substances (TBARS) (Kim et al. 2010b). Moreover, this 
Gly antioxidant activity was found to be greater than that of its parent compound 
daidzein. The same study also showed Glys inhibition of H2O2-induced ROS production 
in hepatoma cells (hepa1c1c7) (Kim et al. 2010b). Subsequent studies indicated that Glys 
antioxidant activity in hepatoma cells was through the upregulation of antioxidant 
enzymes (heme oxygenase 1, gamma-glutamylcysteine synthase, and glutathione 
reductase), by the induction of the nuclear translocation of nuclear factor eythroid-
derived 2-like 2 (Nrf2), a transcription factor and regulator of cellular antioxidant 
enzymes (Kim et al. 2011b). Moreover, the study suggested that Gly caused the Nrf2-
mediated enzyme induction through activation of thePI3K signaling pathway and by 
regulating Nrf2 interaction with kelch-like ECH-associated protein 1 (Keap1), which is 





soybeans infected with Aspergillus oryzae had a high accumulation of Gly I and 
phytoalexin coumestrol, which significantly prevented H2O2-induced ROS production 
and lipid peroxidation in human HepG2 hepatoma cells (Jeon et al. 2012). Other 
antioxidant effects of Glys include the inhibition of proton-induced ROS generation and 
cell death in human umbilical vein endothelial cells in vitro, which has an important 
application in development of dietary supplements for astronauts who are exposed to 
proton radiation and high-energy particles (Jung et al. 2009). Furthermore, Glys also 
suppressed ROS production in platelet-derived growth factor (PGDF)-stimulated human 
aortic smooth muscle cells (Kim et al. 2012). These results taken together suggest that 
Glys have potent antioxidative properties in animal tissues and cancer cells and have the 
potential to be developed further as a functional dietary supplement that can reduce the 
damage caused by cellular oxidative stress. 
   
Glys anti-inflammatory properties 
Systemic inflammatory responses are often correlated with obsesity, 
cardiovascular disease and type 2 diabetes (Strohacker and McFarlin 2010). In addition to 
antitumor, antimicrobial and antioxidant properties, Glys also exhibit anti-inflammatory 
properties(Kim et al. 2011a; Kim et al. 2012; Yoon et al. 2012). Glys exerted an anti-
inflammatory response in a lipopolysaccharide (LPS)- induced murine macrophage cell 
line (RAW264.7) by suppressing the LPS-induced phosphorylation of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) signaling (Kim et al. 2011a). 
The study showed that Glys inhibited LPS-induced nitric oxide production 





(iNOS) and cyclooxygenase-2 (COX2) (Kim et al. 2011a). Furthermore, Glys were also 
found to suppress 12-O tetradecanoylphorbol-13-acetate (TPA)-induced inflammatory 
response in mouse skin (Kim et al. 2011a). A subsequent study found that in addition to 
the suppression of LPS-induced gene expression, Glys also inhibited the expression of 
other known pro-inflammatory cytokines such as (IL-1β and IL-18 as well as tumor 
necrosis factor (TNF)-α, while upregulating the expression of anti-inflammatory 
cytokines including IL-10 in the RAW264.7 cell line (Yoon et al. 2012). The anti-
inflammatory response of Glys in macrophages has also been attributed to the 
dosedependent inhibition of nuclear factor of kappa light polypeptide gene enhancer in B-
cells inhibitor, alpha (IκBα) kinase (IKK) phosphorylation, thus blocking IκBα 
degradation and the formation of an NF-κB-DNA binding complex (Yoon et al. 2012). 
Thus, Glys show potential as therapeutic agents in the treatment of chronic diseases that 
are associated with systemic inflammation.   
 
Glys effects on glucose and lipid metabolism 
 
Recently, Glys have shown great promise in the regulation of glucose and lipid 
metabolism. Glys enhanced insulin-stimulated glucose uptake and decreased triglyceride 
accumulation in adipocyte cells (3T3-L1) (Park et al. 2010). Glys also alleviated the 
effects of palmitate,a long chain, saturated free fatty acid that promotes pancreatic β-cell 
dysfunction and apoptosis through induction of genes involved in endoplasmic reticulum 
stress in insulinoma cells (Min6) (Park et al. 2010). Glys not only improved glucose-
stimulated insulin secretion (GSIS), but also decreased the expression of endoplasmic 





the secretion of glucagon-like peptide 1 (GLP-1) in enteroendocrine cells (NCI-H716), 
thus enhancing β-cell survival (Park et al. 2010). Another study showed that Glys 
decreased blood glucose levels in prediabetic rats that were given an oral dose of either 
30 or 90 mg/kg of Glys (Boué et al. 2012). The same study provided evidence that Glys 
improved basal, insulin-stimulated and insulin-independent glucose uptake in 3T3-L1 
adipocytes, an effect that was attributed to the increase in expression of glucose 
transporters (GLUT1 and GLUT4) (Boué et al. 2012). Furthermore, in a streptozotocin-
induced mouse model of type-2 diabetes, mice fed a high fat diet (HFD) along with 10% 
fermented soybeans containing Glys showed the lowest peak for blood glucose and 
higher levels of serum insulin compared to mice fed a HFD with no soybeans or those fed 
a HFD containing 10% fermented soybeans without Glys (Park et al. 2012). A Glys-
enriched soybean diet also dropped blood glucose levels more than control (high-fat diet 
without soybeans) during insulin tolerance testing. This improvement in glucose 
metabolism was found to be due to the potentiation of protein-kinase B (Akt), adenosine-
monophosphate kinase (AMPK) and acetyl-coA carboxylase phosphorylation in the liver 
along with a decrease in phosphoenolpyruvate carboxykinase (PEPCK) expression, 
which enhanced lipid and glucose metabolism in the liver (Park et al. 2012). Thus, Glys 
improve glucose metabolism partly through increasing insulin secretion in the early phase 
and partly through the enhancement of liver insulin sensitivity. A more recent study 
provided evidence that Glys reduce both blood glucose and lipid levels and increase 
insulin sensitivity by decreasing janus-kinase (JNK) activity in insulin-resistant db/db 
mice (Yoon et al. 2013). The study also showed Glys’ ability to decrease endoplasmic 





dependent protein kinase kinase (CaMKK-AMPK) activity in skeletal muscle tissue and 
L6 myotubes, leading to a stimulation in glucose uptake and fatty acid oxidation in 
muscle cells (Yoon et al. 2013). Glys also reduced serum insulin, triglycerides and 
increased high-density lipoprotein (HDL) levels in db/db mice with no change in plasma 
low-density lipoprotein (LDL) levels (Yoon et al. 2013). Similar to this finding, Glys 
exhibited cholesterol-lowering activity in male Syrian hamsters that were fed a HFD 
along with 250 mg/kg Glys by significantly reducing total lipid content, plasma very low-
density lipoprotein (VLDL) and hepatic cholesterol esters, with no change in plasma 
LDL, fecal bile acid or cholesterol content (Huang et al. 2013). However, no increase in 
plasma HDL was observed in hamsters, unlike in the db/db mice (Yoon et al. 2013). 
Lastly, gene expression in mammary tissues of postmenopausal cynomolgus monkeys 
that were fed a diet consisting of Gly-enriched soy exhibited a gene expression profile 
distinct from the mammary tissues of those fed a standard soy diet (Wood et al. 2012). 
The Gly-enriched soy diet increased the expression of lipid metabolism genes such as 
peroxisome proliferator-activated receptor (PPAR-γ) and adiponectin, as well as leptin, 
lipin 1 and lipoprotein lipase (Wood et al. 2012). In conclusion, these reports provide 
evidence supporting the development of Glys as dietary supplements that may alleviate 
hyperglycemia in type 1 and type 2 diabetes and reduce the risk of HFD-induced obesity 
and cardiovascular disease through the enhancement of glucose and lipid metabolism in 
various tissues.   
 





The health-promoting effects of any dietary supplement or drug depend on its 
bioavailability, its systemic absorption when administered orally and its intestinal 
transport and metabolism. Intestinal transport of Glys was found to be rapid in human 
intestinal Caco-2 cells and dominated by a passive diffusion mechanism (Chimezie et al. 
2014). The same study also found that Glys had no effect on the expression of P-
glycoprotein (Pgp), which plays a protective role by limiting the uptake of orally 
consumed xenobiotics in the small intestines (Chimezie et al. 2014). Subsequent studies 
showed that Glys inhibited the function of two apical efflux transporters, multidrug-
resistance associated protein 2 (MRP2) and breast cancer resistance protein (BCRP), with 
no alteration of their gene expression by Glys in Caco-2 cells (Chimezie et al. 2016; 
Schexnayder and Stratford 2016). Moreover, Glys appeared to inhibit the metabolism of 
the phytoalexin genistein, but did not inhibit the intestinal transport of aglycone, a 
metabolite of genistein (Chimezie et al. 2016; Schexnayder and Stratford 2016). As 
efflux transporters play an important role in restricting the absorption of drugs across the 
intestine and blood-brain barrier, these findings provide preliminary evidence for the 
potential of Glys to enhance the delivery of other drugs (like genistein) to cells.   
 
Potential CNS effects  
Research on Glys has provided evidence in support of its antitumor, antioxidant, 
antimicrobial effects as well as its effects on metabolism, and until recently, not much 
was known about the effects of Glys on the nervous system aside from one study that 
revealeds antioxidant effects of Glys in brain extracts (Kim et al. 2010b).Recent work in 
our lab focused on determining the effects of Glys on gene expression in the female 





of Gly and the non-ER related reports are more recent, our initial hypothesis was that 
Glys would act anti-estrogenically when combined with E2, but would have no 
independent effect on gene expression when used alone. Although we detected 
potentially ER-mediated anti-estrogenic effects of Glys on expression of a few genes,  
Glys also exhibited a gene expression profile distinct from both E2 groups (E2 and 
E2+Gly), indicating potential ER-independent effects on gene expression (Bamji et al. 
2015). Interestingly, Glys alone upregulated expression of genes including Nr4a1, an 
orphan nuclear receptor that is involved in memory formation (Hawk and Abel 2011), 
and microRNA-495, which affects the expression of brain-derived neurotrophic factor 
(BDNF) (Mellios et al. 2008), a gene involved in synaptic plasticity and neurogenesis. On 
the other hand, Glys downregulated the expression of peptidylprolyl isomerase A (Ppia), 
which promotes neurodegeneration and apoptosis (Bamji et al. 2015; Nigro et al. 2013). 
These initial findings suggest that Glys may have neuroprotective effects and potentially 
exhibit SERM-like effects in the female mouse brain, but further research is needed to 
support this claim.   
 The aim of this review was to summarize the literature on Glys’ effects in vitro 
and in vivo. These reports predominantly involve a mixture of Glys, but also include 
recent studies showing the independent effects of the different Gly isomers. Given the 
slight differences in structure and binding affinity of the Gly isomers to ERs, future 
investigations focusing on independent effects of the different Gly isomers may be useful 
in the development of disease-specific therapeutic interventions. From the research 
presented here, it is clear that Glys have the potential to be developed not only as 





diabetic patients and as dietary supplements with potent antioxidant, antimicrobial and 
possibly neuroprotective functions. Further research focusing on determining the 
effective doses of Glys and the safety and possible side effects of Glys in non-target 
tissues is required to realize the potential application of Glys as dietary supplements or 
therapeutic agents.   
Dissertation Objectives  
 The main purposes of this dissertation are to evaluate the effects of Glys on gene 
expression in the female mouse brain, make predictions about the underlying mechanisms 
of Gly action in the brain and relate that action to brain activity and function. Toward this 
end, in Chapter 2 we first examined the effects of a chronic exposure (multiple doses of 
Gly for 11 consecutive days) to Glys alone  and in combination with E2 on gene 
expression in the whole female mouse brain using microarray (Bamji et al. 2015). Due to 
limitations with the microarray technique, especially in the detection of low-expression 
genes of interest, in Chapter 3 we performed a whole brain RNA-sequencing (RNA-Seq) 
experiment with the same samples used in Chapter 2. In Chapter 4, we tested the effects 
of acute (single dose of Glys followed by tissue harvest at 2, 24 and 48 hr) and chronic 
(multiple doses of Gly for 7 consecutive days) Glys exposure on expression of select 
genes in three distinct brain regions, i.e., the hypothalamus, hippocampus, and cortex. We 
were especially interested in determining if Glys affected gene expression differently in 
different brain regions and if there was any difference between the acute vs. chronic dose 
of Glys on gene expression. Lastly, in Chapter 5 we tested five different immortalized 
hypothalamic cell lines (mHypoA-50, 51, 55, 59 and 63) derived from adult female mice 





one or more cell lines for future investigations evaluating if Glys affect gene expression 
through direct action at the neuron or through indirect peripheral effects. Results from our 
whole brain experiments (Chapter 2 and Chapter 3) suggest that Gly in combination with 
E2 can oppose E2’s effects on gene expression, E2 in combination with Gly can oppose 
Gly’s effect on gene expression, Gly can regulate gene expression similarly to E2 and can 
also have E2-independent effects on gene expression. In Chapter 4, we observed that both 
Gly treatments (Gly and E2+Gly) upregulated the expression of growth hormone (Gh) at 
the 2hr Gly exposure time in all brain regions, and prolactin (Prl) at the 2h Gly exposure 
time in the hypothalamus and cortex and at the 24h Gly exposure time in the 
hypothalamus. The results indicate that Gly may potentially affect neuronal processes 
through the regulation of genes including Gh and Prl, but the mechanism of action still 
remains unclear. In Chapter 5, based on the reliable detection of our genes of interest and 
E2-responsiveness of the cell lines, we identified two cell lines (mHypoA-55 and 






Fig. 1.1: Biosynthetic pathway of glyceollins in soybeans. 4CL, 4-coumarate:coenzyme 
A ligase; C4H, cinnamic acid 4-hydroxylase; CHI, chalcone isomerase; CHR, chalcone 
reductase; CHS, chalcone synthase; G2-DT, glycinol 2-dimethylallyl transferase; G4-DT, 
glycinol 4-dimethylallyl transferase; GS, glyceollin synthase; IFOH, isoflavone 2’-
hdroxylase; IFR, isoflavone reductase; IFS, isoflavone synthase; P6αH, pterocarpan 6α-

















SOY GLYCEOLLINS REGULATE TRANSCRIPT ABUNDANCE IN THE FEMALE 
MOUSE BRAIN 
Introduction 
Glyceollins are soy-derived isoflavonoid phytoalexins that are biologically active in 
vertebrates(Boue et al. 2012; Burow et al. 2001; Salvo et al. 2006).  Several recent 
studies have reported that mixtures of the isomers glyceollin I, II, and III (Gly) affect 
mammalian physiology in vivo and in vitro, and what has emerged is a complicated and 
incomplete picture of how Gly affects mammalian physiology (Fig. 2.1). Among the 
most exciting findings to date are results which indicate that Gly opposes the activity of 
17-estradiol (E2) in estrogen-responsive tissues, such as mammary and uterus. For 
example, Gly suppressed E2-mediated proliferation of MCF-7 human breast tumor cell 
lines in vitro (Burow et al. 2001). As another example, Gly inhibited E2-stimulated 
growth of MCF-7 breast cancer and BG-1 ovarian cancer cells, implanted as xenograft 
tumors in ovariectomized athymic nude mice in vivo (Salvo et al. 2006). Such results 
were reported to indicate an estrogen receptor (ER) mediated anti-estrogenic effect of 
Gly, mainly through its activity at ERα (Zimmermann et al. 2010). However, other 
studies concluded that Gly can also exhibit weak estrogenic activity via ERβ, which 
appears to enable Gly to promote the proliferation of MCF-7 breast tumor cells in vitro 





a selective estrogen receptor modulator (SERM) whose relative estrogenic/anti-estrogenic 
action varies in a tissue- and/or condition- dependent manner. 
 Despite the promise that Gly has shown in estrogen-responsive cancer models, not 
all interest in Gly relates specifically to women’s health. In particular, recent studies have 
shown that Gly decreases blood glucose levels in pre-diabetic male rats and db/db mice in 
vivo and increases insulin-stimulated and basal glucose uptake in 3T3-L1 adipocytes and 
insulin sensitivity in myotubules in vitro (Boue et al. 2012; Park et al. 2010; Yoon et al. 
2013). Interestingly, these effects of Gly on insulin signaling are independent of classical 
ER-mediated effects (Boue et al. 2012), and were found to work via the CaMKK-AMPK 
pathway in one study (Yoon et al. 2013). Other non-ER-mediated mechanisms of Gly 
action have been found: Gly suppresses tumorigenesis in a xenografted triple-negative 
breast cancer cell line that lacks ERs (Rhodes et al. 2012), inhibits lipid peroxidation in 
tissue extracts of rat brain, kidney and liver (Kim et al. 2010b), upregulates expression of 
genes involved in lipid metabolism (Wood et al. 2012), and inhibits p70S6-mediated 
phosphorylation of ERα (Bratton et al. 2015). Collectively, these findings indicate that 
Gly may have multiple, context-dependent mechanisms of action, that E2 signaling is not 
the only target of Gly activity, and that in some cases E2 signaling is indirectly modified 
by Gly. Thus, a better understanding of how Gly affects mammalian physiology is 
needed before glyceollins are used as anti-cancer therapeutics and/or dietary 
supplements. 
It is well established that compounds that interact with ERs can have effects that 
vary markedly between the CNS and the periphery (Arevalo et al. 2011; Halbreich and 





anti-estrogenic in the periphery, acts like a SERM in the brain (Alfinito et al. 2008). In 
the hypothalamus, fulvestrant exhibits anti-estrogenic activity, increasing gonadotropin 
releasing hormone (GnRH) pulse frequency by inhibiting estrogen’s negative feedback 
on GnRH (Alfinito et al. 2008). Conversely, fulvestrant has estrogenic activity in the 
hippocampus, mimicking the effects of estradiol benzoate on place learning behavior 
(Alfinito et al. 2008; Steyn et al. 2007). SERMs have complicated central effects and the 
CNS is essential to the orchestration of both E2 and insulin signaling; therefore, it is 
impossible to do a rigorous cost/benefit analysis on the utility of Gly as a potential 
therapeutic for hormonally responsive cancers or metabolic disorders until its effects on 
brain physiology have been investigated. To address this question, we examined the 
mouse brain transcriptome using the Affymetrix Mouse Gene 1.0 ST Array after 
treatment of ovariectomized (ovx) mice with E2, Gly, both E2 and Gly (E2+Gly), or 
negative control (Con). The results show that effects of Gly and E2 interact for 
expression of 167 genes and that Gly also regulates gene expression independent of E2, 
indicating that Gly affects gene expression in mouse brain through more than one 
mechanism, some of which probably do not involve ERs. 
 
Materials and Methods 
Study animals, experimental manipulations, and plasma samples 
Ovariectomized adult female CFW mice were purchased from Charles River 
Laboratories, maintained on a 12L:12D photoperiod (lights on at 6am), and given ad 
libitum access to phytoestrogen-reduced rodent chow (Teklad 2016) and tap water. The 





0.1mg E2 or placebo (Innovative Research of America, Sarasota, FL) was implanted s.c. 
at the midline between neck and shoulders under isoflurane anesthesia followed by s.c. 
ketoprofen analgesia (day 1). Daily 50l i.p. injections of 20mg/kg Gly or 1:1 
DMSO/PBS vehicle began on day 1 and continued every afternoon for 11 days. The 
glyceollin mixture (glyceollins I, II, and III) was isolated using a procedure described 
previously (Salvo et al. 2006). Treatment groups were as follows (n = 3): placebo pellet + 
vehicle control (‘Con’), placebo pellet + Gly (‘Gly’), E2 pellet + vehicle (‘E2’), and E2 
pellet + Gly (‘E2+Gly’).  
   On the morning of day 12, mice were weighed and then euthanized by 
decapitation under complete isoflurane anesthesia and trunk blood was collected into 
heparinized tubes. Brain hemispheres were stored in RNAlater (Ambion) overnight at 4C 
and subsequently stored at -20C until further processing. Blood samples were stored on 
ice until centrifuged and plasma was collected and stored at -20C until processed for an 
ELISA assay of E2 by the Ligand Assay and Analysis Core Laboratory at the University 
of Virginia Center for Research in Reproduction. Plasma from ‘E2’ and ‘E2+Gly’ treated 
mice was diluted 1:3 to fit the linear range of the ELISA (detection limits 3–300 pg/ml). 
Body mass (n = 24) and natural log-transformed E2 plasma levels (n = 10) were analyzed 
via 2 x 2 ANOVA using the model described below for the microarray data. 
 
Ethics Statement 
 All protocols used for housing, handling, and euthanasia followed guidelines approved 





were approved by the University of Louisville Institutional Animal Care and Use 
Committee (protocol number 11099). 
 
RNA isolation and microarray platform 
Total RNA was isolated from brain hemispheres of 3 mice per group using 
Trizol/chloroform extraction, followed by spin column purifications (Qiagen RNeasy 
midi kit) that included DNase (Qiagen) digestions. A Nanodrop 2000 spectrophotometer 
was used to assess sample purity and RNA concentration and an Agilent Bioanalyzer was 
used to verify sample integrity (RIN 7.9 - 9).  RNA samples were then submitted to the 
University of Louisville Genomics Facility where they were processed according to 
standard Affymetrix protocols and independently hybridized to Affymetrix Mouse Gene 
1.0 ST Arrays. 
 
Microarray analysis 
Low level analyses, quality control, and expression summarization 
We examined all arrays at the probe level by inspecting box plots, histograms, pair-wise 
M v A plots of replicate GeneChips, and pseudo-images of the log2(intensity) data for 
each GeneChip.  We then fit a probe level model (PLM) to the background adjusted and 
normalized probe level data and rendered pseudo-images for each GeneChip of the 
weights, residuals, and residual signs that were obtained by fitting the PLM (Bolstad et 
al. 2005).  Finally, we used the gene expression estimates and standard errors obtained 
from the PLM to render relative log expression (RLE) and normalized unscaled standard 





clear that two GeneChips (one E2 and one E2 + Gly) were aberrant, a conclusion that was 
reinforced by conducting similar quality control (QC) analyses at the transcript cluster 
(i.e., gene) level.  We therefore removed these aberrant chips and re-inspected the probe 
level data, which revealed no further problems.  We then generated expression summaries 
at the transcript cluster level using the robust multiarray average (RMA) algorithm of 
Irizarry et al. (2003).  All of these procedures were conducted using the ‘oligo’ package 
(Carvalho and Irizarry 2010) that is freely available from Bioconductor for the R 
statistical computing environment (R Development Core Team, 2012). 
 
Data filtering and identification of genes differentially expressed between treatments 
Because the Mouse Gene 1.0 ST Array covers 35,556 transcript clusters, there is a 
considerable multiple testing burden associated with analyzing gene level data from this 
platform. In order to minimize this burden and avoid conducting tests on genes that are 
unlikely to be expressed in the brain, we removed transcript clusters whose mean 
expression across all chips was ≤ to the mean of the first quartiles across all chips 
(log2(RMA) = 5.953). In addition, we removed transcript clusters that were not part of the 
‘main’ design of the array (i.e., we removed all control and unmapped transcript clusters) 
prior to conducting statistical analyses. Upon applying these filters, 22,056 transcript 
clusters were available for significance testing. 
 We tested each gene for differential expression using a 2 x 2 factorial ANOVA of 
the form log2(RMA)ijk = β0 + Gi + Ej + (GE)ij + εijk where β0= intercept, Gi = the main 
effect of Gly, Ej = the main effect of E2, (GE)ij = the interaction between Gly and E2, and 





treatment j. Differentially expressed genes (DEGs) were identified using P-values 
associated with overall model F-statistics and the multiple testing correction of 
Benjamini and Hochberg (1995; FDR = 0.20) . Once a gene was identified as 
differentially expressed, we then examined which terms in the model were statistically 
significant. When significant interaction terms were detected, we used Tukey’s honest 
significant differences (HSD) to determine which levels (i.e., Con, Gly, E2, E2+Gly) 
differed and did not attempt to interpret the main effects. However, when no significant 
interaction was detected, the main effects were interpreted unambiguously via F-statistics 




DEGs were further analyzed using MetaCore version 6.18 software 
(www.portal.genego.com). The genes on 4 different DEG lists (main Gly effect only, 
main E2 effect only, main E2 and main Gly effects with no interaction, and significant 
interaction effects) were uploaded as separate files. The ‘Enrichment Analysis’ function 
was then applied to each list to identify genes that potentially affect biological pathways, 
maps or gene ontology (GO) terms that are brain-specific. Further, MetaCore’s ‘Build 
Network’ function was used to look for any direct interactions among genes on each of 
the separate DEG lists. As we only used gene lists that were already deemed 
differentially expressed between treatment groups, we did not use P-value threshold 





among treatments (see below), we did not use any fold-change cut offs when conducting 
analyses in MetaCore.   
 
RT-qPCR 
Genes and reaction conditions 
Reference genes (Hmg20b, Efnb2) for reverse transcription quantitative real-time PCR 
(RT-qPCR) were chosen based on the degree of within and between group variation in 
the microarray data. Eight genes of interest (GOIs) were chosen for further investigation 
via RT-qPCR for a variety of reasons including: known E2 responsiveness and 
importance to endocrine signaling (Prl, Gh), identification via microarray screening 
(Nr4a1), and marginal statistical significance and/or relatively large fold change values 
(~ 2 fold) between two or more experimental groups in the array study (Ngp, Fcrls, 
Cdh12, Slc6a4, Tph2). The same RNA samples used for the microarray analysis were 
used to make cDNA via the High Capacity cDNA Reverse Transcription Kit according to 
manufacturer’s instructions (Applied Biosystems). TaqMan primers (Life Technologies, 
Supplementary Table 2.1) were chosen, using manufacturer recommendations, to avoid 
detection of non-target sequences and to have small amplicon lengths. PCRs were 10 µl 
reactions and were run on an ABI ViiA7 in 384 well plates. Reaction conditions were 
50ºC for 2min, 95ºC for 10min, then 40 cycles of 95ºC for 15sec and 60ºC for 1min. 
Each PCR was technically replicated in triplicate and each plate contained three template-
free controls per primer pair.  
 





We fit logistic and log-logistic models (Spiess et al. 2008) to the cycle-by-cycle 
fluorescence data (ΔRn) associated with each PCR using the ‘qpcR’ software package by 
Ritz and Spiess (2008).  Seven, six, and five parameter logistic and log-logistic models 
were considered for each GOI and for each reference gene.  Models were selected on a 
GOI-by-GOI basis via a combination of graphical inspection and consideration of model 
fitting metrics, such as corrected Akaike’s information criterion (AICc) and R2.  
Preference was given to models that could be successfully applied with high goodness of 
fit to as many of the amplification curves under consideration as possible. When different 
models were chosen for different GOIs, each respective model was independently applied 
to the reference gene data, to ensure that relative expression ratios (RE) for each GOI 
were calculated from efficiency (E) and quantification cycle (Cq) estimates that were 
based on a common mathematical framework. Amplification data were smoothed using 
Friedman’s super smoother with the span set to 0.1 as recommended in the ‘qpcR’ 
documentation. The ‘uni2’ option was used to test for outlier curves that lacked sigmoidal 
structure and reactions flagged by this test, as well as reactions where model fitting 
failed, the fitted model had an R2 < 0.99, or E < 1.5, were removed prior to the 
calculation of RE.  RE values were calculated according to the relative expression model 
of Hellemans et al. (2007). Quantification cycles (Cq) were defined as the second 
derivative maximum (SDM) of the logistic or log-logistic equation estimated via 
nonlinear regression. The reaction efficiency (E) of each PCR at Cq was determined as 
described in Spiess et al. (2008). Sample Cq estimates were based on the average of 
technical replicates that passed all QC measures, and gene-specific E estimates were 





cycle for each respective gene was the average Cq estimate across all samples (Hellemans 
et al. 2007). Log2 transformed RE values (Page and Stromberg 2011) were analyzed using 




Body mass did not differ among groups (F3,20 = 1.1210, P = 0.3643, R
2 = 0.1439; Fig. 
2.2a); however, natural log-transformed plasma E2 levels were highly statistically 
significant (F3,6 = 72.37, P < 0.0001, R
2 = 0.9731; Fig. 2.2b; raw values, mean (pg/ml) + 
SEM: Con, 4.13 + 1.13; Gly, 3.17 + 0.003; E2, 265.65 + 55.65; E2+Gly, 76.05 + 21.15). 
The interaction between Gly and E2 was not quite statistically significant (F1,6 = 4.6177, 
P = 0.0752), so post-hoc multiple pairwise comparisons were not warranted. However, 
given this marginally significant interaction effect, it is not surprising that the main effect 
of Gly was also statistically significant (F1,6 = 7.8018, P = 0.0315). As expected, the 
main effect of E2 was highly statistically significant (F1,6 = 206.6632, P < 0.0001); on the 
raw scale, E2-exposed animals had nearly 47 times the circulating E2 levels of non-E2 
exposed animals, whose plasma E2 levels were at or near the lower detection limit of the 
assay. Collectively, these results show that animals in the E2 groups had significantly 
higher plasma E2 as compared to non-E2 exposed animals and that Gly may lower 
circulating E2 concentrations in animals exposed to E2.   
 
Microarray data 





We identified a total of 279 DEGs at an FDR of 0.20.  Hierarchical clustering of the 
DEGs and samples enabled us to recover the four levels of the interaction between E2 
and Gly and revealed that, in general, E2 and E2+Gly were most similar to each other 
among the four treatments, while Gly was the most distinct (i.e., in general, if a gene is 
up regulated relative to controls by E2 and E2+Gly, then it is down regulated by Gly and 
vice versa, Fig. 2.3).  
 To better understand the functions of DEGs identified by different combinations 
of terms in our statistical model (α = 0.05), we divided the 279 DEGs into the following 
categories, which are illustrated schematically in Supplementary Figure 1.1: [1] 33 DEGs 
with only a significant E2 main effect, [2] 5 DEGs with only a significant Gly main 
effect, [3] 74 DEGs with both significant Gly and E2 main effects, but no significant 
interaction term, and [4] 167 DEGs with significant interaction terms. For genes with 
significant interaction terms we further categorized genes based on patterns of 
significance (adjusted P-value < 0.05) for the six possible pair-wise comparisons 
obtained via Tukey’s HSD. The DEGs relevant to brain function are described in Tables 
1.1 to 1.4 (see Supplementary Tables 2.2-2.5 for tables listing all DEGs in each of the 4 
categories). 
 
Main effect of E2 on gene expression 
Of the 33 DEGs with only a significant E2 main effect (Supplementary Table 2.2), but no 
interaction effect, 21 genes were upregulated in the E2 groups (i.e., E2 and E2+Gly) 
(Supplementary Figure 2.1a) when compared to the non-E2 groups (i.e., Con and Gly). 





analysis using MetaCore revealed genes involved in pathways such as ‘cholesterol and 
sphingolipid transport’ (Arf1), ‘development/activation of astroglial cell proliferation’ 
(Arf1), ‘DNA damage nucleotide excision repair’ (Ercc8), and ‘development, 
neurogenesis and synaptogenesis’ (Apba2). Some E2-upregulated genes also annotated to 
GO processes such as ‘response to topologically incorrect protein’ (Hsp105, Ubc6, 
Ube2j2), ‘protein modification by small protein conjugation’ (Ercc8, Fbxo21, Ubc6, 
Ube2j2), and ‘primary microRNA processing’ (Dgcr8). Twelve of the 33 DEGs were 
downregulated by E2 (Supplementary Figure 2.1b), but none of the downregulated genes 
annotated to any pathways or GO processes in MetaCore, nor did these have any known 
functions in brain. 
In short, E2 upregulated several genes involved in general brain functions like 
maintenance of neuronal function and synaptic plasticity, neurogenesis, neurotransmitter 
release as well as general protein modification and miRNA processing. 
 
Main effect of Gly on gene expression 
Of the 5 genes that have only a Gly main effect (Supplementary Figure 2.1c-d, 
Supplementary Table 2.3), 4 have known brain-related functions (Table 2.2). Four DEGs 
were upregulated in Gly groups (i.e., Gly and E2+Gly) as compared to the non-Gly 
groups (i.e., Con and E2), including miR-495, which was 1.75-fold higher in Gly vs. non-
Gly groups and has brain derived neurotrophic factor (Bdnf) as a predicted target (Wu et 
al. 2010). In general, Gly upregulated DEGs that are involved in neurogenesis, synaptic 
plasticity and tissue development and downregulated one DEG (Ppia, Supplementary 





downregulated gene (Ppia) was identified by Metacore analysis for the pathway 
‘cholesterol and sphingolipid transport from golgi and ER to the apical membrane’ and 
the GO process ‘negative regulation of protein phosphatase type 2b activity’. 
 
Joint main effects of E2 and Gly on gene expression in the absence of an interaction 
Seventy-four DEGs, 11 of which have brain-related functions, had main effects of both 
E2 and Gly with no interaction term (Table 2.3). These 74 genes fell into 4 different 
patterns of expression (Supplementary Figure 2.1e-h, Supplementary Table 2.4) as 
described below. 
a. Upregulated in the Gly groups (i.e., Gly and E2+Gly) compared to non-Gly 
groups (i.e., Con and E2) and downregulated in the E2 groups (i.e., E2 and 
E2+Gly) as compared to non-E2 groups (i.e., Con and Gly) (33 DEGs, 
Supplementary Figure 2.1e). MetaCore enrichment analysis of these revealed the 
pathway map ‘immune response, oncostatin M-signaling via JAK-STAT in mouse 
cells’ (Socs3) and the GO process ‘regulation of membrane potential’ (miR-138-
1).   
b. Downregulated in the Gly groups compared to non-Gly groups and upregulated in 
the E2 groups compared to non-E2 groups (28 DEGs, Supplementary Figure 
2.1f). MetaCore enrichment analyses of these genes identified pathway maps such 
as ‘development: epigenetic and transcriptional regulation of oligodendrocyte 
precursor cell differentiation and myelination’ (Hdac1 and Olig2), ‘cholesterol 
and sphingolipid transport’ from golgi and ER to the apical membrane (Ppia) and 





included ‘positive regulation of oligodendrocyte differentiation’ (Hdac1 and 
Olig2), ‘negative regulation of protein phosphatase type 2b activity’ (Ppia), 
‘negative regulation of kinase activity’ (Prdx3, Socs3 and Taf10), and ‘regulation 
of membrane potential’ (Cd9, Kcnip1, miR-138-1, Olig2, Prdx3 and Stoml2). 
MetaCore analysis also revealed involvement in process networks such as 
‘response to hypoxia and oxidative stress’ (Prdx3), ‘development: neurogenesis in 
general’ (Cd9), ‘transcription regulation of initiation’ (eIF4a1), and ‘transcription 
by RNA polymerase II’ (Taf10). Note that although the gene Ppia appears in both 
the Gly main effects and in the joint E2 and Gly main effects lists, it is 
represented by different transcript cluster IDs in each case (Supplementary Tables 
2.3 and 2.4). 
c. Upregulated in Gly groups compared to non-Gly groups and also upregulated in 
E2 groups compared to non-E2 groups (10 DEGs, Supplementary Figure 2.1g). 
MetaCore analysis identified only one of these genes, Zfyve28, which is included 
in the GO process ‘negative regulation of kinase activity’.  
d. Downregulated in Gly groups compared to non-Gly groups and also 
downregulated in E2 groups compared to non-E2 groups (3 DEGs, 
Supplementary Figure 2.1h). None of these genes annotated to GO processes or 
pathway maps on MetaCore.    
Overall, the joint main effects of Gly and E2 indicate that genes upregulated in Gly 
groups and downregulated in E2 groups are involved in immune response, apoptosis 
and maintenance of synaptic plasticity, whereas genes upregulated in E2 groups and 





neurogenesis, apoptosis, transcriptional regulation, cholesterol and lipid transport and 
regulation of membrane potential as well as kinase activity. One of the 3 genes 
(Prok1) downregulated in both Gly and E2 groups compared to non-Gly and non-E2 
groups, respectively, is involved in developmental neurogenesis.    
 
E2 and Gly interaction effects on gene expression 
A total of 167 DEGs were found to have statistically significant E2 x Gly interaction 
terms (Supplementary Table 2.5). Twenty-one of these have known brain-related 
functions (Table 2.4), such as embryonic brain development and neuronal differentiation. 
The 167 DEGs were further categorized based on the individual patterns of significance 
for six-possible pair-wise comparisons (Gly vs Con, E2 vs Con, E2 + Gly vs Con, E2 + 
Gly vs E2, E2 + Gly vs Gly, and E2 vs Gly). A combined view of all the different 
pairwise comparisons for each of the genes on this list with directionality taken into 
account reveals that these genes follow 20 unique patterns of expression. Sixty-five 
DEGs have one pattern of particular interest: upregulated in Gly compared to control, the 
E2 group not different from control, but E2+Gly gene expression significantly lower than 
that of Gly alone (Supplementary Figure 2.1i). 
MetaCore enrichment analysis revealed that some genes on this list are involved in 5 
different pathway maps: ‘microRNA-dependent inhibition of epithelial to mesenchymal 
transition’ (miR-200a), ‘DNA damage mismatch repair’ (Mlh1, Msh2), ‘immune response 
– IFN alpha/beta signaling pathway’ (Ifnα, Pml), ‘keratan sulfate metabolism’ (B4gt4, 
Chst2) and ‘aminoacyl tRNA biosynthesis in the mitochondrion’ (Lars2, Tarsl1). Two 





and ‘microglia development’ (Itgam), were revealed in MetaCore, which also found 
metabolic networks ‘L-tryptophan pathways and transport’ (Lars2, Nanog) and ‘lipid 
metabolism – blood group glycolipid-neo-lactoseries metabolism’ (B4gt4, Chst2), the 
latter especially interesting given known lipid-processing effects of Gly in the periphery 
(Wood et al. 2012). To summarize, genes with significant interaction effects are involved 
in broad functional categories like brain development, neuronal differentiation, immune 
response, DNA damage repair and lipid metabolism.   
 
RT-qPCR data 
The five parameter log-logistic model described by Spiess et al. (2008) was selected for 
all GOIs except Prl, for which the seven parameter logistic model was selected. In 
general, the correlation between the microarray data and the RT-qPCR data was strong 
(mean r = 0.831, minimum = 0.605, maximum = 0.952, n = 8). As can be seen in Fig. 4, 
we were generally able to replicate the trends in the microarray data using RT-qPCR. 
GOIs investigated via RT-qPCR can be broken into the following three categories based 
on the results of 2-way ANOVAs at the 0.05 level (Supplementary Table 2.7): no 
statistical significance at the overall model level (Fcrls, Gh, Slc6a4, Tph2), statistical 
significance at the overall model level and for the main effect of E2 (Cdh12, Ngp, Prl), 
and statistical significance at the overall model level and for the main effects of E2 and 
Gly (Nr4a1).  Collectively, these results show that we were able to replicate the general 
trends and magnitudes of gene expression estimated via microarray using RT-qPCR for a 
variety of genes, many of which were not strongly differentially expressed among 






To determine potential mechanisms of action of Gly in the female mouse brain, we 
measured the effects of soy-derived Gly action alone and in conjunction with E2 on gene 
expression. Given the anti-estrogenic effects of Gly via ER-mediated mechanisms in the 
periphery (Ng et al. 2011; Nwachukwu et al. 2013), we expected the primary pattern of 
differential expression in the brain to be Gly opposition of the effects of E2 (i.e., 
significant E2 vs Con and E2+Gly vs E2 comparisons, but not Gly vs Con comparison). 
However, only 4 (Tmem79, Ssh1, Brf2, Olfr411) of the 167 genes with a significant 
interaction term showed this pattern. On the other hand, 65 of the genes on this list 
showed the opposite pattern of expression, with E2 appearing to oppose the effects of Gly 
(i.e., significant E2+Gly vs Gly comparison) on expression of genes that were not 
significantly affected by E2 compared to controls (Supplementary Figure 2.1i). Our 
whole brain microarray analysis showed that the Gly treatment produced the most distinct 
gene expression pattern, while the two E2 groups (E2 and E2 + Gly) were the most 
similar to each other in terms of gene expression (Fig. 2.3). We identified a total of 279 
DEGs, but the fold-change values for the DEGs were modest, with Nr4a1 exhibiting the 
largest change (FC = 1.89, Gly vs Con). This could be due to the fact that our microarray 
analysis reflects the overall expression of these genes across the whole brain. Future 
studies looking at expression of gene targets in specific brain regions may reveal higher 
fold-change effects between treatment groups in discrete brain regions. 
Estrogens perform several functions in the brain related to neuroprotection, cognition, 
stress, food intake, etc., and ERs are distributed throughout the brain (Mitra et al. 2003). 





Calmin, Spondin1, Dgcr8 and Apba2) are predominantly involved in pathways and 
processes such as neurogenesis, maintenance of synaptic plasticity, dendritic spine 
maintenance and axonal growth (Feinstein et al. 1999; Fenelon et al. 2013; Kirov et al. 
2008; Takaishi et al. 2003). Some ‘classic’ E2-responsive genes (e.g., estrogen or 
progesterone receptors, prolactin, growth hormone), however, did not make our DEG list, 
often due to variability within groups. For example, the average expression of Prl in the 
E2 group was 11.19 fold-change higher than that of controls, but intra-group variability 
prevented the identification of Prl as a DEG.   
Average plasma E2 levels in the E2+Gly group (76.05 + 21.15 pg/ml) were only about 
30% that of the E2 treatment group (265.65 + 55.65 pg/ml). Although the interaction 
term was only marginally significant (P=0.0752), this difference in plasma E2 could be 
biologically relevant. Regarding individual genes for which expression differed in mice 
treated with E2+Gly compared to E2 alone (e.g., Nr4a1, Svop; Table 2.4, Supplementary 
Table 2.5), one explanation besides direct anti-estrogenic effects of Gly is that some 
differences in E2-driven gene expression could be due to lower plasma E2 levels in the 
E2+Gly group, a possibility that we cannot exclude in the current study. An interesting 
point for future studies is that Gly might have suppressed plasma E2 levels in the E2+Gly 
animals, perhaps via enhanced clearance of E2. The hormone concentrations we observed 
could also be due to pellet variability in maintaining plasma E2 levels (Ingberg et al. 
2012).  
Regardless of the source of plasma E2 variability, the difference in plasma E2 
concentrations between these two groups appears to have had little overall effect on gene 





the groups that received a placebo pellet, as seen in Fig. 1.3. Furthermore, 79 DEGs had 
significant Gly effects (5, Gly main effect only; 74, Gly and E2 main effects with no 
interaction), suggesting that Gly has effects on gene expression in the brain that are 
independent of plasma E2 status. Three of the 5 genes upregulated by Gly alone (i.e., 
miR-495, Hmcn1 and Tnfsf13b) are involved in neurogenesis, tissue development and 
immune response functions, respectively (Farina et al. 2007; Wu et al. 2010; Xu et al. 
2013) (Table 2.2). Interestingly, Ppia, which is downregulated in Gly groups (Tables 2.2, 
2.3), is involved in apoptosis and promotes neurodegeneration by initiating a pro-
inflammatory pathway leading to neuronal damage and loss of synaptic connections 
(Nigro et al. 2013). These results indicate that Gly by itself can regulate genes belonging 
to these pathways and may potentially have neuroprotective effects.  
The mechanisms by which Gly affects gene expression in the brain remain unclear and 
need to be tested empirically, perhaps using ER knockout mice to verify which effects of 
Gly are indeed through ER-mediated vs. non ER-mediated mechanisms. Testing effects 
of Gly on gene expression in neural cell culture would also determine if the effects of Gly 
reported here are due to direct effects at the neuron or due to systemic effects (e.g., stress, 
plasma E2) that affected gene expression detected at the whole brain level. Given the 
interest in Gly’s anti-cancer and glucose handling effects in the periphery (Boue et al. 
2012; Salvo et al. 2006), understanding its CNS effects is an important component of 






Fig. 2.1 Known in vitro and in vivo effects of Gly (glyceollin I structure shown) that are 


















Fig. 2.2 Interaction plots showing a) body mass (mean + SEM, ANOVA p = 0.36) b) 
natural log transformed plasma E2 levels (mean + SEM, ANOVA p < 0.0001, E2 p < 
0.0001, Gly p = 0.0315, E2 x Gly interaction p = 0.075).  = Con,  = E2,  = Gly, = 
E2 + Gly. Left columns (circles) = no Gly; right columns (triangles) = Gly. Dotted lines 
















Fig. 2.3 Heat map of the 279 DEGs. Columns correspond to individual GeneChips for 
samples from the Gly, Con, E2, and E2 + Gly treatments, with animal IDs shown. The 
dendrograms on top and to the left were obtained via hierarchical clustering of a pair-





























































































Fig. 2.4 Bar plots of the microarray (grey bars) and RT-qPCR (black bars) data for the 
eight genes (Cdh12, Fcr1s, Gh, Prl, Nr4a1, Ngp, Tph2, Slc6a4) whose expression levels 
were technically replicated. Log2(RMA) values from the microarray experiment and 
















































































































































































Table 2.1. Brain-related DEGs with significant main E2 effect only, no interaction term 
Gene 
Symbol 
Gene Name Function P-value FCa Ref 
Apba2 amyloid beta (A4) 
precursor protein-
binding, family A, 
member 2 
neurotransmitter release 0.0002 1.14 Kirov et al, 2008 
Clmn Calmin development & maintenance 
of neuronal function 
0.0003 1.27 Takaishi et al, 
2003 
Dgcr8 DiGeorge syndrome 
critical region gene 8 
maintenance of short & long 
term synaptic plasticity 
0.0002 1.13 Fenelon et al, 
2013 
Spon1 Spondin-1 dendritic & axonal growth - 
hippocampus 
0.0002 1.11 Feinstein et al, 
1999; Ho et al, 
2004 
aFC = fold change (E2 + E2+Gly) / (Con + Gly) 
 
Table 2.2. Brain-related DEGs with significant main Gly effect only, no interaction term 
Gene 
Symbol 
Gene Name Function P-value FCa References 
Hmcn1 hemicentin 1 cell division & development of tissue 
architecture 
0.0007 1.24 Xuehong et al, 
2013 
miR-495 microRNA 495 targets BDNF involved in synaptic 
plasticity & neurogenesis 









Nigro et al, 
2013 




innate & adaptive immune response in 
the CNS 
0.0006 1.12 Farina et al, 
2007 






















Gly up, E2 downa 






















enriched in GABAergic 
neurons 
0.0030 1.15 0.0031 0.88 Hardt et al, 
2008 
miR-211 microRNA 211 antiproliferative effects 
on glioma cells 
0.0048 1.12 0.0005 0.83 Asuthkar et 
al, 2012 
miR-30d microRNA 30d expressed in aging 
mouse brains 
0.0044 1.09 0.0002 0.86 Li et al, 
2011; Eda et 
al, 2011 
miR-503 microRNA 503 promotes apoptosis of 
dendritic cells 
0.0022 1.19 0.0004 0.79 Min et al, 
2013 






















0.0233 0.95 0.0003 1.13 Weeber et 
al, 2002 
Gly up, E2 upa 
Lnx1 ligand of numb-










Gly down, E2 downa 
Prok1 prokineticin 1 maintenance & 
proliferation of enteric 
neural crest cells 
0.0008 0.89 0.0002 0.86 Ngan et al, 
2008 
aGly refers to any group with glyceollin treatment (Gly or E2+Gly); E2 refers to any group with E2 treatment (E2 







Table 2.4 Brain-related DEGs with significant E2 x Gly interaction effects 
Gene 
Symbol 
















Alkbh3 alkB, alkylation 
repair homolog 3 
(E. coli) 
RNA metabolism & mRNA export 0.0127 1.02 1.03 1.23 1.21 1.19 1.01 Zheng et al, 
2013 
Alkbh5 alkB, alkylation 
repair homolog 5 
(E. coli) 
RNA metabolism & mRNA export 0.0172 0.94 1.10 1.22 1.29 1.11 1.16 Zheng et al, 
2013 
Bcs1l BCS1-like (yeast) expressed in neuronal processes 
during neuronal development 
0.0019 0.86 1.04 1.27 1.48 1.22 1.22 Kotarsky et 
al, 2007 
Coro7 coronin 7 expressed in the developing 
mouse brain at early embryonic 
stages 
0.0265 1.06 1.04 1.26 1.19 1.21 0.98 Rybakin et al, 
2004 
Derl2 Der1-like domain 
family, member 2 
degradation of misfolded 
glycoproteins in the ER 
0.0212 0.81 1.03 1.00 1.24 0.97 1.28 Oda et al, 
2006 





neurotrophic factor family 
receptor found in cerebellum & 
spinal cord  





expressed in pituitary & 
hypothalamus 
0.0089 0.77 1.04 1.06 1.38 1.02 1.35 Bischof et al, 
2005 












expressed in purkinje cells in 
cortex, hippocampus & 
cerebellum 
0.0225 0.81 1.04 0.98 1.21 0.94 1.29 Lindholm et 
al, 2008 
miR-210 microRNA 210 hypoxia-induced apoptosis of 
neuroblastoma cells 
0.0057 1.19 0.96 0.98 0.82 1.02 0.81 Chio et al, 
2013 
miR-23a microRNA 23a oligodendrocyte differentiation & 
myelin synthesis 




Nlrc5 NLR family, CARD 
domain containing 
5 
innate immune system 
responses  





involved in glial-neuronal cell fate 
determination 
0.0207 0.90 1.07 1.11 1.23 1.03 1.19 Owlanj et al, 
2012 
Nr4a1 nuclear receptor 
subfamily 4, group 
A, member 1 
cytokine & metabolic pathways, 
long-term memory 
0.0028 1.89 0.97 1.23 0.65 1.26 0.52 Zhao et al, 
2010; 
McNulty et al, 
2012 
Ryr1 ryanodine receptor 
1, skeletal muscle 
promotes calcium release from 
central neurons 









subfamily a-like 1 
replication stress-response 0.0115 0.90 1.07 1.14 1.28 1.07 1.20 Bansbach et 
al, 2009 
Spg11 spastic paraplegia 
11 
expressed in cortical & spinal 
motor neurons 









Svop SV2 related protein expressed in adult mouse 
hippocampus & cerebellum, 
sugar-transporter 
0.0478 1.05 1.12 1.34 1.27 1.20 1.06 Cho et al, 
2009 
Usp22 ubiquitin specific 
peptidase 22 
expressed in the developing 
mouse brain at early embryonic 
stages 





expressed in the developing 
mouse brain 
0.0147 0.87 1.04 1.03 1.18 1.00 1.19 Abu-Khalil et 
al, 2004 
Zbtb7a zinc finger and BTB 
domain containing 
7a 
oligodendrocyte differentiation  0.0005 0.83 1.04 1.05 1.25 1.00 1.25 Dobson et al, 
2012 








Supplementary Figure 2.1 Interaction plots showing representative patterns of expression of 
DEGs. a-b) DEGs with main E2 effect only, no interaction effect (n=33); c-d) DEGs with main 
Gly effect only, no interaction effect (n=5); e-h) DEGs with main E2 and main Gly effects, no 
interaction effect (n=74); e) Gly up, E2 down; f) Gly down, E2 up; g) Gly up, E2 up; h) Gly 
down, E2 down; i) One of the 20 significant interaction effects patterns, which indicates possible 
E2 opposition of Gly effects on gene expression (65 of 167 DEGs, see text).  = Con,  = E2, 
 = Gly, = E2 + Gly. Left columns (circles) = no Gly; right columns (triangles) = Gly. Dotted 





Supplementary Table 2.1. Genes measured with RT-PCR, and Life Technologies assay 














Gene code Gene name Gene ID Assay ID 
Efnb2 Ephrin B2 NM_010111 Mm01215897_m1 
Hmg20b High mobility group 20B NM_010440 Mm00468918_m1 
Prl Prolactin NM_011164 Mm00599950_m1 
Ngp Neutrophilic granule protein NM_008694 Mm00476389_m1 
Fcrls Fc receptor-like S NM_030707 Mm00472833_m1 
Nr4a1 Nuclear receptor subfamily 4 NM_010444 Mm01300401_m1 
Gh Growth hormone NM_008117 Mm00433590_g1 
Cdh12 Cadherin 12 NM_001008420 Mm01165359_m1 
Slc6a4 Solute carrier family 6 NM_010484 Mm00439391_m1 






Supplementary Table 2.2. DEGs with significant main E2 effect only, no interaction 
effect 
Cluster ID Gene Name Gene Symbol E2 P-
value 
FC - E2/No 
E2 
10402473 calmin Clmn 0.0002778 1.272591485 
10444927 nurim (nuclear envelope membrane protein) Nrm 0.0003073 1.272512378 
10420237 ubiquitin-conjugating enzyme E2, J2 homolog 
(yeast) 
Ube2j2 0.0004253 1.250372284 
10518494 patched domain containing 2 Ptchd2 0.0004024 1.24588567 
10498296 COMM domain containing 2 Commd2 0.0003058 1.240037953 
10382701 SAP30 binding protein Sap30bp 0.0002989 1.198836286 
10475830 mitochondrial ribosomal protein S5 Mrps5 0.0004473 1.198301029 
10424060 Smg-5 homolog, nonsense mediated mRNA 
decay factor pseudogene 
A930017M01Rik 0.0002298 1.194212595 
10394429 RIKEN cDNA 1110057K04 gene 1110057K04Rik 0.0002304 1.189768918 
10535637 pentatricopeptide repeat domain 1 Ptcd1 0.000214 1.188513774 
10563583 serum amyloid A-like 1  Saal1 0.0001505 1.174200366 
10407057 excision repaiross-complementing rodent 
repair deficiency, complementation group 8 
Ercc8  0.0003957 1.15482094 
10535904 heat shock 105kDa/110kDa protein 1 Hsph1 4.74E-05 1.149153469 
10524941 F-box protein 21 Fbxo21  0.0002588 1.14900239 
10598389 WD repeat domain 45 Wdr45 0.0003289 1.144614549 
10553917 amyloid beta (A4) precursor protein-binding, 
family A, member 2 
Apba2  0.0002452 1.136367819 
10580169  coiled-coil domain containing 130  Ccdc130 0.0004312 1.133102262 
10453792 THO complex 1 Thoc1  0.0003816 1.13075786 
10438313 DiGeorge syndrome critical region gene 8  Dgcr8 0.0002161 1.127223329 
10386370 ADP-ribosylation factor 1  Arf1 0.0001687 1.126823468 
10556509 spondin 1, (f-spondin) extracellular matrix 
protein 
Spon1 0.0001597 1.114214783 





10526718 sperm motility kinase 3A Smok3a 0.0002448 0.871153708 
10558698 outer dense fiber of sperm tails 3 Odf3  0.0001787 0.85634709 
10493903 late cornified envelope 3C Lce3c 0.0005959 0.841790711 
10589625 protease, serine, 43 Prss43 0.0002384 0.82190624 
10357696 predicted gene 10188 Gm10188 0.0003313 0.820374562 
10364155 RIKEN cDNA 2610028H24 gene 2610028H24Rik 0.0003097 0.817654509 
10569896 CD209g antigen Cd209g 0.0002588 0.801977346 






Supplementary Table 2.3. DEGs with significant main Gly effect only, no interaction 
effect 
 
Cluster ID Gene Name Gene 
Symbol 
Gly P-value FC - Gly/No 
Gly 
10482507 peptidylprolyl isomerase A Ppia 0.00027473 0.914567569 
10398402 microRNA 495 Mir495 0.00057025 1.751643961 
10576951 tumor necrosis factor (ligand) superfamily, 
member 13b 
Tnfsf13b 0.00058411 1.116875689 
10358611 hemicentin 1 Hmcn1  0.00066053 1.24250467 








Supplementary Table 2.4. DEGs with significant Gly and significant E2 main effects, no 
interaction effects 
Cluster ID Gene Name Gene Symbol E2 P-value Gly P-value FC-E2/No 
E2 
FC - Gly/No 
Gly 
10424555 ---  0.002195973 0.00124968 0.69027004 1.505967514 
10504121 predicted gene 3893 Gm3893 0.036336185 0.00065509 0.88785647 1.323358338 
10504148  RIKEN cDNA 
4933409K07 gene 
4933409K07Rik 0.031914404 0.00086073 0.8880316 1.296291092 
10504169  RIKEN cDNA 
4933409K07 gene 
4933409K07Rik  0.02651595 0.00079573 0.88575532 1.292134123 
10504172 RIKEN cDNA 
4933409K07 gene 
4933409K07Rik 0.033764379 0.00068863 0.89660009 1.287345527 
10392699 ---  0.009216708 0.00071232 0.86586133 1.278074156 
10590462 microRNA 138-1 Mir138-1 0.005892133 0.00212107 0.83509886 1.26151245 
10369927 ---  0.00092109 0.0111436 0.7579822 1.212772051 
10392834 predicted gene 11711 Gm11711 0.006612927 0.00149895 0.87931996 1.199375158 
10559172 keratin associated 
protein 5-3 
Krtap5-3 0.000426792 0.00830389 0.75050392 1.196567733 
10604612 microRNA 503 Mir503  0.000374233 0.00224243 0.78507007 1.189765774 
10529385  zinc finger, FYVE 
domain containing 28 
Zfyve28 0.014657347 0.00069105 1.08962178 1.17398773 
10606389 ---  0.000978379 0.01017972 0.79228767 1.161735161 




Atp12a 0.000390177 0.02043303 0.76292553 1.158240903 
10507961 metal response 
element binding 
transcription factor 1 
Mtf1  0.005048835 0.00044364 1.081455 1.148285719 
10569011 interferon induced 
transmembrane 
protein 5 
Ifitm5 0.00309811 0.00302969 0.88148091 1.145363656 
10575074 transmembrane and 
coiled-coil domains 7 
Tmco7 0.000425722 0.00070862 1.1730721 1.14500354 
10363970 RAB36, member RAS 
oncogene family 
Rab36 0.002111967 0.00117055 1.1370113 1.143333248 
10535747 predicted gene 10858 Gm10858  0.000283642 0.00717405 0.7764139 1.143208962 





10559175 keratin associated 
protein 5-4 
Krtap5-4 0.000280936 0.00243769 0.8424084 1.131668739 
10553895 microRNA 211  Mir211 0.000496499 0.00484091 0.83467245 1.124439293 
10375553 olfactory receptor 
1389 
Olfr1389 0.001122493 0.00151768 0.88472251 1.120751727 




Nsun4  0.000391448 0.00976323 1.2412183 1.118227032 
10434754 cDNA sequence 
BC106179 
BC106179 0.000316209 0.01806873 0.77665781 1.117170896 
10451481 cDNA sequence 
BC032203 
BC032203 0.000577131 0.00287683 1.15990174 1.115019833 
10474004 diacylglycerol kinase 
zeta 
Dgkz 0.001056113 0.02468176 0.83982308 1.11256167 
10505779  alkaline ceramidase 
2 
Acer2 0.000446772 0.02432106 1.29264789 1.108196309 
10481262 ficolin B  Fcnb 3.71E-05 0.00028789 0.87402403 1.099320058 
10414772  predicted gene 
10890 
Gm10890  0.000454958 0.01973874 0.82201726 1.095959985 
10429199 microRNA 30d  Mir30d 0.000230439 0.00440432 0.86355439 1.09204143 
10530666 ligand of numb-
protein X 1 
Lnx1 0.03934717 0.00052707 1.03502155 1.090166633 
10391555 pancreatic 
polypeptide 
Ppy 0.000868686 0.01393784 0.87676346 1.083460407 
10399387  mesogenin 1 Msgn1  0.000183581 0.00217594 0.87968247 1.081950768 
10513592 WD repeat domain 31 Wdr31 0.000305246 0.02162895 1.18557831 1.075204956 
10507671 guanylate cyclase 
activator 2a (guanylin) 
Guca2a 0.000476461 0.01459981 0.88490962 1.073229988 
10559989 aurora kinase C Aurkc  0.000164036 0.00622595 0.8880848 1.067976341 
10397428  RIKEN cDNA 
1700020O03 gene 
1700020O03Rik 6.58E-05 0.0101924 1.18652492 1.06389794 
10551435 RIKEN cDNA 
9530053A07 gene 
9530053A07Rik 6.19E-05 0.0409589 0.83033149 1.063634937 
10383010 suppressor of 
cytokine signaling 3 
Socs3  7.80E-05 0.03374494 0.81265095 1.062245274 
10507719 schlafen like 1 Slfnl1  0.000994175 0.03603581 0.9036554 1.056997435 
10560237 G protein-coupled 
receptor 77 





10454984 WD repeat domain 55 Wdr55 1.95E-05 0.00663639 1.16794343 0.952327991 
10577534 voltage-dependent 
anion channel 3 
Vdac3 0.000333508 0.02332508 1.1261931 0.948005801 
10387545 eukaryotic translation 
initiation factor 4A1 
 Eif4a1 0.004091706 0.0016437 1.05044103 0.947087953 
10427772 threonyl-tRNA 
synthetase 





Ndufv2 0.005686588 0.00132796 1.04964645 0.934488745 
10566525 TAF10 RNA 
polymerase II, TATA 
box binding protein 
(TBP)-associated 
factor 
Taf10 3.51E-05 0.0018658 1.15786613 0.929120738 
10447004 histone deacetylase 1 Hdac1 0.000143653 0.0002311 1.08889386 0.927286391 
10463704 arsenic (+3 oxidation 
state) 
methyltransferase  
As3mt 0.000857271 0.02811834 1.15974357 0.926548707 
10468869  peroxiredoxin 3 Prdx3  0.000717133 0.02349014 1.17408008 0.925094664 
10441902 SPARC related 
modular calcium 
binding 2 
Smoc2 0.000929691 0.00602154 1.11529782 0.92171861 
10567574 peptidylprolyl 
isomerase A 




 Qrsl1 0.000373931 0.01444949 1.19353599 0.913499024 
10561140 mitochondrial 
ribosomal protein L41 
Mrpl41 0.000788042 0.00808273 1.14801946 0.911506194 
10512443 stomatin (Epb7.2)-like 
2  
Stoml2  0.000693955 0.04051634 1.24198993 0.91113441 
10560548 gem (nuclear 
organelle) associated 
protein 7 
Gemin7 0.000828162 0.02259287 1.19516696 0.910974675 
10516652 IQ motif containing C  Iqcc 0.002498413 0.00080395 1.07724756 0.909791887 
10351491 olfactomedin-like 2B Olfml2b 0.001460787 0.00539464 1.13607036 0.9020669 
10345926  RIKEN cDNA 
1500015O10 gene 
1500015O10Rik 0.001418663 0.00371689 1.1240296 0.901512304 
10501084 prokineticin 1 Prok1 0.000223595 0.00076156 0.86064223 0.887671109 





interacting protein 1 
10510197 protein phosphatase 
2, regulatory subunit 
B (B56), alpha 
isoform 
Ppp2r5a 0.005412457 0.00059226 1.08823765 0.879242806 
10548030 CD9 antigen Cd9  0.00193229 0.00171101 1.13442297 0.874130093 
10516778 zinc finger, CCHC 
domain containing 17 
Zcchc17 0.001020832 0.00444588 1.20274783 0.86794695 
10540275 glucoside 
xylosyltransferase 2 
Gxylt2 0.004810183 0.00180108 0.89207655 0.8655777 
10506496 phosphatidic acid 
phosphatase type 2B 
Ppap2b 0.005596524 8.78E-06 1.04668334 0.852024197 
10436823 oligodendrocyte 
transcription factor 2 




Cmbl 0.028033234 0.00127775 1.08991123 0.826956277 
10569368 ---  0.002858606 0.00039387 1.14747467 0.806451477 
10552311 ---  0.002248153 0.00257408 1.23216774 0.803644701 
10356457 DnaJ (Hsp40) 
homolog, subfamily B, 
member 3 








Supplementary Table 2.5. DEGs with significant interaction effects 
Cluster ID Gene Name Gene Symbol Int P-value 
10555039 potassium channel tetramerisation domain containing 21 Kctd21 0.00081238 
10414911 T cell receptor alpha variable region 13-3 Trav13-3 0.00432031 
10551169 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 8 B3gnt8 0.00491566 
10431912 solute carrier family 38, member 2 Slc38a2 0.00930295 
10497920 ankyrin repeat domain 50 Ankrd50 0.01594006 
10402570 predicted gene 10427 Gm10427 0.02333913 
10541524 Nanog homeobox  Nanog 0.02512536 
10600301 signal sequence receptor, delta Ssr4  0.0303531 
10414594 methyltransferase 11 domain containing 1  Mett11d1 0.00111753 
10595718 carbohydrate sulfotransferase 2 Chst2 0.00126477 
10566213 olfactory receptor 605 Olfr605 0.04246859 
10380285 transmembrane protein 100  Tmem100 0.00531559 
10435724 
UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, 
polypeptide 4 B4galt4 0.00042491 
10573342 microRNA 23a  Mir23a 0.00349054 
10388728 predicted gene 11190  Gm11190 0.00790087 
10605943 PDZ domain containing 11 Pdzd11 0.0105884 
10598287 LOC100270707 LOC100270707 0.03367059 
10346780 eukaryotic translation initiation factor 4A1 Eif4a1 0.0314693 
10519266 microRNA 200a Mir200a 0.00038099 
10533474 RIKEN cDNA 1500011H22 gene 1500011H22Rik 0.0000612 
10567380 uromodulin Umod 0.00025501 
10399038 zinc finger protein 386 (Kruppel-like) Zfp386 0.00048782 
10378082 gamma-glutamyltransferase 6 Ggt6 0.00069264 
10505888 interferon alpha 5 Ifna5 0.0006976 
10594053 promyelocytic leukemia Pml 0.00078797 
10347417 BCS1-like (yeast) Bcs1l 0.00187542 
10427035 nuclear receptor subfamily 4, group A, member 1  Nr4a1 0.00281126 
10463448 progressive external ophthalmoplegia 1 (human) Peo1 0.00109516 
10488185 beaded filament structural protein 1, in lens-CP94 Bfsp1 0.00162073 
10500218 threonyl-tRNA synthetase 2, mitochondrial (putative) Tars2 0.00172527 
10450296 superkiller viralicidic activity 2-like (S. cerevisiae) Skiv2l 0.00205481 
10369264 oncoprotein induced transcript 3 Oit3 0.00220297 
10497968 predicted gene 16508  Gm16508 0.00232913 
10458183 
glial cell line derived neurotrophic factor family receptor 
alpha 3 Gfra3 0.00476846 
10495781 breast cancer anti-estrogen resistance 3 Bcar3 0.00872323 
10557862 integrin alpha M Itgam 0.00894082 
10570119 carbohydrate kinase domain containing Carkd 0.00958363 
10546944 transmembrane protein 111 Tmem111 0.01069165 





regulator of chromatin, subfamily a-like 1 
10440131 G protein-coupled receptor 15  Gpr15 0.01696801 
10593903 COMM domain containing 4 Commd4 0.01861085 
10566564 mitochondrial ribosomal protein L17 Mrpl17 0.02876081 
10569308 keratin associated protein 5-1 Krtap5-1 0.03114893 
10561748 cation channel, sperm-associated, gamma 2 Catsperg2 0.00734316 
10545337 peptidylprolyl isomerase A Ppia 0.04245722 
10364984 zinc finger and BTB domain containing 7a Zbtb7a 0.00051312 
10445855 kinesin family member 6 Kif6 0.00119466 
10414751 T cell receptor alpha variable 13N-1 Trav13n-1 0.00156947 
10351515 U1b1 small nuclear RNA Rnu1b1 0.00161936 
10514323 LOC100037413 LOC100037413 0.00212262 
10494413 U1b1 small nuclear RNA Rnu1b1 0.00230563 
10574100  NLR family, CARD domain containing 5 Nlrc5 0.00306202 
10476590 MACRO domain containing 2 Macrod2 0.00317966 
10405001 bicaudal D homolog 2 (Drosophila) Bicd2 0.00363827 
10520010 peptidase (mitochondrial processing) beta Pmpcb 0.0036612 
10396231 
translocase of outer mitochondrial membrane 20 homolog 
(yeast)-like Tomm20l 0.00381057 
10373642 olfactory receptor 810 Olfr810 0.00393616 
10534343 elastin Eln 0.00426135 
10571302 transmembrane protein 66 Tmem66 0.00438588 
10570587 defensin beta 34 Defb34 0.00446013 
10538466 growth hormone releasing hormone receptor Ghrhr 0.00462289 
10569100 microRNA 210 Mir210 0.00567214 
10604761 microRNA 504 Mir504 0.00642339 
10441610 radial spoke 3A homolog (Chlamydomonas) Rsph3a 0.00750799 
10414775 predicted gene 17006 Gm17006 0.00782767 
10387516 sex hormone binding globulin Shbg 0.00796872 
10490982 cDNA sequence BC002189 BC002189 0.00866363 
10452639 myosin, light chain 12B, regulatory Myl12b 0.00866468 
10411508 pentatricopeptide repeat domain 2 Ptcd2 0.00870187 
10390907 keratin associated protein 1-3 Krtap1-3 0.00873647 
10604473 immunoglobulin superfamily, member 1 Igsf1 0.00891861 
10447619 radial spoke 3A homolog (Chlamydomonas) Rsph3a 0.00906843 
10597748 golgi reassembly stacking protein 1 Gorasp1 0.00925192 
10485198 tetraspanin 18 Tspan18 0.01092499 
10414906 predicted gene 13978 Gm13978 0.01142163 
10427063 1700011A15Rik 1700011A15Rik 0.01240035 
10398332 microRNA 673 Mir673 0.01328989 
10368893 lactation elevated 1 Lace1 0.01346342 
10431210 wingless-related MMTV integration site 7B Wnt7b 0.01472102 





10389865 non-metastatic cells 1, protein (NM23A) expressed in Nme1 0.02072888 
10388033 Der1-like domain family, member 2 Derl2 0.02117396 
10570178 A230072I06Rik A230072I06Rik 0.02175148 
10578262 microRNA 383 Mir383 0.02215785 
10591735 elongation factor 1 homolog (ELF1, S. cerevisiae) Elof1 0.02233775 
10596575 mesencephalic astrocyte-derived neurotrophic factor Manf 0.02253612 
10505436 microRNA 455 Mir455 0.02311658 
10436372 discoidin, CUB and LCCL domain containing 2 Dcbld2 0.02476946 
10569288 keratin associated protein 5-4 Krtap5-4 0.02555693 
10366407 predicted gene 10752 Gm10752 0.02728883 
10582006 predicted gene 10620 Gm10620 0.02924252 
10390352 karyopherin (importin) beta 1 Kpnb1 0.02955975 
10465411 
solute carrier family 22 (organic anion/cation transporter), 
member 12 Slc22a12 0.03021274 
10440717 keratin associated protein 16-8 Krtap16-8 0.03215136 
10449061 rhomboid, veinlet-like 1 (Drosophila) Rhbdl1 0.03396643 




10576940 family with sequence similarity 155, member A Fam155a 0.03906579 
10434930 1700025H01Rik 1700025H01Rik 0.04189886 
10606941 ripply1 homolog (zebrafish) Ripply1 0.04819616 
10570671 defensin, alpha, 22 Defa22 0.00083945 
10499348 transmembrane protein 79 Tmem79 0.00229643 
10532767 slingshot homolog 1 (Drosophila) Ssh1 0.00822885 
10577948 
BRF2, subunit of RNA polymerase III transcription initiation 
factor, BRF1-like Brf2 0.0094499 
10581523 telomeric repeat binding factor 2 Terf2 0.00572701 
10388308 olfactory receptor 411 Olfr411 0.00112187 




10549889 aurora kinase C Aurkc 0.01059349 
10574159 NLR family, CARD domain containing 5 Nlrc5 0.01137177 
10376685 alkB, alkylation repair homolog 5 (E. coli) Alkbh5 0.01716566 
10397083 RNA binding motif protein 25 Rbm25 0.02287385 
10572497 interleukin 12 receptor, beta 1 Il12rb1 0.02350707 
10542395 activating transcription factor 7 interacting protein Atf7ip 0.0254685 
10447395 mutS homolog 2 (E. coli) Msh2 0.0265917 
10458782 protein geranylgeranyltransferase type I, beta subunit Pggt1b 0.0309373 
10486710 leucine carboxyl methyltransferase 2 Lcmt2 0.03242389 
10480379 mitochondrial ribosomal protein S5 Mrps5 0.03519811 
10588482 POC1 centriolar protein homolog A (Chlamydomonas) Poc1a 0.01234184 
10409629 kelch-like 3 (Drosophila) Klhl3 0.00044438 





10597288 mutL homolog 1 (E. coli) Mlh1 0.0008876 
10462276 predicted gene 815 Gm815 0.00132461 
10490690 uridine-cytidine kinase 1-like 1 Uckl1 0.00245731 
10575291 zinc finger protein 821 Zfp821 0.00253378 
10380591 SNF8, ESCRT-II complex subunit, homolog (S. cerevisiae) Snf8 0.00274997 
10556244 small nucleolar RNA, H/ACA box 23 Snora23 0.00275466 
10486154 A430105I19Rik A430105I19Rik 0.00278218 
10425000 leucine rich repeat containing 14 Lrrc14 0.00278311 
10464153 NHL repeat containing 2 Nhlrc2 0.00347658 
10550978 pleckstrin homology-like domain, family B, member 3 Phldb3 0.00535724 
10386636 ubiquitin specific peptidase 22 Usp22 0.00631343 
10385022 EF-hand calcium binding domain 9 Efcab9 0.01263034 
10485282 alkB, alkylation repair homolog 3 (E. coli) Alkbh3 0.01266648 
10404815 
sirtuin 5 (silent mating type information regulation 2 
homolog) 5 (S. cerevisiae) Sirt5 0.01312765 
10486403 phospholipase A2, group IVE Pla2g4e 0.0197829 
10437399 coronin 7 Coro7 0.02650838 
10405125 F-box and WD-40 domain protein 17 Fbxw17 0.02729384 
10561561 ryanodine receptor 1, skeletal muscle Ryr1 0.02965675 
10590563 leucyl-tRNA synthetase, mitochondrial Lars2 0.03945992 
10426782 amiloride-sensitive cation channel 2, neuronal Accn2 0.04727799 
10532784 SV2 related protein Svop 0.04780432 
10486754 diphosphoinositol pentakisphosphate kinase 1 Ppip5k1 0.04931709 




Supplementary Table 2.6. Body weight (g) and plasma E2 (pg/ml) measures on day 12 (mean + 
SEM). 
 
Measure Con E2 Gly E2+Gly 
body wt (g) 26.3 + 1.1 27.8 + 1.1 26.1 + 0.8 28.1 + 0.8 
plasma E2 (pg/ml) 4.13 + 1.13a 265.65 + 55.65 b 3.17 + 0.03 a 76.05 + 21.15 b 











Supplementary Table 2.7. RT-qPCR statistical outcomes 
           
GOI Gene name 
Overall F 
(df) Overall P R2 E2 F (df) E2 P Gly F (df) Gly P Int F (df) Int P 
Cdh12 Cadherin 12 8.114 (3, 6) 0.016 0.802 22.526 (1, 6) 0.003 1.057 (1, 6) 0.344 1.122 (1, 6) 0.330 
Fcrls 
Fc receptor-like 
S 1.823 (3, 6) 0.243 0.477 5.166 (1,6) 0.063 0.265 (1, 6) 0.625 0.087 (1, 6) 0.778 
Gh Growth hormone 1.684 (3, 6) 0.269 0.457 3.730 (1,6) 0.102 1.168 (1, 6) 0.321 0.361 (1, 6) 0.570 
Ngp 
Neutrophilic 
granule protein 7.425 (3, 6) 0.019 0.788 22.2196 (1, 6) 0.003 0.025 (1, 6) 0.880 0.019 (1, 6)  0.894 
Nr4a1 
Nuclear receptor 
subfamily 4 10.64 (3,6) 0.008 0.842 9.088 (1, 6) 0.024 13.566 (1, 6) 0.010 5.047 (1, 6) 0.066 
Prl Prolactin 8.339 (3, 6) 0.015 0.807 22.763 (1, 6) 0.003 1.751 (1, 6) 0.234 0.919 (1, 6)  0.375 
Slc6a4 
Solute carrier 
family 6 1.285 (3, 6) 0.362 0.391 2.976 (1, 6) 0.135 0.273 (1, 6) 0.620 0.434 (1, 6) 0.534 
Tph2 
Tryptophan 













NEXT GENERATION SEQUENCING ANALYSIS OF SOY GLYCEOLLINS AND 
17- ESTRADIOL: EFFECTS ON TRANSCRIPT ABUNDANCE IN THE FEMALE 
MOUSE BRAIN 
Introduction 
Glyceollins (Glys) are produced by soy plants in response to stressful conditions 
including fungal infections, UV exposure or changes in temperature. Research on Glys 
was initially focused on its anti-estrogenic actions through estrogen receptors (ERs), 
mainly ERα, suppressing estrogen-responsive breast and ovarian tumors both in vitro in 
cancer cell lines (Burow et al. 2001) and in vivo in mice (Salvo et al. 2006). Although 
some studies have shown that Glys can exhibit weak estrogenic activity at ERβ, thus 
promoting breast tumor proliferation (Kim et al. 2010a), Glys also exhibit non ER-
mediated effects, suppressing triple-negative tumors that lack ERs (Rhodes et al. 2012), 
increasing insulin-stimulated glucose uptake in adipocytes (Boue et al. 2012; Park et al. 
2010) and upregulating lipid metabolism genes in mammary tissue (Wood et al. 2012). A 
recent study showed that different isomers of Glys (e.g., Gly I, II and III) can possess 
antagonistic/agonistic actions at different human ERs, depending on the prenylation 
pattern of the isomers, the structure of the backbone and the length of the compound (van 
de Schans et al. 2016). For example, Gly I, II and III exhibit agonistic activity at ERβ, 




receptor (SERM)-like activity at ERα (van de Schans et al. 2016). Thus, Glys may not be 
purely anti-estrogenic but may possess SERM-like activity in a tissue- and/or condition-
dependent manner.  
Prior research did not focus on the effects of Glys in the brain, the mechanism of 
which is still unclear. We recently published data from a microarray experiment 
describing the effects of Glys on gene expression in the female mouse brain (Bamji et al. 
2015). Ovariectomized (ovx) mice were treated with 17-β estradiol (E2), Gly, both E2 
and Gly (E2+Gly), or negative control (Con). Differential gene expression analysis 
among treatment groups revealed that the gene expression patterns of the two E2 
treatments were the most similar, with Gly exhibiting a gene expression profile distinct 
from both E2 groups (Bamji et al. 2015). However, we did not observe statistically 
significant differences in expression among treatment groups for some of the genes of 
interest such as estrogen receptors (ERs), growth hormone (Gh) and prolactin (Prl) that 
are commonly affected by E2 treatment in the brain.  
Although microarrays have been powerful tools to study differential gene expression, 
there are limitations to the technique. The requirement of transcript-specific probes in 
microarrays inhibits the detection of novel gene transcripts, with the method relying 
heavily on prior knowledge of the genome sequence (Wang et al. 2009). Another issue is 
the differences in hybridization events or cross-hybridization among array probes, 
leading to high background signal for low expression transcripts and signal saturation for 
highly expressed transcripts (Fu et al. 2009; Mortazavi et al. 2008). Due to these 
limitations, RNA-Seq technology has gained momentum, offering a more robust 




efficiency of detecting differential gene expression, especially for transcripts that are 
either very high or very low in expression within cells. Moreover, RNA-Seq technology 
has been used to quantify transcript expression in the adult mouse brain, to evaluate 
parental biases in the expression of imprinted genes (Gregg et al. 2010), to detect 
differential gene expression in the mouse striatum (Bottomly et al. 2011) or to classify 
specific cell types in the mouse cortex and hippocampus (Zeisel et al. 2015). Given the 
clear benefits of using RNA-Seq technology over microarrays, we evaluated the 
usefulness of this technique to identify differential gene expression between treatments 
and hypothesized that Gly would oppose the effect of E2 on gene expression in the 
female mouse brain. Toward this end, we re-examined the mouse brain transcriptome 
using paired-end RNA sequencing performed on the Illumina GAIIx platform after 
treatment of ovx mice with E2, Gly, both E2 and Gly (E2+Gly), or negative control 
(Con), the same samples used in the prior microarray study. Overall, the genes regulated 
by E2 and Gly, independently and in combination, were involved in similar pathway 
maps and networks in both RNA-Seq and microarray experiments. Gly in some cases 
may oppose the effect of E2 on gene expression and vice versa, but Gly can also regulate 
genes similarly to E2  (e.g., if E2 upregulates the expression of a gene, Gly also 
upregulates the gene, although the magnitude of the effect may differ). Thus, Gly may 
not be a pure anti-estrogen, but may act as a selective estrogen receptor modulator 
(SERM) in the brain.  
Materials and Methods 




The raw reads and gene expression data have been deposited in the National Center for 
Biotechnology Information (accession no. GSE81336). 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=mtkpkkusrxmzfob&acc=GSE813
36) 
Study animals and experimental treatments  
Ovariectomized adult female Swiss Webster (CFW) mice were purchased from 
Charles River Laboratories, maintained on a 12L:12D photoperiod (lights on at 6:00 
AM), and given ad libitum access to phytoestrogen-reduced rodent chow (Teklad 2016, 
phytoestrogen levels range from less than detectable to 20ppm) and tap water. The 
animals were allowed to acclimate for one week before a 21-day slow-release pellet of 
0.1mg E2 or placebo (Innovative Research of America, Sarasota, FL) was implanted s.c. 
at the midline between neck and shoulders under isoflurane anesthesia followed by s.c. 
ketoprofen analgesia (day 1). Daily 50μl i.p. injections of 20mg/kg Gly or 1:1 
DMSO/PBS vehicle began on day 1 and continued every afternoon for 11 days. The Gly 
mixture (Gly I, II, and III) was isolated using a procedure described previously (Salvo et 
al. 2006). Three mice were in each of four treatment groups, which were as follows: 
placebo pellet + vehicle control (Con), placebo pellet + Gly (Gly), E2 pellet + vehicle 
(E2), and E2 pellet + Gly (E2+Gly).  
   On the morning of day 12, mice were weighed and then euthanized by 
decapitation under complete isoflurane anesthesia. Brain hemispheres were stored in 






 All protocols used for housing, handling, and euthanasia followed guidelines 
approved by the Guide for the Care and Use of Laboratory Animals: Eighth Edition 
(2011) (Council 2011) and were approved by the University of Louisville Institutional 
Animal Care and Use Committee (protocol number 11099). 
 
RNA isolation and microarray platform 
Total RNA was isolated from brain hemispheres of 3 mice per group using 
Trizol/chloroform extraction, followed by spin column purifications (Qiagen RNeasy 
midi kit) that included DNase (Qiagen) digestions. A Nanodrop 2000 spectrophotometer 
was used to assess sample purity and RNA concentration, and an Agilent Bioanalyzer 
was used to verify sample integrity (RIN 7.9 - 9).  RNA from mice in each treatment 
group was pooled into one sample each per treatment. The outliers detected in the 
microarray experiment through quality control analyses (Bamji et al. 2015) were not 
included in the pooled RNA samples, so RNA from only two biological replicates were 
pooled for the E2 and E2+Gly treatments. RNA samples were sent to Cofactor Genomics 
(St. Louis, MO) for processing and sequencing. Paired-end RNA sequencing was 
performed using the Illumina GAIIx platform (sequencer ID @HWI-ST522), generating 
50-bp raw sequence data.  
 
RNA-Seq Analysis 
Aligned RNA-Seq reads were assembled according to the mm10.gtf annotation file 
(downloaded from ENSEMBL using cufflinks, version 2.2.1). For the pairwise 




E2, E2+Gly vs Gly, Gly vs E2), both cufflinks assemblies were merged, and the resulting 
merged gtf file served as the transcript input for use in cufflinks and cuffdiff. For the 
comparisons of both E2 groups vs. non-E2 groups (E2 and E2+Gly vs Con and Gly) and 
both Gly groups vs. non-Gly groups (E2+Gly and Gly vs E2 and Con), both cufflinks 
assemblies were merged, and the resulting merged gtf file served as the transcript input 
for use in cufflinks and cuffdiff. 
Differentially expressed genes (DEGs) were then identified using a cut off log2FC ≥ 4 
by comparing the treated condition with the control using the tuxedo suite of programs 
included in cufflinks and cuffdiff (version 2.2.1). The DEGs in each treatment that had an 
FPKM value 0 in one treatment and an FPKM value < 1 in the other treatment, were 
eliminated from any further analysis. After the sorting, all 0 values in any treatment were 
replaced by the minimum FPKM value observed across all genes for that treatment (Con 
– 1.01 x10-6, E2 – 2.2 x10-6, Gly – 2.6 x10-7, E2+Gly – 4.72x10-7) in order to avoid a zero 
in the denominator when calculating FC.  
 
Enrichment analyses 
DEGs in the 8 different treatment comparisons were uploaded as separate files and 
analyzed using MetaCore version 6.18 software (www.portal.genego.com). The 
‘Enrichment Analysis’ function was then applied to each DEG list to identify genes that 
potentially affect biological pathways, maps or gene ontology (GO) terms. As we only 
used gene lists that were already deemed differentially expressed between treatment 








Overview of the RNA-Seq data 
We identified a total of 58,059 DEGs in 8 different treatment comparisons (E2 vs 
Con; Gly vs Con; E2+Gly vs Con; E2+Gly vs E2; E2+Gly vs Gly; E2 vs Gly; E2 and 
E2+Gly vs Con and Gly; Gly and E2+Gly vs E2 and Con) (Table 3.1). A combined view 
of the different treatments revealed that not only were the two E2 treatments (E2 and 
E2+Gly) most similar to each other in terms of gene expression, but also that Gly was 
similar to E2 in several cases (Fig.3.1). Some of the interesting patterns include: (1) Gly 
exhibiting a gene expression pattern similar to control, but opposing the E2 effect on 
gene expression in the E2+Gly group (i.e., a ‘classic’ anti-estrogenic response); (2) E2 
affecting gene expression similarly to control, but opposing the Gly effect on gene 
expression in the E2+Gly treatment, (3) Gly, E2 and E2+Gly showing similar gene 
expression patterns that are all different from control and (4) Gly and E2 patterns of gene 
expression being similar to each other and differing from control, but in combination 
(E2+Gly) being similar to control.   
 
Effect of E2 on gene expression 
To evaluate the overall effect of E2 on gene expression, we observed patterns in three 
different comparisons: (i) E2 vs Con (i.e., effect of E2 alone); (ii) E2+Gly vs Gly (i.e., 





Of the 8,223 DEGs that were identified in the E2 vs Con comparison, 5,505 genes 
were upregulated by E2 (Table 3.1). Enrichment analysis using MetaCore revealed that 
the genes upregulated by E2 compared to control were involved in signaling pathways 
including nociceptin receptor, angiotensin and neurohormone signaling. E2 also 
upregulated genes that play a role in general cystoskeletal remodeling, epigenetic 
regulation of gene expression, protein folding, cell cycle regulation and inflammation 
(Supplementary Table 3.1a).  E2 downregulated 2,718 genes compared to control (Table 
3.1) which are involved in signaling pathways including K-Ras, ERK1/2, STK3/4 and 
YAP/TAZ, PTMs in BAFF-induced signaling and cholecystokinin signaling 
(Supplementary Table 3.1a). E2 also downregulated genes that regulate cell adhesion, 
spermatogenesis, sperm motility and copulation (Supplementary Table 3.1a). 
Further, 8,705 genes were identified in the E2+Gly vs Gly comparison (Table 3.1). 
E2+Gly upregulated 4,647 DEGs compared to Gly, which are involved in pathways such 
as cytoskeletal remodeling, LRRK2 signaling, ESR1 signaling and neurogenesis 
(Supplementary Table 3.1b). E2+Gly downregulated 4,058 DEGs compared to Gly 
(Table 3.1), which are involved in immune responses, signal transduction pathways, 
cytoskeletal functions, protein folding and cell adhesion (Supplementary Table 3.1b). 
In addition, 4,514 DEGs were identified in a comparison of both the E2 groups (E2 
and E2+Gly) vs. the non-E2 groups (Gly and Con) (Table 3.1). Of these, 2,703 were 
upregulated in the E2 groups, some of which were enriched for pathways such as 
nociception receptor signaling and various neurophysiological processes (Supplementary 




DEGs, involved in signal transduction, immune response and neurophysiological 
pathways (Supplementary Table 3.1c). 
Overall, E2 alone or in combination with Gly upregulated genes involved in 
nociception receptor signaling and several neurophysiological processes like regulation 
of nerve impulse, hormone signaling, cytoskeletal remodeling, inflammation and cell 
cycle regulation. In addition, E2 downregulated genes involved in the LRRK2, Hippo and 
ERK1/2 pathways as well as genes involved in immune response and inflammatory 
pathways. 
 
Effects of Gly on gene expression 
To evaluate the overall effect of Gly on gene expression, we observed patterns in 
three different comparisons: (i) Gly vs Con (i.e., effect of Gly alone); (ii) E2+Gly vs E2 
(i.e., effect of Gly on E2); and (iii) Both Gly groups (Gly and E2+Gly) vs non-Gly groups 
(E2 and Con). 
In the Gly vs. Con comparison, we identified a total of 9,931 DEGs, of which 5,707 
were upregulated by Gly (Table 3.1). Enrichment analyses using MetaCore revealed that 
the genes upregulated by Gly vs. Con were involved in PKA signaling, renal water 
reabsorption, protein folding, cytoskeleton remodeling (PKA), immune responses and 
regulation of lipid metabolism (Supplementary Table 3.2a). Gly downregulated 4,224 
DEGs compared to Con, which are involved in pathways such as HBV signaling, 
cytoskeleton remodeling (TGF/WNT), Endothelin1/EDNRA signaling, PTEN signal 




Additionally, 6,079 DEGs were identified in the E2+Gly vs. E2 comparison, i.e., the 
effect of Gly on E2 signaling (Table 3.1). Of these, 2,520 DEGs were upregulated in the 
E2+Gly treatment, which were enriched for pathways such as ERK1/2, adenosine A2A 
receptor and G-protein (RAS family), FSH beta and amphoterin signaling 
(Supplementary Table 3.2a). Further, E2+Gly downregulated the expression of 3,559 
DEGs compared to E2. These downregulated DEGs were involved in pathways including 
immune responses, WNT signaling, neurogenesis and neurophysiological processes and 
cell adhesion (Supplementary Table 3.2b).   
Lastly, 3,857 DEGs were identified when the two Gly groups (Gly and E2+Gly) were 
compared to the non Gly groups (E2 and Con) (Table 3.1). There were 1,782 DEGs 
upregulated in the two Gly groups, which enriched for pathways including cytoskeleton 
remodeling, immune response, ESR1 signaling and neurophysiological processes 
(Supplementary Table 3.2c). Both Gly groups downregulated the expression of 2,075 
genes, some of which play a role in pathways such as Flt3 signaling, cytoskeleton 
remodeling, JNK signaling, cell adhesion and transcriptional regulation (Supplementary 
Table 3.2c).  
In summary, Gly upregulated genes belonging to signal transduction pathways (PKA, 
ESR1), regulation of nerve impulse, cytoskeletal remodeling, hormone signaling as well 
as genes involved in immune responses and lipid metabolism. In addition, Gly 
downregulated genes involved in developmental neurogenesis, synaptogenesis, cell 






The objective of this study was to determine the potential mechanisms of action of 
Gly alone and in combination with E2 by examining the mRNA transcriptome of female 
mice in the whole brain, using RNA-Seq technology and comparing results with those 
obtained from our whole brain microarray analysis. Even though our whole brain 
microarray study indicated that Gly might affect gene expression through both ER-
mediated and non ER-mediated mechanisms, we did not observe any statistically 
significant differential expression for some of our low expression genes of interest (e.g., 
ERs, Prl and Gh). ERs (Esr1, Esr2 and Gper1) are expressed throughout the brain and 
are all generally downregulated by E2. Gh and Prl are also widely distributed in the brain 
and are usually upregulated after E2 treatment. The lack of differential expression among 
treatments for ERs, Gh and Prl in the microarray analysis could possibly be due to the 
limitations of the technique in detection of low expression genes. We anticipated that 
with higher specificity and sensitivity in detection of differential expression, the RNA-
Seq technique would help us detect differences in expression of ERs, Gh and Prl, if any, 
among treatments. Additionally, we expected that RNA-Seq would give us a broader, 
more detailed perspective on the whole transcriptome effects of Gly on gene expression 
in the female mouse brain.  
Given the known anti-estrogenic effects of Gly in peripheral tissues, the initial 
hypothesis was that Gly by itself would have no effect compared to control, but would 
oppose the E2 effect on gene expression in the brain (i.e., significant differences in E2 vs 
Con and E2+Gly vs E2 comparison, but not the Gly vs Con comparison). Results from 




a few genes, as expected, but with an unexpected E2 opposition of the independent 
effects of Gly on gene expression as well (Bamji et al. 2015).  
The microarray analysis also indicated that Gly had the most distinct gene expression 
pattern, with both E2 and E2+Gly effects on gene expression being the most similar. The 
RNA-Seq analysis also indicated that both E2 groups had the most similar gene 
expression patterns. However, the RNA-Seq experiment additionally showed that for 
several genes, Gly affects gene expression similarly to E2 (in most cases both E2 and Gly 
upregulate the expression of genes) when compared to control, although the magnitude of 
the effect may differ. This difference in overall expression patterns in the microarray vs. 
the RNA-Seq results can be attributed to a difference in analytical methods, the 
presence/absence of biological replicates and the differences in gene lists between the 
two experiments. Thus, it is important to note that the microarray analysis was performed 
using a two-factor ANOVA with biological replicates (N=2-3 per treatment) whereas the 
RNA-Seq analysis was performed using a one-factor ANOVA design with pooled RNA 
from biological replicates (N=1 per treatment). Further, we are comparing a list of 279 
DEGs identified as significant in the microarray experiment with a list of over 58,000 
DEGs identified in the RNA-Seq experiment. Nevertheless, we observed some 
similarities between the RNA-Seq and microarray experiments. First, both methods 
identified Gly’s opposition of the E2 effect on gene expression and E2 opposing the Gly 
effect on gene expression. Second, a comparison of the E2-regulated and Gly-regulated 
genes from the microarray and RNA-Seq analyses revealed common DEGs that were 
identified in both experiments. Sixty-four DEGs with significant E2 effects and 50 DEGs 




Finally, the most highly upregulated gene by Gly in our microarray data, Nr4a1 (FC = 
1.89), was similarly upregulated by Gly compared to Con in the RNA-Seq data (FC = 
2.32), with E2 opposition of the Gly upregulation, but this effect was not found to be 
statistically significant.  Thus, while there was some agreement of the RNA-Seq results 
with those of the microarray, the RNA-Seq experiment revealed Gly regulation of gene 
expression that was more similar to E2 than the microarray results suggested. 
Estrogens regulate numerous functions in the brain including reproduction 
(Wintermantel et al. 2006), food intake (Brown and Clegg 2010), cognition (Daniel 2013) 
neuronal synaptic plasticity (Li et al. 2004) and pain perception (nociception) (Craft et al. 
2004) through ERs distributed throughout the brain (Mitra et al. 2003). Hence, 
unsurprisingly, E2 upregulated the expression of genes involved in hormone signaling, 
nociception receptor signaling, cytoskeletal remodeling, regulation of nerve impulse, 
inflammation and cell cycle regulation (Supplementary Table 3.1a-c). Interestingly, E2 
downregulated genes involved in the Hippo (YAP/TAZ) pathway that regulates organ 
growth, cell function and regeneration as well as tumor suppression (Johnson and Halder 
2014), which is unsurprising given the ability of E2 to promote tumor proliferation. 
Previous work has shown that E2 often downregulates the expression of its classical 
receptors, Esr1 and Esr2, but the effects may differ by brain region, timing, sex and 
species (Lauber et al. 1991; Nomura et al. 2003; Patisaul et al. 1999; Simerly and Young 
1991). Neither of the classical ERs were found to be differentially expressed in the RNA-
Seq experiment, which is similar to our microarray results (Bamji et al. 2015). E2 also 
exerts rapid effects such as kinase activation, calcium mobilization and rapid 




(Prossnitz and Maggiolini 2009). Like the classical ERs, Gper1 was also not 
differentially expressed in any of the treatment comparisons in the RNA-Seq experiment. 
Considering that the expression of the different ERs is highly brain-region specific and 
that we are measuring gene expression across the whole brain, this result is perhaps to be 
expected. Future studies focused on brain-region specific effects on gene expression may 
reveal a clearer picture of the effects of Gly alone and in combination with E2 on 
expression of ERs in the mouse brain. 
In addition to ERs, other E2-responsive genes (Gh, Prl) were detected as 
differentially expressed in RNA-Seq, unlike in the microarray study. E2 is known to 
upregulate Gh and Prl expression in the rodent brain (Addison and Rissman 2012; Torner 
et al. 1999), and we expected to see Gly opposition of this E2 upregulation. 
Unsurprisingly, E2 upregulated both Gh and Prl compared to Con (Table 3.2). It should 
be noted here that the high FC values observed for both Gh and Prl are due to the fact 
that there was little to no expression (FPKM values < 0.0018) of either of these genes in 
the Con treatment. Thus, the small increases in FPKM values in the treated (E2) 
condition (e.g., Prl FPKM = 1.15 and Gh FPKM = 7.77 in the E2 treatment) led to high 
FC values that are misleading regarding absolute expression. Surprisingly, Gly alone 
slightly upregulated Gh compared to Con, but when combined with E2 (E2+Gly), Gh 
expression did not reach that stimulated by E2 alone compared to Con (Table 3.2). On the 
other hand, Gly downregulated Prl compared to Con, and in combination with E2, 
completely opposed the E2 upregulation of Prl in the E2+Gly treatment (Table 3.2).  
Neither Gh nor Prl were differentially expressed in the Gly vs. Con comparison, and the 




and 0.15% of E2 vs Con for Prl expression. Therefore, Gly alone had no pronounced 
effect on Gh or Prl gene expression compared to Con, but in combination with E2, Gly 
exhibited an anti-estrogenic effect. This result is in agreement with Gly’s anti-estrogenic 
activity in other cell types, e.g. MCF-7 breast cancer cells (Burow et al. 2001; Salvo et al. 
2006). 
The RNA-Seq experiment revealed a pattern of Gly regulation of genes in the female 
mouse brain that was not observed in the microarray study. Gly upregulated genes that 
are involved in hormone signaling, cytoskeletal remodeling, regulation of nerve impulse 
and immune responses (Supplementary Table 3.2a-c), which was similar to the pathway 
maps/networks regulated by E2 in the brain. For example, the brain-specific insulin gene 
Ins2 was upregulated by both E2 (FC = 1,227,422) and Gly (1,600,791) compared to Con 
and is potentially involved in learning and memory as well as food intake (Mehran et al. 
2012). As mentioned earlier for Gh and Prl, the high FC values observed for Ins2 are also 
due to little to no expression of this gene in the Con treatment. Gly also upregulated 
genes involved in lipid metabolism, specifically insulin’s regulation of glycogen 
metabolism, which is not true of E2 treatment. This is interesting as neuronal glycogen 
accumulation is associated with neurodegeneration and glycogen metabolism is 
important, especially under stressful conditions in the mouse brain (Duran and Guinovart 
2015). Moreover, this finding is in agreement with a prior study that showed upregulation 
of lipid metabolism genes in mammary gland tissues of postmenopausal female 
cynomolgus monkeys that were fed a Gly-rich soy diet (Wood et al. 2012). Interestingly, 
Gly downregulated some pro-apoptotic genes in the PTEN-signaling pathway (e.g., Bad 




showed that neuronal apoptosis in the developing rat brain after hypoxia-ischemia (HI) 
involves the PTEN-Akt-FOXO3 signaling pathway (Li et al. 2009). The study suggested 
that PTEN inhibition followed by downregulation of bcl2-interacting-mediator of cell 
death (Bim) attenuated apoptosis in rat neurons and may play a neuroprotective role in 
the rat brain after HI (Li et al. 2009). Gly also downregulated genes involved in 
synaptogenesis and neurogenesis. One example of a Gly-downregulated gene is 
synaptophysin (Syp), which is involved in formation, exocytosis and endocytosis of 
synaptic vesicles (Kwon and Chapman 2011) and is usually upregulated by E2 (Frick et 
al. 2002). Of importance is the fact that, like the microarray data, the RNA-Seq data also 
revealed that Gly by itself, compared to Con, regulates the expression of many more 
genes than when the two Gly groups (Gly and E2+Gly) are compared to the non-Gly 
groups (E2 and Con); the difference in these two sets of comparisons is the addition of E2 
treatment in the latter (Table 3.1). Thus, in some cases, Gly may act similarly to E2, 
while in other cases, Gly exhibits either anti-estrogenic or non E2-like effects on gene 
expression in the brain. 
Although 3 biological replicates of whole brain homogenates were pooled in the 
RNA-Seq experiment and thus a direct comparison of the RNA-Seq and microarray 
results cannot be made, the genes regulated by E2 and Gly independently and in 
combination were enriched for similar pathway maps and networks in both studies. 
Moreover, unlike the microarray study, RNA-Seq enabled the detection of differential 
expression of low expression genes like Prl and Gh, both of which are expressed in the 




(Addison and Rissman 2012; Torner et al. 1999) and in the current study serve as 
examples of Gly’s anti-estrogenic effects in the brain.  
The mechanism by which Gly affects gene expression in the brain is still unclear. To 
gain a deeper understanding of Gly’s mechanisms of action in the female mouse brain, 
future studies should focus on 1) evaluating the effects of Gly on gene expression in 
specific brain regions, 2) using brain-specific ER-knockout mice to identify which of 
Gly’s effects are ER-mediated vs. non ER-mediated and 3) using a neuronal cell culture 
system to test if Gly affects gene expression directly at the neuron or through an indirect 







Fig. 3.1: Heat map of 15,000 DEGs (rows) with log2FC ≥ 4 for at least one comparison 
and FPKM ≥ 1. Columns correspond to pooled treatment groups (L-R): Control, Gly, E2 
and E2+Gly. Black to red = downregulation of a given gene (row); orange = average 
expression of a gene; yellow to white = upregulation relative to the average expression 






















Table 3.1. Number of DEGs identified in 8 different treatment comparisons using a 
log2FC ≥ 4 cut off in the RNA-Seq experiment. 
Comparisons Total Upregulated Downregulated 
E2 vs Control 8223 5505 2718 
Gly vs Control 9931 5707 4224 
E2+Gly vs Control 9900 5968 3932 
E2+Gly vs E2 6079 2520 3559 
E2+Gly vs Gly 8705 4647 4058 
Gly vs E2 6850 4237 2613 
E2 groups vs Non-E2 groups 4514 2703 1811 
Gly groups vs Non-Gly groups 3857 1782 2075 
Differentially expressed genes (DEGs) identified using log2FC ≥ 4 cut off. E2 groups (E2 
and E2+Gly); Non-E2 groups (Gly and Con); Gly groups (Gly and E2+Gly); Non-Gly 
groups (E2 and Con)  
 
 
Table 3.2. Fold change values for Gh and Prl compared to Con.  
 
 E2 vs Con Gly vs Con E2+Gly vs Con 
Gh *7,685,409 1.66 64870 
Prl *648 0.58 1 











Supplementary Table 3.1a. E2 vs Con effects on gene expression in the whole female 
mouse brain. RNA samples from different animals within each treatment were pooled 
into one sample per treatment group. Pathway maps/process networks were obtained 
using the “enrichment analysis” function in MetaCore 6.18 and only ones with the top 5 
highest z-scores are reported. 
Direction Pathway maps/ Process 
networks 
Genes 
Upregulated Nociception – Nociceptin receptor 
signaling 
Adrbk1, Arrb1, Cacna1b, Cacng5, Fos, 
Gnao1, Jak1, Jak2, Limk1, Limk2, Mapk1, 
Mapk9, Pla2g4c, Prkar1a, Prkcg, Rps6ka1, 
Src   
 Development – Angiotensin signaling 
via beta-Arrestin 
Adrbk1, Ap2b1, Arrb1, Arrb2, Calm2, 
Map3k5, Mapk1, Mapk10, Mdm2, Prkcg, Src 
 Cytoskeleton remodeling Actn4, Csnk2b, Eif4a2, Eif4g1, Eif4g3, Ilk, 
Itgav, Limk1, Limk2, Mapk1, Myh10, Myl1, 
Myl9, Paxn, Pik3r2, Pip5k1c, Ptk2, Smad3, 
Src 
 Transcription – Epigenetic regulation 
of gene expression 
Ehmt2, H3f3a, Hdac6, Hdac8, Kat2a, Kat2b, 
Kat6b, Kat7, Kdm3a, Kdm4c, Kdm5c, 
Kmt2a, Prmt5, Sirt3, Smyd2 
 Neurophysiological process – ACM 
regulation of nerve impulse 
Cacna1a, Cacna1b, Cacna1c, Cacna1g, 
Cacna1h, Calm2, Fkbp1a, Gnao1, Plcb4, 
Ppp3cb, Prkar1b, Prkcg, Trpc3 
 Protein folding and maturation – 
insulin processing 
Ins2 
 Cell cycle G1-S – Growth factor 
regulation 
Akt1, Akt2, Akt3, Ccnd3, E2f1, Erbb2, Fgfr1, 
Fos, Foxn3, Gsk3a, Ikbkb, Jak2, Mapk1, 
Mapk9, Prkcg, Ptk2, Src  
 Inflammation – Amphoterin signaling Akt1, Akt2, Akt3, Ccl12, Hmgb1, Ikbkb, 
Ikbkg, Irak1, Irak2, Itgam, Limk1, Limk2, 
Mapk1, Mapk8, Mapk9, Mapk10, Myl1, Myl9 
 Reproduction, feeding and 
neurohormone signaling 
Adam9, Akt2, Calm2, Ccnd3, Cpeb1, 
Csnk2b, Fos, Gnao1, H3f3a, Hspa9, Ide, 
Itgam, Ptk2, Slpi, Src, Stx2  
Downregulated K-RAS signaling in pancreatic cancer Akt2, Braf, Cdkn1a, Chuk, Exoc2, Kras, 
Map2k2, Pdpk1, Pten, Rac1, Raf1, Ralgds, 
Tiam1, Vegfa 
 Signal Transduction – ERK1/2 
signaling pathway 
Araf, Braf, Grb10, Kras, Map2k2, Mras, 
Prkcd, Raf1, Rapgef3, Rapgef4 
 Development – Positive regulation of 
STK3/4 (Hippo) pathway and 
Actb, Actg1, Adcy3, Adcy7, Amotl2, Crb3, 




negative regulation of YAP/TAZ 
function 
Prkab1, Prkar1a, Prkar1b, Raf1, Rassf5, 
Stk4, Stk11, Yap1 
 Signal Transduction – PTMs in BAFF-
induced signaling 
Akt2, Bcl2l11, Foxo3, Map2k2, Map2k4, 
Map2k7, Mapk14, Pdpk1, Pim2, Prkcd, 
Raf1, Tnfrsf13b, Trim2 
 Signal transduction – Cholecystokinin 
signaling 
Adcy3, Adcy7, Akt2, Chuk, Fgfr2, Gnag, 
Map2k2, Mras, Oprl1, Oprm1, Plce1, 
Prkar1b, Prkacb, Ptk2b, Rac1, Raf1, Sp1, 
Src 
 Cell adhesion – Cell junctions Actb, Actg1, Actn4, Arhgef2, Cask, Cdh4, 
Cgn, Crb3, Csnk2a1, Ctnnb1, Ctnnd1, 
Epb41, Erbb2ip, Fer, Git1, Git2, Gjc1, Inadl, 
Jup, Mpdz, Mtdh, Ocln, Plcg1, Prkcd, Prkci, 
Prkd3, Ptn, Rac1, Sp1, Src, Tiam1, Zeb2 
 Reproduction - spermatogenesis, 
copulation and motility 
Adcy7, Akt2, Bmpr1a, Brd2, Brd7, Cacna1i, 
Csnk2a1, Daxx, Ddc, Dnmt3a, Fancg, 
Fkbp4, Ggt1, Gpx4, Hmga1, Hspa4, 
Mapk14, Nr6a1, Prkacb, Prkar1b, Prkcd, 
Prkci, Prkd3, Raf1, Src, Rapgef3, Rapgef4, 


















Supplementary Table 3.1b. E2+Gly vs Gly effects on gene expression in the whole 
female mouse brain. RNA samples from different animals within each treatment were 
pooled into one sample per treatment group. Pathway maps/process networks were 
obtained using the “enrichment analysis” function in MetaCore 6.18 and only ones with 
the top 5 highest z-scores are reported. 




remodeling - TGF, WNT 
and cytoskeletal 
remodeling 
Actn4, Akt1, Axin2, Cav1, Ccnd1, Col4a1, Ctnnb1, Dvl1, 
Grb2, Gsk3b, Ilk, Limk2, Map2k1, Map2k2, Map3k7, 
Mdm2, Myl12a, Mylpf, Pik3cd, Pik3r2, Ppard, Rac1, Raf1, 
Sos2, Sp1, Src, Tcf7l1, Tcf7l2, Tln1, Vegfa 
 LRRK2 in neurons in 
Parkinson's disease 
Actg1, Ap2a1, Ap2b1, Cdk5rap2, Cltc, Gsk3b, Hsp90ab1, 
Lrrk2, Map2k1, Mapk1, Mapk3, Mapt, Mark2, Nsf, Prkacb, 
Rac1 
 Signal Transduction – 
ESR1 signaling pathway 
Adcy3, Bcas3, Bcl11a, Bloc1s1, Cav1, Ccnd1, Ccng2, 
Cdc25b, Ddx5, Erbb4, Gsk3b, Hdac1, Isl1, Kmt2d, Maob, 
Map2k1, Map2k2, Mapk1, Med1, Msh2, Mta1, Mta2, 
Ncoa2, Ncoa5, Ncoa6, Ncor1, Nrip1, Pelp1, Phb2, Pik3ca, 
Pik3r2, Ppargc1b, Prkacb, Prkar1a, Prmt2, Raf1, Rara, 
Rexo4, Rps6ka1, Rxra, Safb2, Smad3, Smd4, Socs3, 
Sos2, Sp1, Src, Stat5b, Tbp, Tcf20, Ube2d2a, Vegfa 
 Development 
Neurogenesis – Axonal 
guidance 
Ablim1, Actb, Actg1, Adam10, Adam17, Adam23, 
Adcyap1r1, Arhgap26, Baiap2, Braf, Calm1, Dctn1, Efna1, 
Efnb1, Epha7, Ephb2, Evl, Fez1, Gas7, Gda, Itgb2, Itpr2, 
L1cam, Limk2, Map2k1, Map2k2, Mapk1, Mical1, Myl1, 
Ngf, Nrp2, Pik3cd, Plcb4, Plxnd1, Ppp1cc, Ppp1r1b, 
Ppp3ca, Prkar1a, Prkca, Rac1, Rapgef3, Rapgef4, 
Rps6ka3, Rtn4, Sdcbp, Sema6d, Sema4d, Sepp1, Unc5c, 
Vasp, Wasf2 
Downregulated Immune response – 
Platelet activating factor/ 
PTAFR pathway 
signaling 
Actb, Chuk, Il1b, Jak2, Map3k5, Mapk14, Nfatc2, Stat2 
 Signal transduction – 
Erk Interactions: 
Inhibition of Erk 
Dusp1, Dusp3, Dusp7, Dusp16, Prkcd, Prkce, Prkcz, 
Ptpn5, Ptprr, Vrk3 
 Signal transduction – 
PTMs (phosphorylation 
in TNF-alpha induced 
NF-kB signaling 
Akt1, Azi2, Chuk, Csnk2a1, Ikbkg, Map3k14, Pik3r2, Prkcd, 
Prkcec, Tab2, Tnfrsf1a 
 Cytoskeleton – Actin 
filaments 
Ablim1, Actb, Ank3, Cdc42bpa, Cttn, Diap1, Epb41, 
Fermt2, Flna, Klhl20, Kptn, Lasp1, Limk1, Myh10, Myl1, 
Mylk3, Myo1b, Myo1c, Myo6, Nebl, Pacsin2, Pacsin3, 

























 Protein folding – Protein 
folding nucleus 
Csnk2a1, Ctnnb1, Dnajc1, Faf1, Fkbp1a, Fkbp8, Hcfc1, 
Hdac1, Hdac2, Hnrnpd, Hsp90aa1, Hsp90ab1, Hsp90b1, 
Hspa8, Hyou1, Nfya, Npm1, Park7, Ppp3ca, Rbbp4, 
Rbbp7, Ruvbl2, Taf1, Taf3, Tbp, Trap1 
 Cell adhesion – 
Synaptic contact 
Actb, Anxa4, Ctnnb1, Ctnnd1, Cttn, Dlgap4, Dnm2, Epb41, 
Grik2, Grip1, Grm1, Homer3, Itsn1, Kcnj3, Kcnj13, Lin7a, 
Nrxn1, Ocln, Opcml, Pfn2, Shank3, Sharpin, Stx8, Stx16, 




Supplementary Table 3.1c. Gene expression in E2 groups (E2, E2+Gly) vs Non-E2 (Gly, 
Con) groups in the whole female mouse brain. RNA samples from different animals 
within each treatment were pooled into one sample per treatment group. Pathway 
maps/process networks were obtained using the “enrichment analysis” function in 
MetaCore 6.18 and only ones with the top 5 highest z-scores are reported. 
Direction Pathway maps/ Process 
networks 
Genes 
Upregulated Nociception – Nociceptin 
receptor signaling 
Adrbk1, Arrb1, Cacna1a, Cacna2d1, 
Cacnb1, Cacng5, Gna15, Gnao1, Limk2, 
Mapk9, Plcb1, Prkacb, Prkar1a, Prkcg, 
Rac1, Th 
 Neurophysiological process – 
ACM regulation of nerve impulse 
Cacna1a, Cacna1g, Fkbp1a, Gnao1, Itpr2, 
Plcb1, Ppp3cb, Prkacb, Prkar1a, Trpc3  
 Neurophysiological process – 
Constitutive and regulated 
NMDA receptor trafficking 
Cask, Dlg1, Dlg3, Dlg4, Exoc4, Gnao1, 
Itpr2, Plcb1, Ppp1r1b, Ppp3cb, Prkacb, 
Prkar1a 
 Neurophysiological process – 
Synaptic vesicle fusion and 
recycling in nerve terminals 
Ap2b1, Ap2m1, Cacna1a, Dnm1, Nsf, 
Pip5k1c, Ppp3cb, Snap91, Snapin, Syp, 
Syt1 
 Neurophysiological process – 
Activity-dependent synaptic 
AMPA receptor removal 
Ap2a1, Ap2b1, Ap2m1, Dlg4, Dnm2, 
Gria1, Itpr2, Nsf, Pip5k1c, Plcb1, Ppp3cb 
 Neurophysiological process – 
Dynein-dynactin motor complex 
in axonal transport in neurons 
Actr1b, Dctn1, Dync1i1, Dync1i2, Dynlt3, 
Kpna1, Ntrk3, Osbpl1a, Snapin 
Downregulated Signal transduction – Additional 
pathways of NF-kB activation (in 
the cytoplasm) 
Adcy3, Akt1, Akt2, Akt3, Map3k3, Pdpk1, 
Pik3r2, Prkcd, Prkce, Prkci, Rps6ka1, Src 
 Immune response – IL-15 
signaling 
Adam17, Akt1, Akt2, Akt3, Il15ra, Mknk1, 
Pdpk1, Pik3r2, Prkce, Rps6kb2, Src 
 Signal transduction – PTMs 
(phosphorylation) in TNF alpha-
induced NF-kB signaling 
Adam17, Adcy3, Akt1, Pdpk1, Pik3r2, 
Prkcd, Prkce, Src 
 Neurophysiological process – 
NMDA-dependent postsynaptic 
long term potentiation in CA1 
hippocampal neurons 
Akt1, Akt2, Akt3, Braf, Grin2a, Grm1, 






Supplementary Table 3.2a. Gly vs Con effects on gene expression in the whole female 
mouse brain. RNA samples from different animals within each treatment were pooled 
into one sample per treatment group. Pathway maps/process networks were obtained 
using the “enrichment analysis” function in MetaCore 6.18 and only ones with the top 5 
highest z-scores are reported.  
Direction Pathway maps/ Process 
networks 
Genes 
Upregulated Signal transduction – PKA 
signaling 
Akap2, Akap7, Akap11, Akap13, Gnao1, Gnas, 
Pde4a, Pdpk1, Phkg1, Phkg2, Pkig, Ppp1r1b, 
Ppp2r2c, Ppp2r4, Ppp2r5b, Prkar2b, Rps6ka1, Smad3 
 Transport – Role of AVP in 
regulation of Aquaporin 2 and 
renal water reabsorption 
Akap7, Calm2, Fos, Gnas, Mapk14, Mylk3, Prkar2b, 
Sipa1, Stx4a, Tpm1  
 Protein folding and maturation 
– Insulin processing 
Ins2 
 Cytoskeleton remodeling – 
Role pf PKA in cytoskeleton 
reorganization 
Abl1, Add1, Akap13, Calm2, Gnas, Lasp1, Limk1, 
Mylk3, Pak1, Pxn, Vasp  
 Immune response – Platelet 
activating factor/ PTAFR 
pathway signaling 
Akt1, Arrb1, Chuk, Gnao1, Il1b, Jak2, Map2k3, 
Map3k5, Mapk14, Nfatc2, Nfkb1 
 Regulation of lipid metabolism 
– Insulin regulation of glycogen 
metabolism 
Akt1, Akt2, Calm2, Gck, Gys2, Ins2, Pdpk1, Phkg1, 
Phkg2, Pygm, Rps6ka1  
Downregulated HBV signaling via protein 
kinases leading to HCC 
Hras, Igf2, Jak1, Map2k2, Map2k4, Map3k1, Mapk1, 
Mapk8, Mapk10, Prkca, Prkci, Prkd2, Prkd3, Ptk2b, 
Raf1, Sos2, Sp1, Src   
 Cytoskeleton remodeling – 
TGF, WNT and cytoskeletal 
remodeling 
Actg1, Actn4, Cav1, Cdkn1a, Csnk2a1, Ctnnb1, Dvl1, 
Foxo3, Gsk3b, Hras, Limk2, Map2k2, Map3k7, Mapk1, 
Mdm2, Mknk1, Myc, Myl12a, Mylpf, Pik3cd, Pik3r3, 
Rac1, Raf1, Sos2, Sp1, Src, Tcf7, Tcf7l1, Tcf7l2, 
Vegfa, Wnt5b 
 Development – Endothelin-
1/EDNRA signaling 
Adcy3, Adcy7, Ccnd1, Ctnnb1, Gnaq, Gsk3b, Hras, 
Map2k2, Map2k4, Map3k1, Mapk1, Mapk8, Pik3cd, 
Pik3r2, Ptk2b, Rac1, Raf1, Sos2, Src  
 Signal transduction – PTEN 
pathway 
Bad, Cdkn1a, Ctnnb1, Foxo3, Gsk3b, Hras, Igf1, 
Magi2, Map2k2, Mapk1, Mdm2, Pcna, Pik3cd, Pik3r3, 
Raf1, Sos2, Src, Tcf7, Tcf7l1, Tcf7l2 
 Development – Neurogenesis 
and synaptogenesis 
Actg1, Adarb1, Agrn, Atn1, Dlg3, Dlgap2, Fgf7, Kcng2, 
Nlgn2, Nos1, Nrg4, Park2, Ppfia1, Prkca, Rims3, 




Supplementary Table 3.2b. E2+Gly vs E2 effects on gene expression in the whole female 
mouse brain. RNA samples from different animals within each treatment were pooled 
into one sample per treatment group. Pathway maps/process networks were obtained 
using the “enrichment analysis” function in MetaCore 6.18 and only ones with the top 5 
highest z-scores are reported. 
Direction Pathway maps/ Process networks Genes 
Upregulated Signal transduction – ERK1/2 
signaling pathway 
Araf, Braf, Grb10, Map2k1, Map2k2, Mapk3, Mras, 
Raf1, Rapgef3, Rapgef4, Sos2 
 Development – Adenosine A2A 
receptor signaling 
Braf, Chuk, Gnas, Ikbkb, Map2k1, Map2k2, Mapk3, 
Mapk14, Nfkb1, Pak1, Prkacb, Prkar1b, Prkcz, 
Rapgef3, Rps6ka3   
 Cytoskeleton remodeling Col4a1, Csnk2a1, Ctnnb1, Eif4g1, Flna, Map2k2, 
Map2k3, Mapk3, Mapk14, Mknk1, Myl12a, Mylpf, Pak1, 
Pip5k1c, Pten, Rac1, Raf1, Smad3, Sos2, Tln2, Vegfa  
 G-protein signaling – Ras family 
GTPases in kinase cascades 
(schema) 
Braf, Map2k1, Map2k2, Map2k3, Map2k4, Mapk3, 
Mapk14, Pak1, Rac1 
 
 Reproduction – FSH beta signaling 
pathway 
Acvr1, Adcy3, Chuk, Ctgf, Etv4, Gnas, Map2k1, 
Map2k2, Map2k3, Mapk3, Nfkb1, Ppp2r1a, Prkacb, 
Raf1, Ror2, Rps6ka3, Sp1, Tgm2, Vegfa 
 Inflammation – Amphoterin signaling Chuk, Ikbkb, Itgb2, Map2k1, Map2k2, Mapk3, Nfkb1, 
Pak1, Rac1, Raf1, Sp1    
Downregulated Immune response – Platelet 
activating factor/ PTAFR pathway 
signaling 
Actb, Akt1, Akt2, Arrb1, Arrb2, Ccl12, Gnao1, Gnb2, 
Jak2, Lsp1, Map3k5, Pik3r2, Plcb4, Ppp3ca, Src, Stat2, 
Stat5a 
 Development – WNT signaling 
pathway, degradation of beta catenin 
in the absence of WNT signaling 
Apc, Csnk1d, Csnk1e, Ctbp2, Fbxw11, Lef1, Tcf7l2 
 Neurophysiological process – 
Dynein-dynactin motor complex in 
axonal transport in neurons 
Akt1, Akt2, Dync1i1, Dync1i2, Hap1, Hdac6, Kpna4, 
Mapk8ip3, Mapk10, Nde1, Ntf3, Ntrk3, Osbpl1a, Prnp 
 Cell adhesion – Synaptic contact Actb, Actn4, Dlg1, Dlgap4, Dnm2, Epb41, Grip1, Grm1, 
Kalrn, Kcnj13, Kcnj16, L1cam, Lin7a, Nlgn2, Nrxn1, 
Nrxn3, Shank3, Sptan1, Stx16, Synpo, Tanc1, Tip1 
 Development – Neurogenesis and 
synaptogenesis 
Actb, Dlg1, Dvl3, Fgfr2, Grip1, Grm1, Lin7a, Lrp8, Mog, 
Nlgn2, Nrg2, Nrxn1, Nrxn3, Nsf, Ntf3, Ntrk3, Park2, 
Ppfia3, Shank3, Stx16, Synpo, Syp, Tbr1, Wnt5a 
 Regulation of CFTR activity (normal 
and CF) 
Adcy3, Flna, Gnas, Ppp2r1a, Ppp2r4, Ppm1d, Prkab1, 




Supplementary Table 3.2c. Gene expression in Gly groups (Gly, E2+Gly) vs Non-Gly 
(E2, Con) groups in the whole female mouse brain. RNA samples from different animals 
within each treatment were pooled into one sample per treatment group. Pathway 
maps/process networks were obtained using the “enrichment analysis” function in 
MetaCore 6.18 and only ones with the top 5 highest z-scores are reported. 
Direction Pathway maps/ Process networks Genes 
Upregulated Cytoskeleton remodeling Ctnnb1, Eif4a1, Eif4g1, Eif4g3, Flna, Mknk1, Myl2, 
Mylpf, Pak1, Pik3r2, Pip5k1c, Rac1, Smad3 
 Immune response – CD28 
signaling 
Akt1, Nfatc2, Nfkb1, Pak1, Pik3r2, Pip5k1c, Rac1  
 Mitogenic action of Estradiol/ ESR1 
(nuclear) in breast cancer 
Carm1, Ccne, Chd8, Nfya, Pou2f1, Ppm1d  
 Immune response – Phagosome in 
antigen presentation 
Derl2, Hsp90b1, Nfkb1, Pak1, Pik3r2, Psme4, 
Rac1, Ralgds, Vasp 
 Neurophysiological process – 
Transmission of nerve impulse 
Agtr2, Dlg4, Gnas, Gria1, Gria3, Grik2, Homer3, 
Kcnma1, Trim28 
Downregulated Development – Flt3 signaling Atf2, Bad, Flt3l, Hras, Map2k3, Map2k7, Map3k1, 
Mapk8, Mapk14, , Pdpk1, Src  
 Cytoskeleton remodeling – 
Reverse signaling by ephrin B 
Actg1, Ephb4, Gnb1, Gnb2, Gnb4, Gng7, Gngt2, 
Hras, Ilk, Mapt, Pxn, Rgs3, Src, Wipf1 
 Signal transduction – JNK pathway Atf2, Daxx, Hras, Map2k7, Map3k7, Map3k1, 
Map3k12, Map4k2, Mapk8, Tnfrsf1a  
 Neuroprotective action of lithium Atf2, Bdnf, Grin2a, Hspa5, Map2k3, Map2k7, 
Mapk8, Mapk14, Mapt, Ptk2b, Src  
 Cell adhesion – Synaptic contact Actg1, Actn4, Dlg1, Dlgap4, Dnm2, Epb41, Itsn1, 
Kalrn, Kcnj16, Nrxn3, Ntm, Sdcbp, Shank1, 
Sharpin, Sptan1, Syt3, Syt6, Tanc1  
 Reproduction – Spermatogenesis, 
motility and copulation 
Arsa, Atf2, Brd2, Cacna1i, Crem, Daxx, Dbh, 
Fkbp4, Gpx4, H2afz, Hras, Hspa5, Map3k7, 
Mapk14, Mkks, Myc, Ncoa4, Odf2l, Sp1, Spag4, 
Spag9, Src, Xrn2  
 Transcription – Nuclear receptors 
transcriptional regulation 
Hmgb1, Hras, Map2k3, Map3k1, Map3k7, Mapk14, 










ACUTE VS. CHRONIC EXPOSURE TO SOY GLYCEOLLINS AFFECTS MRNA 
EXPRESSION OF ESTROGEN RECEPTOR–REGULATED GENES IN DISTINCT 
BRAIN REGIONS OF THE FEMALE MOUSE 
Introduction 
Glyceollins (Gly) are phytoalexins produced by soy plants in response to stressful 
stimuli including fungal infections, exposure to UV or changes in temperature. Research 
on Gly gained momentum mainly because, unlike other soy compounds such as genistein 
and daidzein that exhibit estrogenic properties, Gly exhibited anti-estrogenic effects. Gly 
opposes the effects of 17-β estradiol (E2) in vitro in cancer cell lines as well as in vivo in 
peripheral tissues through action at estrogen receptors (ERs), mainly ERα (Zimmermann 
et al. 2010). For example, Gly suppresses E2-responsive breast (MCF-7) and ovarian 
(BG-1) tumors both in vitro and in vivo (Burow et al. 2001; Salvo et al. 2006) and 
decreases E2-stimulated uterine growth in vivo (Salvo et al. 2006). However, other 
studies suggested that Gly can have weak estrogenic activity at ERβ, thereby promoting 
proliferation of MCF-7 breast tumors in vitro (Kim et al. 2010a). A recent study showed 
that different Gly isomers (e.g., Gly I, II and III) possess antagonistic/agonistic actions at 
different human ERs, depending on the prenylation pattern of the isomers, the structure 
of the backbone and the length of the compound, with the effects being selective estrogen 




(van de Schans et al. 2016). Thus it is likely that Gly acts like a SERM, with 
antagonistic/agonistic action at ERs in a tissue- and/or condition-dependent manner. 
Although Gly is well known for its ER-mediated effects, Glys also exhibit non 
ER-mediated effects. Some examples include suppression of triple-negative breast 
carcinomas (which lack ERs) (Rhodes et al. 2012); increasing insulin-stimulated glucose 
uptake in 3T3-L1 adipocytes (Boue et al. 2012; Park et al. 2010); decreasing blood 
glucose levels in rodents (Park et al. 2012); increasing lipid metabolism gene expression 
(Wood et al. 2012); inhibiting lipid peroxidation in rat brain, kidney and liver extracts 
(Kim et al. 2010b); and inhibiting melanogenic enzymes in B16 melanoma cells (Lee et 
al. 2010).  
The antitumor, antifungal, antioxidant and nutrient metabolism effects of Gly are 
well established (see Chapter 1); however, the effects of Gly on brain physiology and 
function remain unclear. Compounds that act at ERs may exhibit varied effects in the 
periphery and the central nervous system. One example is ICI 182,720 (fulvestrant), 
which is purely anti-estrogenic in the periphery but acts more like a SERM in the brain 
(Alfinito et al. 2008). Fulvestrant inhibits E2’s negative feedback on GnRH, thus acting 
as an anti-estrogen in the hypothalamus, whereas it mimics the effect of E2 on place-
learning behavior in the hippocampus (Alfinito et al. 2008; Steyn et al. 2007). In order to 
evaluate the effect of Gly in the brain, a microarray experiment was performed on whole 
brain samples of female mice. The goal of the study was to determine if 11-days of 
chronic treatment with Gly alone affected gene expression compared to control, and 
whether Gly, when in combination with E2 (E2+Gly), opposed the E2 effect on gene 




expression of a few genes, but exhibited a gene expression pattern distinct from both E2 
groups (E2 and E2+Gly) (Bamji et al. 2015). In addition, an RNA-Sequencing (RNA-
Seq) experiment was performed on pooled whole brain homogenate samples from the 4 
treatment groups to provide a genome-wide view of Gly’s actions on gene expression in 
the brain and to examine Gly’s effects on some of the low expression genes of interest. 
Our RNA-Seq results indicated that, depending on the gene, Gly can oppose the effect of 
E2, act similarly to E2 or regulate genes in a manner different from E2 action (Chapter 
3). Thus, our microarray and RNA-Seq experiments suggested that Gly potentially 
exhibits a SERM-like effect in the female mouse brain. 
One limitation of the previous experiments was that they did not take into account 
the heterogeneity of the brain. Not only do different brain regions perform distinct and 
unique functions, but also gene expression can be highly brain-region specific 
(Merchenthaler et al. 2004). In order to assess the effects of Gly on gene expression in 
specific brain regions, in the present study we focused on:  1) hypothalamus — the 
neuroendocrine center that regulates the release of hormones from the pituitary, sexual 
behavior and reproduction, food and water intake, temperature regulation, circadian 
rhythms, emotional responses and stress; 2) hippocampus — responsible for learning, 
short term, long term and spatial memory, and plays an important role in hypothalamic-
pituitary-adrenal (HPA) axis negative feedback; 3) cortex — involved in general 
cognition, executive function, motor control and processing of multisensory functions 
(Kandel et al. 2000). Additionally, we evaluated the effects of a chronic 7-day vs. acute 





Genes of interest were selected based on their known expression in the brain, their 
responsiveness to E2, and results of the previous whole brain microarray (Bamji et al. 
2015) and RNA-Seq studies (Chapter 3). It is well known that ER (Esr1), G-protein 
coupled estrogen receptor 1 (Gper1), an orphan nuclear receptor (Nr4a1), growth 
hormone (Gh) and prolactin (Prl) are expressed in the hypothalamus, hippocampus and 
cortex and are all regulated by E2 (Addison and Rissman 2012; Brown et al. 2010; Furigo 
et al. 2014; Hazell et al. 2009; Lundholm et al. 2008; Mitra et al. 2003; Saucedo-
Cardenas and Conneely 1996; Simerly and Young 1991). We evaluated the mRNA 
abundance of all genes of interest using quantitative real-time polymerase chain reaction 
(qPCR). Our results suggest that unlike E2, Gly does not seem to have brain-region 
specific effects on the expression of Esr1, Gper1 or Nr4a1 in the hypothalamus, 
hippocampus or cortex but similar to known E2 regulation, affects the expression of Gh 
in all three brain regions and Prl in the hypothalamus and cortex after only a single acute 
dose (2hr or 24hr Gly exposure). Thus Gly, through its effects on Gh and Prl, can 
potentially regulate neuronal processes involved in food intake, stress and cognition in 
the female mouse brain, but the exact mechanism of Gly action is still unclear.  
 
Materials and Methods 
Study animals  
All protocols for housing, handling and euthanasia followed guidelines approved 
by the Guide for the Care and Use of Laboratory Animals: Eighth Edition (Council 2011) 




Committee (protocol number 13013). Adult female Swiss Webster (CFW) mice 
(approximately 31-35 days old) were purchased from Charles River Laboratories and 
given ad libitum access to phytoestrogen-reduced chow (Teklad 2016) and tap water. 
Animals were group housed, 3 mice/cage and maintained on a 12L:12D photoperiod 
(lights on at 6 AM). 
Ovariectomy, hormone replacement, experimental manipulations and plasma samples 
Animals were allowed to acclimate for 1 week after arrival before they were 
ovariectomized (ovx) under isoflurane anesthesia and implanted s.c. with Silastic 
capsules (Dow Corning; effective length 14mm, 1.57mm inner diameter x 3.18mm outer 
diameter), filled with either 35μl sesame oil (placebo) or 35 μl of 36 μg/ml E2 dissolved 
in sesame oil. One-week post ovx, mice were injected i.p. with 50 μl of either 1:1 DMSO: 
PBS (vehicle) or Gly (20 mg/kg/day) dissolved in 1:1 DMSO: PBS. Our four treatment 
groups were as follows (n = 96, 6 per treatment group per time point): negative controls 
(Con; Silastic placebo + vehicle injection), estrogen only (E2; Silastic E2 + vehicle 
injection), Gly only (Gly; Silastic placebo + Gly injection) and E2+Gly (Silastic E2 + Gly 
injection). Mice were euthanized at 2hr, 24hr or 48hr after a single dose of Gly or vehicle 
(acute exposure) or after 7 daily doses of Gly or vehicle (chronic exposure).  Mice were 
weighed weekly: at arrival, at ovx, one week post-ovx (7d only), and at euthanasia (2hr, 
24hr, 48 hr, or 7d after Gly treatment started). After decapitation under heavy isoflurane 
anesthesia, brains were rapidly extracted and placed in RNALater for 24h at 4C before 
storage at -20C. Trunk blood samples were stored on ice until centrifuged and plasma 
was collected and stored at -20°C until processed for an ELISA assay of E2 by the 




Research in Reproduction. Plasma from E2 and E2+Gly-treated mice were diluted 1:2 to 
fit the linear range of the ELISA (detection limits 3-300pg/ml). Only a few samples from 
the non-E2 groups (Con, n = 2 and Gly, n = 4) were sent for analysis. Samples with a 
%CV > 30 or with values outside the detection range of the assay were excluded (5 E2 
samples, 2 E2+Gly samples and 3 Gly samples).  
RNA extraction, cDNA amplification and quantitative real-time polymerase chain 
reaction (qRT-PCR) 
Total RNA was extracted from brain regions using the RNeasy Micro Kit 
(Qiagen) for the hypothalamus tissue and the PureLink RNA Mini Kit (Life 
Technologies) for hippocampus and cortex tissues. A nanodrop 2000 spectrophotometer 
was used to assess sample purity and RNA concentration. Extracted RNA samples 
(1ug/ml) were then used to make cDNA using the High Capacity cDNA Reverse 
Transcription kit (ThermoFisher Scientific, 4368814) according to manufacturer’s 
instructions. All cDNA samples were diluted 1:20 before use in qPCR reactions.  
Taqman primers were selected, using the manufacturer’s recommendations, to 
avoid the detection of non-target sequences (Supplementary Table 4.1). All qPCR 
reactions were 10 µl reactions and were run on ABI ViiA7 in 384-well plates. Reaction 
conditions were 50°C for 2 mins, 95°C for 10 min followed by 40 cycles of 95°C for 15 
secs and 60°C for 1 min. Each qPCR reaction was technically replicated in triplicate and 
each plate contained three template-free controls per primer pair for each of the genes of 
interest: Esr1, Gper1 (7 day Gly exposure – hypothalamus only), Nr4a1, Gh and Prl 





Body weight and plasma E2 data: Body weight data were analyzed via two-factor 
repeated measures ANOVA with treatment and week as factors using SigmaStat 3.1, with 
acute and chronic groups analyzed separately.  Plasma E2 data (E2 groups vs non-E2 
groups) was analyzed using a two-sample F-test for variances followed by a two-sample 
T-test  assuming unequal variances in Excel. 
Estimation of initial target concentrations: Raw fluorescence data was collected from the 
Applied Biosystems ViiA7 Real-Time PCR System and the x1m1 filter values were used 
in the estimation procedure. Initial target concentrations in micromoles/L were estimated 
for each sample using the kinetic model of Cobbs (Cobbs 2012). The kinetic model was 
adapted for use with the taqman detection system by modeling hybridization kinetics of 
the taqman probe with the same model used for hybridization kinetics of the primers 
(Cobbs 2012) but with unique equilibrium constants for both probe and primers. Baseline 
fluorescence was modeled as a linear trend, and intercept and slope parameters for 
baseline fluorescence were included in the model. The model was fit to data using the 
nlsLM function in the minpack.lm package of R which gives least squares estimates of 
parameter values using the Levenberg-Marquardt algorithm (Elzhov et al. 2013). 
Parameter starting values for each fit were obtained by searching a grid of 50625 
parameter vectors, and the one with the lowest sum of squared deviations between the 
observed and predicted fluorescence values was used as the starting vector for the nlsLM 
function. Each fit was evaluated by examination of the mean square residual and by 
visual inspection of a plot of the observed and fitted fluorescence values vs. cycle number 




amplify were eliminated from any further analysis. Among the 4968 samples tested that 
were not water controls, 446 failed to amplify and 2 were found to be unusable because 
of poor fit to the model.  The rest all showed good fit to the model and the estimated 
initial target concentration was used in the analysis. 
Statistical analysis of gene expression: Base 10 logarithm of initial target concentration 
was the response variable in all analyses. All analyses modeled technical replicate values 
as a random effect nested in biological replicate values. The biological replicate value 
was modeled as a random effect and nested in the fixed factors in the model. The fixed 
effect factors (Brain region, Exposure time, E2, and Gly) were crossed and interaction 
effects were dropped only if found to be non-significant by p-value and if their removal 
resulted in a decrease in AIC. Model residuals were found in all cases to satisfy the 
assumptions of normality and homogeneity of variance. All analyses were done with the 
lmer function of the lme4 package of R (Bates et al. 2014). Variance inflation factors 
(VIF) were used to indicate any problems with multi-collinearity and were obtained using 
the vif function in the car package of R (Fox and Weisberg 2011). Linear contrasts were 
tested with the glht function in the multcomp package of R version 3.0.2 (Hothorn et al. 
2008).   
Results 
Effects of E2 and Gly on Body Weight and Plasma E2  
 We observed a significant interaction effect between treatment and week on body 
weight at the acute time points (P = 0.041; Fig. 4.1a) and the chronic Gly exposure time 




either acute or chronic Gly exposure times on body weight (Fig. 4.1a-b). As expected, 
there was a highly significant difference (P < 0.001) in plasma E2 levels in the E2 groups 
(E2 and E2+Gly; 32.67 + 3.44 pg/ml) vs. the non-E2 groups (Con and Gly; 8.83 + 0.66 
pg/ml).    
Effects of brain region and exposure time within treatments  
Although the primary objective of this study is to compare effects of treatments (see 
below), we also explored expression patterns within the different treatment groups for 
each gene of interest (Fig. 4.2, Table 4.1). Overall, we observed moderate (Esr1, Nr4a1, 
Gper1) to low (Gh, Prl) levels of mRNA expression in all brain regions (Gper1 only 
tested in hypothalamus, log10 initial target concentration range -11.49 to -11.22μM, which 
corresponds to 3.23 x 10-12 to 6.02 x 10-12μM, not shown in Fig. 4.2).  There was a highly 
significant brain region and exposure time interaction effect on Esr1 expression in the 
Con (P < 0.0001), Gly (P = 0.0004) and E2+Gly treatments (P < 0.0001; Fig. 4.2a, 4.2c-
d). There was also a significant main effect of exposure time (P = 0.012) and brain region 
(P < 0.0001) on Esr1 expression after E2 treatment (Fig. 4.2b). Initial target 
concentration of Esr1 was the highest in the hypothalamus, compared to the hippocampus 
and cortex, irrespective of time point or treatment group. Esr1 levels were similar to each 
other in hippocampus and cortex at all time points in the Gly group; for the other 
treatment groups, Esr1 levels were also similar within treatments at the 2hr and 7d time 
points but diverged at 24 and 48 hr time points, such that Esr1 concentration was the 
lowest in the cortex, with expression in the hippocampus being intermediate to the 
hypothalamus at both time points (Fig. 4.2a-d). In the case of Nr4a1, there was a highly 




Fig. 4.2e), a significant exposure time main effect in the E2 (P = 0.002; Fig. 4.2f) and 
E2+Gly treatments (P = 0.046; Fig. 4.2h) and a significant brain region main effect in the 
Gly (P < 0.0001; Fig. 4.2g), E2 (P < 0.0001; Fig. 4.2f) and E2+Gly (P < 0.0001; Fig. 
4.2h) treatments. Nr4a1 had a relatively lower initial target concentration in the 
hypothalamus compared to the other two regions, irrespective of exposure time or 
treatment, except at the 24hr time point in the control treatment, for which expression 
was similar in hypothalamus and cortex (Fig. 4.2e-h). Further, Nr4a1 had the highest 
concentration in the hippocampus at all acute exposure times, particularly in the Con 
group (Fig. 4.2e-h). At the chronic exposure time, however, expression levels in the 
hippocampus are as low as in the hypothalamus, with cortex Nr4a1 expression being the 
highest at this time point, irrespective of treatment (Fig. 4.2e-h). In contrast to Esr1 and 
Nr4a1, no significant interaction was observed between brain region and exposure time 
on Gh expression in any of the treatments (Fig. 4.2i-l). However, there was a significant 
main effect of exposure time in the E2 (P = 0.008; Fig. 4.2j) and E2+Gly (P = 0.038; Fig. 
4.2l) treatments, and a significant main effect of brain region in the Gly (P = 0.04; Fig. 
4.2k) and E2+Gly (P = 0.044; Fig. 4.2l) treatment groups on Gh expression. The initial 
target concentration of Gh was higher at the 48hr Gly time point compared to the 2hr in 
the hypothalamus after E2 treatment (Fig. 4.2j) and was higher in all brain regions at 48hr 
compared to the 24hr time point in the E2+Gly treatment (Fig. 4.2l), explaining the 
exposure time main effects. The brain region main effects on Gh expression are due to 
higher Gh expression in the hypothalamus compared to the hippocampus and cortex at 
the 24hr time point in the Gly treatment (Fig. 4.2k) and due to higher hypothalamic Gh 




to Gh, there was no interaction of brain region and exposure time in any treatment 
condition on Prl expression (Fig. 4.2m-p), but it should be noted that we do not have Prl 
data for hippocampus or cortex at the 7d time point. We did observe a significant main 
effect of exposure time in the Con (P = 0.007; Fig. 4.2m) and E2 (P = 0.039; Fig. 4.2n) 
treatments and a significant main effect of brain region in the Con (P < 0.0001; Fig. 
4,2m), Gly (P = 0.034; Fig. 4.2o) and E2+Gly (P = 0.002; Fig. 4.2p) treatments on Prl 
expression. Prl initial target concentration was higher at the 24hr and 48hr time points 
compared to the 2hr time point in the Con treatment in both the cortex and hippocampus 
(Fig. 4.2m) and was higher in the 48hr compared to the 2hr time point in the E2 treatment 
in all brain regions (Fig. 4.2n). Further, Prl target concentration was higher at all acute 
Gly exposure times in the hippocampus compared to the cortex and hypothalamus within 
the Con treatment (Fig. 4.2m); was higher in the hippocampus and hypothalamus 
compared to the cortex at the 24hr time point within the Gly treatment (Fig. 4.2o) and 
was higher in the hypothalamus compared to the cortex and hippocampus at 24h and 48h 
time points in the E2+Gly treatment (Fig. 4.2p).  
Effects of E2 and Gly treatments on gene expression in the hypothalamus 
Both E2 groups (E2 and E2+Gly) downregulated the expression of Esr1 
compared to non E2 groups (Con and Gly) at the 2hr time point, but the E2 main effect 
was only marginally significant (FDR-P = 0.069; Fig. 4.3a). There was no significant E2 
main effect on expression of Gper1, Nr4a1, Gh or Prl in the hypothalamus. There was a 
significant Gly main effect on expression of hypothalamic Gh and Prl, with both Gly 
groups upregulating Gh (FDR-P = 0.009; Fig. 4.3b) and Prl (FDR-P = 0.035; Fig. 4.3c) at 




with both Gly groups upregulating Prl expression (FDR-P = 0.041; Fig. 4.3d). There was 
no significant Gly main effect on expression of Esr1, Gper1 or Nr4a1 in the 
hypothalamus. No significant E2 and Gly interaction effects were observed for Esr1, 
Gper1, Nr4a1, Gh or Prl in the hypothalamus.  
Effects of E2 and Gly treatments on gene expression in the cortex 
 Both E2 groups upregulated Prl expression in the cortex at the 24hr time point, 
although the E2 main effect was only marginally significant (FDR-P = 0.069; Fig. 4.3g). 
There was no significant main effect of E2 on Esr1, Nr4a1 or Gh expression in the 
cortex. Similar to the hypothalamus, we observed a significant Gly main effect at the 2hr 
time point, with both Gly groups upregulating the expression of both Gh (FDR-P = 
0.049; Fig. 4.3e) and Prl (FDR-P = 0.049; Fig. 4.3f) in the cortex. No significant Gly 
main effect was observed for Esr1 or Nr4a1 in the cortex. We did not observe any 
significant E2 and Gly interaction effects for the expression of Esr1, Nr4a1, Gh or Prl in 
the cortex. 
Effects of E2 and Gly treatments on gene expression in the hippocampus 
There was no significant E2 main effect on the expression of any of the genes of 
interest in the hippocampus. Both Gly groups downregulated Esr1 expression at the 24hr 
time point in the hippocampus, although the Gly main effect was only marginally 
significant (P = 0.06; Fig. 4.3h). A significant Gly main effect on Gh expression was 
observed at the 2hr time point, with both Gly groups upregulating hippocampal Gh 
expression (P = 0.049; Fig. 4.3i). There was no significant Gly main effect on the 




interaction effect was observed for the expression of Esr1, Nr4a1, Gh or Prl in the 
hippocampus. 
Discussion 
The main goals of this study were to better understand the effect of Gly on gene 
expression in the brain by a) evaluating the effects of acute vs. chronic Gly exposure on 
expression of Esr1, Gper1, Nr4a1, Gh and Prl in three different brain regions: 
hypothalamus, hippocampus and cortex, and b) comparing the results from this study 
with the data obtained from the whole brain microarray and RNA-Seq experiments. In 
general, the strongest treatment effects were due to Gly exposure, with no statistically 
significant interaction effects of Gly and E2. We found that all effects of Gly on gene 
expression occurred at acute (2hr, 24hr) exposures rather than chronic. 
 Given the well-known anti-estrogenic effects of Gly in peripheral tissues, our 
initial expectation was that Gly, by itself, would not have any effect compared to Con, 
but in combination with E2, would oppose effects of E2 on gene expression in the brain. 
Both microarray and RNA-Seq analyses revealed that depending on the gene, Gly 
regulates expression independently of E2 action, similarly to E2, or opposes E2’s effects, 
thus exhibiting potential SERM-like effects in the female mouse brain. Although we 
obtained valuable information from the whole brain microarray and RNA-Seq analyses, 
there are a few limitations. Since the brain is a heterogeneous organ, the whole brain 
analyses were unable to detect differential expression between treatment groups of some 
genes of interest, e.g., ERs like Esr1 and Gper1 that are distributed throughout the brain, 




(Merchenthaler et al. 2004). Additionally, the whole brain experiments were limited to 
one chronic time point (11 consecutive days of Gly exposure), which excludes the 
evaluation of acute Gly effects on gene expression of our select genes. Thus, in the 
current study, we evaluated the effects of acute vs chronic exposure to Gly on expression 
of those select genes in 3 brain regions.  
 
Effects of E2 and/or Gly on expression of ERs   
Firstly, we evaluated the effect of E2 and/or Gly (acute and chronic doses) on 
Esr1 gene expression in the hypothalamus, hippocampus and cortex. Esr1 expression was 
of particular interest as Gly was initially known to exhibit its anti-estrogenic effects 
mainly through ERα (Zimmermann et al. 2010). Although we did not find any significant 
E2 or Gly effects on Esr1 expression in our whole brain experiments, we were interested 
in determining if the effect of E2 and Gly, if any, would be more pronounced in different 
brain regions. Prior studies have shown that Esr1 is the most abundant ER in the 
hypothalamus, especially in the medial preoptic area (MPOA), periventricular nucleus 
(PVN), dorsomedial nucleus and the venterolateral hypothalamic nucleus (Merchenthaler 
et al. 2004; Mitra et al. 2003). Unsurprisingly, Esr1 not only had a relatively higher initial 
target concentration in the hypothalamus compared to other brain regions but was also 
the most highly expressed gene relative to our other genes of interest in this brain region, 
irrespective of treatment (Fig. 4.2a-d). Also, ERs are often downregulated by E2 in the 
mouse brain, an effect that can vary depending on the brain region, timing and dose of E2 
administration and sex of the experimental mice (Lauber et al. 1991; Simerly and Young 




surprising to find only a marginally significant E2 main effect on Esr1 expression, with a 
downregulation of Esr1 expression in both E2 groups (E2 and E2+Gly) compared to non-
E2 groups (Con and Gly) at the 2hr time point in the hypothalamus (Fig. 4.3a). In the 
hippocampus, Esr1 expression is generally scattered and relatively low  compared to the 
hypothalamus (Merchenthaler et al. 2004; Mitra et al. 2003), with Esr1 levels declining 
postnatally, specifically as mice approach puberty (Koboldt et al. 2013). As expected, we 
observed relatively low   Esr1 expression in the hippocampus compared to the 
hypothalamus (Fig. 4.2a-d). Further, the basal expression of Esr1 in the cortex is known 
to be low, especially in adult mice (Merchenthaler et al. 2004; Mitra et al. 2003; Wilson 
et al. 2011), which explains our relatively lower Esr1 expression in the cortex compared 
to the hypothalamus, irrespective of treatment and Gly exposure time (Fig.2a-d).  
Overall, similar to our whole brain experiment, we did not find any significant E2 
or Gly main effects on Esr1 expression in any of the brain regions tested. It should be 
noted though that the lack of chronic Gly exposure effects in this study make it difficult 
to compare results from this study to those from the whole brain experiments (Chapters 2 
and 3). In addition to genomic ERs including Esr1, E2 is also known to stimulate gene 
expression through rapid, non-genomic mechanisms involving membrane ERs. 
Therefore, we evaluated the effects of E2 and acute Gly on the expression of 
hypothalamic Gper1, a known membrane-associated ER, which is highly expressed in the 
arcuate nucleus (ARC), PVN, paraventricular, suprachiasmatic and supraoptic nuclei 
(SON) and the ventromedial hypothalamus (Brailoiu et al. 2007; Hazell et al. 2009). Like 
Esr1, neither E2 nor Gly affected Gper1 expression in the hypothalamus.  Gper1 




11.22μM) in different treatments) than Esr1 in the hypothalamus (log10 initial target 
concentration ranging from -9.77 to -9.45μM). 
Effects of E2 and/or Gly on Gh and Prl expression 
 Next, we evaluated the effects of E2 and/or Gly (acute and chronic doses) on the 
expression of E2-regulated Gh and Prl in the hypothalamus, hippocampus and cortex. 
Both Gh and Prl were upregulated by E2 treatment compared to Con in the microarray 
(Bamji et al. 2015) and RNA-Seq (Chapter 3) whole brain experiments, but the effect was 
significant only in the RNA-Seq experiment. Gly did not significantly affect the 
expression of Gh or Prl compared to Con in the RNA-Seq analysis, but in combination 
with E2 (E2+Gly), inhibited the E2 upregulation of both genes. Thus, the RNA-Seq 
experiment revealed a classic anti-estrogenic effect of Gly on expression of Gh and Prl. 
We were interested in determining the brain-region specific effects of Gly, if any, on 
expression of Gh and Prl. 
Gh is expressed in several hypothalamic nuclei (Addison and Rissman 2012), is 
influenced by gonadal sex and the sex chromosome complement in the hypothalamus and 
can regulate food intake and changes in appetite (Bohlooly-Y et al. 2004; Chan et al. 
1996; Quinnies et al. 2015). Gh is highly upregulated by E2 treatment in the MPOA and 
ARC regions of the mouse hypothalamus (Addison and Rissman 2012). We found a 
similar E2 upregulation of Gh in our whole brain RNA-Seq experiment (Chapter 3). 
Unexpectedly, there was no significant E2 main effect on the expression of Gh, but there 
was a significant Gly main effect on Gh expression at the 2hr Gly exposure time point in 




upregulating Gh expression compared to non-Gly groups (Con and E2; Fig. 4.3b). As 
prior studies have shown upregulation of Gh post E2-treatment in very specific 
hypothalamic regions (MPOA and ARC) (Addison and Rissman 2012), the lack of a 
significant E2 main effect could possibly be due to the fact that we evaluated Gh 
expression in the hypothalamus as a whole. Further, Gh is endogenously produced in the 
hippocampus (Nyberg and Burman 1996; Sun et al.), is upregulated by E2 (Donahue et 
al. 2006) and plays a role in neuronal processes related to memory formation, mood and 
cognition in rats (Donahue et al. 2002; Donahue et al. 2006; Sonntag et al. 2005; Sytze 
van Dam and Aleman 2004). In the cortex, on the other hand, Gh is generally expressed 
in moderate levels (Addison and Rissman 2012), and E2 regulation of Gh in this brain 
region is not well established. We observed moderate to low levels of Gh expression in 
the hippocampus and cortex. Interestingly, just as in the hypothalamus, we did not see 
any significant E2 upregulation of Gh in the hippocampus or cortex. A previous study 
found increased Gh mRNA in the hippocampus 24 hours after two consecutive days of 
s.c. E2 injections (Donahue et al. 2006). Thus, the lack of an E2 main effect in the 
hippocampus in the current study could possibly be due to the fact that Gh expression 
was determined after 7 days (2hr, 24hr and 48hr Gly exposure animals) or 14 days (7 day 
Gly exposure animals) of exposure to E2. However, like in the hypothalamus, there was a 
significant Gly main effect on Gh expression at the 2hr time point, with an upregulation 
of Gh expression in both Gly groups compared to non-Gly groups in the hippocampus 
and cortex (FDR-P = 0.049; Fig. 4.3e and 4.3i).  Similar to our whole brain experiments, 
Gh expression was almost undetectable in the Con mice, resulting in elimination of many 




the Gly group are underestimated. Also, the Gly main effect at 2hr post Gly exposure is 
mostly driven by the high levels of Gh observed in approximately half (2-3) of the 6 total 
mice in both the Gly and E2+Gly treatments in all three brain regions. Although E2 was 
reported to increase Gh expression in other studies, the addition of E2 is not driving this 
effect in the current study, as plasma E2 levels and Gh expression were not correlated and 
half the Gly-only treatment animals also showed the same increase.  
The effects of E2 and/or Gly on Prl expression were similar to Gh in the current 
study.  There was a significant Gly main effect on Prl expression at 2hr in the 
hypothalamus and cortex, similar to Gh, as well as at 24hr in the hypothalamus, with Gly 
groups (Gly and E2+Gly) upregulating Prl expression compared to non-Gly groups (Con 
and E2; Fig. 4.3c-d and 3f). Also, similar to Gh, the main effects of Gly on Prl expression 
must be interpreted carefully, due to undetectable Prl expression in most control mice 
(i.e., those samples eliminated from analysis) and only half the Gly and E2+Gly treated 
animals driving the significant Gly main effect. Prl was of interest as it is expressed in 
several hypothalamic nuclei, is generally upregulated by E2 and is involved in 
neurogenesis, maternal behavior, food intake and stress (Marano and Ben-Jonathan 2014; 
Torner et al. 2004; Torner et al. 1999). Furthermore, Prl immunoreactive neurons are 
found in the rat cerebral cortex (DeVito 1988), with E2 having no effect on Prl mRNA or 
protein expression in the cortex of hypophysectomized rats (DeVito et al. 1992). In 
contrast to our whole brain RNA-Seq data, there was no significant main effect of E2 on 
Prl expression in the hypothalamus or hippocampus, with only a marginally significant 
E2 effect at the 24hr time point in the cortex (Fig. 4.3g). Prl expression was not affected 




(2hr or 24hr) can affect the expression of genes including Gh and Prl, involved in 
neuronal processes that regulate food intake, stress and cognition, independent of an E2 
effect. Thus, Gly may regulate these pathways, but via a mechanism that remains to be 
determined.  
Effects of E2 and/or Gly on Nr4a1 expression  
Lastly, we evaluated the expression of Nr4a1, an orphan nuclear receptor, which 
was of interest as it was the most highly upregulated gene by Gly compared to Con in our 
whole brain microarray study (Bamji et al. 2015). However, this Gly upregulation of 
Nr4a1 was not observed in the RNA-Seq experiment. We were interested to determine 
Gly’s brain-region specific effects on Nr4a1 expression in the hypothalamus, 
hippocampus and cortex. Nr4a1 is moderately expressed in various hypothalamic nuclei 
(Saucedo-Cardenas and Conneely 1996). Nr4a1 is downregulated by E2 in the mouse 
hypothalamus (Lundholm et al. 2008) and plays a functional role in stress responses 
(Helbling et al. 2014), food intake (Chen et al. 2015), and cognition (McNulty et al. 
2012). Nr4a1 is also highly expressed in the hippocampus, with highest expression in the 
CA1 region (McNulty et al. 2012; Saucedo-Cardenas and Conneely 1996). Nr4a1 plays a 
role in memory formation (Hawk and Abel 2011), specifically object location memory 
(McNulty et al. 2012). Thus, it was not surprising to observe relatively higher Nr4a1 
expression in the hippocampus, compared to the hypothalamus and cortex. As it is an 
immediate early-response gene and is upregulated 2 hrs after object location memory 
training in the CA1 region of the mouse hippocampus (McNulty et al. 2012), we expected 
that acute Gly (2hr, 24hr or 48hr), would increase Nr4a1 expression, especially in the 




upregulation of Nr4a1 expression by Gly in any of the brain regions tested, nor did we 
detect E2 downregulation of Nr4a1 in the hypothalamus.  
 In summary, we evaluated the effects of Gly on gene expression in 3 grossly 
dissected brain regions: the hypothalamus — central regulator of reproduction, food 
intake and stress; the hippocampus — involved in learning, memory consolidation and 
cognition; and the cortex — involved in movement, executive function, sensory 
perception and accurate recognition of visual and auditory stimuli in the mouse brain 
(Kandel et al. 2000). Moreover, we focused on expression of genes involved in 
reproduction (Esr1, Gper1, Prl), food intake (Esr1, Gh, Prl), stress (Nr4a1, Gh and Prl) 
and cognition (Esr1, Gh and Nr4a1) to gain a clearer understanding of Gly’s effects in 
the female mouse brain. Our results suggest that Gly does not have brain-region specific 
effects on the expression of Esr1, Gper1 or Nr4a1 in the hypothalamus, hippocampus or 
cortex. On the other hand, Gly upregulates Gh expression in the hypothalamus, 
hippocampus and cortex as well as Prl expression in the hypothalamus and cortex. In 
contrast to prior studies, we did not see any E2 effect on Gh or Prl expression. It should 
be noted that the E2 effect on gene expression at the acute Gly exposure time points is a 
7-day E2 effect (E2 replacements were done a week before tissue harvesting) compared 
to the 2h or 24h effects of a single Gly dose on Gh and Prl expression, which limits a 
direct comparison of E2 and Gly effects observed in the whole brain microarray (Bamji et 
al. 2015) and RNA-Seq (Chapter 3) experiments with the results of this study.. Therefore, 
we cannot rule out the possibility that the significant Gly main effects on Gh and Prl at 
the acute exposure times may be through rapid Gly action at either classical or genomic 




itself did not regulate the expression of these ERs in the current study. Although the exact 
mechanism of Gly action on Gh and Prl expression remains unclear, this was an exciting 
finding, as Gly, through its effects on Gh and Prl, may regulate neuronal processes 
involved in food intake, stress and cognition in the female mouse brain. Future studies 
measuring expression of our select genes through the use of ER knockout experiments 
would help elucidate whether Gly’s effect on expression of our genes of interest is 
through an ER-dependent or ER-independent mechanism in the female mouse brain. 
Furthermore, testing the effects of Gly on a neuronal cell culture model may also help 
determine  
whether the effects observed in this study are due to direct effects at the neuron or 
through some indirect peripheral effects on gene expression. Given the interest in Gly’s 
antitumor, antimicrobial and nutrient metabolism (specifically glucose and lipid) effects, 
understanding its effects in the central nervous system may be important in developing 











Table 4.1. Brain region and Gly exposure time interaction effect and main effect P-values 
within each treatment group for Esr1, Nr4a1, Gh and Prl obtained using a generalized 




























Esr1 Control **<0.001 *0.043 **<0.001 
 E2 0.066 *0.012 **<0.001 
 Gly **<0.001 **<0.001 **<0.001 
 E2+Gly **<0.001 *0.014 **<0.001 
     
Nr4a1 Control *0.006 *0.036 **<0.001 
 E2 0.357 *0.002 **<0.001 
 Gly 0.807 0.596 **<0.001 
 E2+Gly 0.095 *0.046 **<0.001 
     
Gh Control 0.649 0.076 0.087 
 E2 0.994 *0.008 0.304 
 Gly 0.564 0.421 *0.040 
 E2+Gly 0.700 *0.038 *0.044 
     
Prl Control 0.752 *0.007 **<0.001 
 E2 0.971 *0.039 0.088 
 Gly 0.315 0.592 *0.033 




Fig. 4.1. Average weekly body weight (g) (mean + SEM) of animals exposed to a) a 
single acute dose of Gly (2hr, 24hr and 48hr) and b) 7 consecutive days (chronic dose) of 
Gly, measured one week before ovariectomy (B), at ovariectomy (O), one week after 
ovariectomy and beginning of Gly injections (I, chronic only) and at euthanasia (E), 
separated by treatment. Treatments are represented as follows:  = Con,  = E2,  = 
Gly, = E2 + Gly. Dotted lines connect the data points within each of the non-E2 groups 








Fig. 4.2. Brain region and exposure time (hrs) interaction plots within each treatment, 
expressed as log10 initial target concentration (μM) (mean + SEM). Rows (top to bottom) 
represent genes Esr1, Nr4a1, Gh and Prl. Columns (L-R) represent treatments: Control, 
E2, Gly and E2+Gly. Brain regions in each plot are represented as follows: hypothalamus 






















































































































































































































































































































































Fig. 4.3. E2 and Gly treatment interaction plots showing log10 initial target concentration 
(μM) (mean + SEM). Columns (L-R) represent brain regions: hypothalamus, cortex and 
hippocampus, respectively. * significant Gly main effects (FDR-P-value < 0.05); † 
marginally significant Gly main effect (FDR-P-value = 0.06); # marginally significant E2 
main effect (FDR-P-value = 0.069). Treatments are represented as follows:  = Con,  = 
E2,  = Gly, = E2 + Gly. Left columns (circles) = no Gly; right columns (triangles) = 
Gly. Dotted lines connect the non-E2 groups ( and ) and solid lines connect the two 

















































Code Gene Name 
Gene ID 
(NCBI) Assay ID 
Esr1 Estrogen receptor 1 13982 Mm00433149_m1 
Gper1 G-protein coupled estrogen receptor 76854 Mm02620446_s1 
Nr4a1 Nuclear receptor, subfamily 4, group A, 
member 1 
15370 Mm01300401_m1 
Gh Growth hormone 14599 Mm00433590_g1 
Prl Prolactin 19109 Mm00599950_m1 
    












NEUROENDOCRINE CHARACTERIZATION OF CELL LINES DERIVED FROM 
ADULT FEMALE MOUSE HYPOTHALAMUS 
Introduction 
 
The hypothalamus regulates reproductive function, growth, metabolism, stress 
responses and food intake. The arcuate nucleus (ARC) is a site for leptin signaling, which 
regulates body weight and food intake (Coppari et al. 2005), and both ARC and the 
anteroventral periventricular nucleus (AVPV) have Kiss1-expressing neurons forming an 
essential part of reproductive functioning (Clarkson et al. 2009). 17-estradiol (E2) 
signaling in the hypothalamus, both through classical estrogen receptors ERs (ERα and 
ERβ) and membrane-associated ERs, including G protein-coupled estrogen receptor 1 
(GPER1), is involved in regulating the transcription and release of gonadotrophin 
releasing hormone (GnRH) and luteinizing hormone (LH) (Petersen et al. 2003). E2 also 
regulates various neural pathways, such as those involved in sexual receptivity 
(Micevych and Dominguez 2009) and energy homeostasis (Bless et al. 2014).  
Advances in medicine and molecular techniques have led to the discovery of several 
natural and synthetic compounds that act as selective estrogen receptor modulators 
(SERMs). SERMs exhibit neuroprotective effects by inducing neurite outgrowth (Nilsen 
et al. 1998) and preventing neuronal loss after kainic acid injury (Azcoitia et al. 2006) in  
the rodent brain through both genomic and non-genomic mechanisms (Dhandapani 2002; 






selective ER downregulator (SERD) fulvestrant (ICI 182,780), exhibit both antagonistic 
and agonistic activity at ERs and GPER1 in the rodent hypothalamus (Alfinito et al. 
2008; Littleton‐Kearney et al. 2002; McKenna et al. 1992; Patisaul et al. 2004). In 
addition to synthetic SERMs, naturally occurring SERMs, including coumestrol, 
genistein, and daidzein, act through both ERα and ERβ and regulate sexual behaviors and 
gonadotropin secretion in the hypothalamus (Whitten et al. 2002). However, in vivo 
studies fail to answer whether the effects of SERMs on gene expression are through 
direct action at the neuron, specifically in the hypothalamus, or through some indirect, 
systemic effects.      
To explore the molecular mechanisms for effects of estrogens and SERMs in the 
hypothalamus, we tested five cell lines (mHypoA-50, 51, 55, 59, and 63) representative 
of mature neurons from the adult female mouse hypothalamus. All five cell lines exhibit 
gene expression patterns that are characteristic of the ARC or AVPV hypothalamic 
regions (Dhillon et al. 2011; Friedman 2013; Kim 2010; Treen et al. 2016). For more 
information on the cell lines, see Belsham et al., 2009 (Belsham et al. 2009).  
For screening experiments, genes were selected based on their known brain functions 
and their response to E2. From prior studies, each of the aforementioned hypothalamic 
cell lines expresses both Esr1 and Esr2 (Dhillon et al. 2011; Friedman 2013; Kim 2010). 
Further, mHypoA-50 and 55 cells express Gper1 (Friedman 2013). In addition, we 
examined other E2-regulated hypothalamic genes: growth hormone (Gh), prolactin (Prl), 
and kisspeptin (Kiss1), which are expressed in various regions of the hypothalamus 
(Addison and Rissman 2012; Aramburo et al. 2014; Brown et al. 2010; Gottsch et al. 





memory (Donahue et al. 2006; Harvey 2010), and exhibits a sexually dimorphic pattern 
of gene expression in the medial preoptic area (MPOA) and ARC regions of the 
hypothalamus (Addison and Rissman 2012). Prl plays a role in neurogenesis, maternal 
behavior, food intake and stress (Torner et al. 2004; Yip et al. 2012). Kiss1 is involved in 
the stimulation and release of GnRH, LH, and follicle-stimulating hormone (Gottsch et 
al. 2004; Kim 2010). Kiss1 expression was reported in all cell lines tested in this study 
(Friedman 2013; Kim 2010), whereas this is the first examination of Gh and Prl 
expression in these cell lines. In addition, we examined the expression of Nr4a1, an 
orphan nuclear receptor, which is expressed in the hypothalamus, is regulated by E2 
(Lundholm et al. 2008; Saucedo-Cardenas and Conneely 1996) and plays a functional 
role in stress responses (Helbling et al. 2014), food intake (Chen et al. 2015), and 
cognition (McNulty et al. 2012). None of these cell lines had been tested for Nr4a1 gene 
expression. Therefore, a series of qPCR experiments were performed to a) confirm the 
presence of Esr1, Esr2, Kiss1 in each cell line and Gper1 in mHypoA-50 & 55; b) screen 
for presence of Gper1 in mHypoA-51, 59 & 63 and Gh, Prl, and Nr4a1 in all cell lines; 
and c) select one or more cell lines that express the genes of interest and respond to E2 
treatment for use in future experiments to test estrogens and SERMs. 
 
Materials and Methods 
Cell line maintenance and treatments 
Five adult female hypothalamic mouse cell lines (mHypoA-50, 51, 55, 59 & 63) were 
obtained from Cedarlane Labs (Burlington, Ontario, Canada). All cell lines were grown 





fetal bovine serum (FBS) and 1% penicillin/streptomycin and maintained at 37°C with 
5% CO2. For examining E2 responses, all five cell lines were ‘serum starved’ for 16 h 
using phenol red-free DMEM supplemented with 10% charcoal stripped FBS + 1% 
penicillin/streptomycin. Time of serum starvation was optimized to examine E2 
responses without affecting cell viability (data not shown). Cell lines were then treated 
with either dimethyl sulfoxide (DMSO, vehicle control) or 10nM 17β-estradiol (E2) 
dissolved in DMSO for 24 h.   
RNA extraction and cDNA synthesis 
RNA was extracted from cell lines using the miRCURY RNA isolation kit – Cell and 
Plant (Exiqon, 300110) and 800ng/μl of each extracted RNA sample was used to make 
cDNA using the High Capacity cDNA Reverse Transcription kit (ThermoFisher 
Scientific, 4368814) according to manufacturer’s instructions. Due to technical issues 
with both the DMSO and E2 treated mHypoA-50 cells, this cell line was excluded from 
both the screening and subsequent qPCR experiments. Data for mHypoA-50 in Table 5.1 
is from a qPCR experiment conducted independently. All cDNA samples were diluted 
1:3 before further use.  
Quantitative Real-Time PCR (qPCR) & Data Analysis 
Taqman primers were selected, using the manufacturer’s recommendations, to avoid 
the detection of non-target sequences (See Supplementary Table 5.1). All qPCR reactions 
were 10 µl reactions and were run on ABI ViiA7 in 384 well plates. Reaction conditions 
were 50°C for 2 mins, 95°C for 10 min followed by 40 cycles of 95°C for 15 secs and 
60°C for 1 min. qPCR reactions for the four cell line treatments (mHypoA-51, 55, 59 & 





Esr2, Gper1, Nr4a1, Gh, Prl, and Kiss1, relative to control gene Hmg20b. Relative 
expression for each gene was then calculated using the delta-delta CT method, 
normalized to the delta Ct (target Ct – reference gene Ct) for DMSO-treated cells (Livak 
and Schmittgen 2001). Three additional qPCR experiments were run under the same 
conditions as above but only for Esr1, Esr2, Gper1 and Nr4a1 targets in mHypoA-55 and 
mHypoA-63. The mHypoA-55 and mHypoA-63 cells used in these experiments were 
from different passages (mHypoA-55: P30, P19, P20 and mHypoA-63: P31, P19, P18). 
There was no significant passage effect observed in the expression of the indicated genes 
as analyzed by two-factor ANOVA with ‘E2’ and ‘passage’ as factors, thus allowing the 
comparison of results obtained from different cell line passages. Data from these qPCR 
runs were analyzed by performing a student’s t-test (DMSO vs. E2 treatments) for each 
gene in each of the two cell lines.  
 
Results 
Baseline expression of target genes 
We confirmed the presence of both Esr1 and Esr2 in all five hypothalamic cell lines 
(Table 5.1, Fig. 5.1A-B). Similarly, we confirmed the expression of Gper1 in mHypoA-
50 and mHypoA-55 and for the first time report Gper1 expression in mHypoA-51, 
mHypoA-59 and mHypoA-63 (Table 5.1, Fig. 5.1C). The expression of Kiss1 in 
mHypoA-55, mHypoA-59 and mHypoA-63 was confirmed; however, we did not detect 
Kiss1 mRNA expression in mHypoA-50 or mHypoA-51 (Table 5.1, Fig. 5.1D). We 
report the first examination of genes Nr4a1, Gh and Prl in all five hypothalamic cell lines 





level (without any treatment) of mRNA abundance (Table 5.1, Fig. 5.1E). Gh and Prl, on 
the other hand, had extremely low to undetectable levels of basal expression (Table 5.1, 
Fig. 5.1F-G); Prl was not detected in mHypo-55 or -63.  
E2 regulation of genes of interest in cell lines 
E2 increased Esr1 expression in mHypoA-51 and mHypoA-63 cells and Esr2 
transcript expression in mHypoA-63 cells (Fig. 5.1A-B). In contrast to the increase in 
Esr1, E2 treatment resulted in a decrease in Esr2 expression in mHypoA-51 cells (Fig. 
5.1A-B). Unlike mHypoA-51 and mHypoA-63 cells, Esr1 expression was slightly 
decreased in E2-treated mHypoA-59 cells. Treatment with E2 increased the expression of 
Gper1 in mHypoA-55, mHypoA-59 and mHypoA-63, but not mHypoA-51 cells (Fig. 
5.1C). 
Further, E2 increased Gh expression in both mHypoA-59 and mHypoA-63 cells but 
not mHypoA-55 cells, with no detectable levels of Gh expression in E2-treated mHypoA-
51 cells (Fig. 5.1F). With E2 treatment, a modest increase in Prl expression was observed 
in mHypoA-51 cells and a decrease in Prl expression was seen in mHypoA-59 cells. Prl 
expression was undetectable in both mHypoA-55 and mHypoA-63 cells with or without 
E2 treatment (Fig. 5.1G). E2 downregulated Kiss1 gene expression in mHypoA-55 and 
mHypoA-59 cells, but increased Kiss1 transcript expression in mHypoA-63 cells (Fig. 
5.1D). Kiss1 expression was undetectable in mHypoA-51 cells irrespective of E2 
treatment.  
In summary, all four cell lines were E2 responsive, with each cell line exhibiting a 
slightly different pattern of gene expression after 24 h of E2 treatment.     





The mHypoA-55 and mHypoA-63 cells exhibited the most E2 responsivity for our 
genes of interest. Cell line mHypoA-55 showed the most E2 response of the cell lines 
examined, i.e., a 23% decrease in Nr4a1 (Fold Change/FC = 0.77) and a large increase in 
Gper1 (FC = 9.08) expression following E2 treatment (Fig. 5.1E, Fig. 5.1C). Also, 
although the expression of Prl, Kiss1, and Gh was very low in this cell line, mHypoA-55 
cells had the most consistent detection of Gh compared to any of the other cell lines (Fig. 
5.1D, Fig. 5.1F-G). 
Cell line mHypoA-63 exhibited an increase in expression of all ERs with E2 
treatment (Esr1, FC = 1.59; Esr2, FC = 1.76; Gper1, FC = 2.76) when compared with 
DMSO (Fig. 5.1A-C). Further, mHypoA-63 had a relatively reliable detection of both Gh 
and Kiss1 with an increase in both Gh and Kiss1 expression, following E2 treatment (Gh, 
FC = 1.34; Kiss1, FC = 1.62; Fig. 5.1F, Fig.5.1D). 
Due to the aforementioned E2 treatment responses of mHypoA-55 and mHypoA-63, 
we selected these two cell lines to confirm the reliability of our screening results with 
three additional qPCR experiments. Because of the very low to undetectable expression 
of Gh, Prl, and Kiss1, we followed up on gene expression of the ERs and Nr4a1 (Fig. 
5.2A-D).   
Both mHypoA-55 and mHypoA-63 cells showed similar trends in gene expression 
following E2 treatment when compared to the previous qPCR screening results (Fig. 
5.2A-D). However, the Gper1 increase and Nr4a1 decrease post E2 treatment detected in 
our initial screening experiment in mHypoA-55 cells were not statistically significant 
(Gper1 and Nr4a1, P = 0.7; Fig. 5.1C-D). In the case of mHypoA-63 cells, there was no 





E2 treatment (Fig. 5.2A and 5.2D). However, the increase in expression of Esr2 (P = 
0.036; Fig. 5.2B) and decrease in Nr4a1 expression (P = 0.002) in mHypoA-63 cells, 
after 24 h of E2 treatment, were statistically significant. 
 
Discussion 
The aims of this study were a) to screen five immortalized cell lines derived from 
adult female mouse hypothalamus for the expression of established genes of interest due 
to their regulation by E2 in the hypothalamus in vivo, b) examine the E2-responsiveness 
of these cell lines by measuring Esr1, Esr2, Gper1, Kiss1, Nr4a1, Gh, and Prl gene 
expression after E2 treatment, and c) select one or more cell lines for use in future studies 
to evaluate the mechanism of action of estrogens and SERMs in the ARC and AVPV of 
the mouse hypothalamus.  
Earlier characterization of these cell lines had identified mHypoA-51, mHypoA-55, 
mHypoA-59 and mHypoA-63 to have an ARC phenotype and mHypoA-50 to have an 
AVPV phenotype (Dhillon et al. 2011; Friedman 2013; Kim 2010; Treen et al. 2016). 
Prior studies indicate that both classical ERs (Esr1 and Esr2) are expressed in the 
hypothalamus with a relatively higher expression of Esr1 as compared to Esr2, especially 
in the ARC (Kelly and Ronnekleiv 2015; Merchenthaler et al. 2004; Mitra et al. 2003). 
Our experiments confirmed the presence of both Esr1 and Esr2 in all cell lines and also 
indicate a relatively higher abundance of Esr1 in all cell lines (Table 5.1, Fig. 5.1A-B). 
Gper1 expression is high in the hypothalamus of the adult mouse brain, especially in the 
ARC, PVN, AVPV, periventricular hypothalamic nucleus and supraoptic nucleus (Hazell 





axis of the rat (Brailoiu et al. 2007). Gper1 expression was observed in all cell lines 
tested, with overall expression being relatively higher than Esr2 but lower than Esr1 in 
each cell line (Table 5.1, Fig. 5.1A-D). In summary, both classical ERs and GPER 
exhibited moderate to low levels of mRNA expression in these adult female 
hypothalamic cell lines.   
Another important aspect of the study was the selection of hypothalamic cell lines 
that not only express ERs but also show a response to E2 treatment. E2 generally 
downregulates the expression of its receptors, Esr1 and Esr2, in vivo in the rodent brain, 
although these effects may vary by brain region, timing, sex, and species (Lauber et al. 
1991; Nomura et al. 2003; Patisaul et al. 1999; Simerly and Young 1991). E2 decreased 
expression of Esr1 in mHypoA-59 and decreased Esr2 expression in mHypoA-51 in the 
initial screening experiments (Fig. 5.1A-B). In contrast to a previous report (Friedman 
2013), no increase in Esr1 or Esr2 expression was detected in mHypoA-55 with 24 h of 
E2 treatment. The difference in results may be due to the fact that in our experiments the 
cell lines were ‘serum starved’ for 16 h prior to E2 treatment to minimize the impact of 
estrogens in FBS affecting gene expression. In contrast, the previous study used only 4 h 
serum starvation prior to E2 treatment (Friedman 2013). However, we did observe an 
increase in Esr1 mRNA in mHypoA-51 and mHypoA-63 cells and an increase in Esr2 
expression in mHypoA-63 cells after E2 treatment. Importantly, these E2 responses were 
most noticeable in mHypoA-55 and mHypoA-63 cells, with mHypoA-63 cells increasing 
the expression of all ERs and mHypoA-55 cells showing a large increase in Gper1 
transcript abundance with E2 treatment in the screening experiment. This is especially 





naturally occurring estrogens, like E2, regulate the expression of ERs in the ARC of the 
hypothalamus.  
In addition to ERs, of special interest was the finding that these mouse hypothalamic 
cell lines express the orphan nuclear receptor, Nr4a1. Nr4a1 is induced in the 
hypothalamus in response to stress (Helbling et al. 2014), and it plays a role in leptin’s 
central control of food intake (Chen et al. 2015) and in learning and memory (McNulty et 
al. 2012). This is the first report demonstrating Nr4a1 expression in a murine 
hypothalamic cell line. We report here that all five mHypoA cell lines exhibit moderate 
expression of Nr4a1, similar to previously published in vivo studies for mouse 
hypothalamus (Saucedo-Cardenas and Conneely 1996).  Thus, these cell lines will be a 
valuable tool for in vitro mechanistic studies to identify pathways regulating Nr4a1 
expression.   
An earlier study found that E2 treatment downregulates the expression of Nr4a1 in 
the mouse hypothalamus (Lundholm et al. 2008) which, therefore, was the anticipated 
result for our hypothalamic cell lines. E2 suppressed Nr4a1 expression in both mHypoA-
55 and mHypoA-63 cell lines (Fig. 5.2D), with a statistically significant suppression in 
mHypoA-63 (P = 0.002). Both mHypoA-55 and mHypoA-63 not only express Nr4a1 but 
also show a response to E2 treatment, which provides reasonable confidence that these 
lines are appropriate for future studies investigating the role of synthetic and naturally 
occurring SERMs on Nr4a1 gene expression in female mouse hypothalamic neurons.  
Lastly, the presence of gene targets Gh, Prl, and Kiss1 was also evaluated in all cell 
lines. Gh and Prl mRNAs were of interest as they are both synthesized locally in the 





localize with Esr1 in these neurons (Addison and Rissman 2012; Aramburo et al. 2014; 
Brown et al. 2010; Grattan and Kokay 2008; Marano and Ben-Jonathan 2014). Kiss1 is 
highly expressed in mouse hypothalamic nuclei, especially the ARC, AVPV, and PVN, 
and regulates the stimulation and release of GnRH in these regions (Friedman 2013; 
Gottsch et al. 2004; Smith et al. 2005). Also, one study indicated a downregulation of 
Kiss1 expression in mHypoA-51 and mHypoA-63 cells after a 4 h E2 treatment, with the 
decrease less pronounced or lost 24 h post E2 treatment (Kim 2010). A more recent 
study, however, found an increase in Kiss1 expression in mHypoA-51 cells, after a 24 h 
E2 treatment (Mittelman-Smith et al. 2015). We detected low to no expression of Kiss1, 
Gh, and Prl in the five cell lines. Previous studies describing Kiss1 expression in 
mHypoA-51 and mHypoA-63 used an input RNA concentration that was 2.5 times higher 
than that used in our experiments to prepare cDNA for qPCR experiments (Friedman 
2013; Kim 2010; Mittelman-Smith et al. 2015), providing a possible explanation for 
discrepancy among studies regarding detection of Kiss1. Our results indicate an 
extremely low basal mRNA expression of Kiss1, Gh, and Prl in the lines tested.  
In summary, five hypothalamic cell lines derived from adult female mouse 
hypothalamus were screened and evaluated for the relative abundance of the transcripts 
of five genes of interest and their response to E2 treatment. We report the first 
examination of Nr4a1, Gh, and Prl mRNA in these cell lines and our results suggest that 
mHypoA-55 and mHypoA-63 cells may be valuable for future experiments with E2 and 
SERMs. However, further studies comparing the gene expression profiles of these cell 





may provide a deeper insight into the suitability of these cell lines for studying E2 and 








Average Ct values of target gene mRNA in each hypothalamic cell line after 16h cell 
starvation and 24 h DMSO. 
Cell Line Esr1 Esr2 Gper1 Kiss1 Nr4a1 Gh Prl 
mHypoA-50a 30.0 33.8 32.9 - 23.3 35.0 34.9 
mHypoA-51 29.0 32.6 31.5 - 25.0 36.9b 39.1 
mHypoA-55 28.4 32.5 31.0 34.6b 24.6 35.7 - 
mHypoA-59 27.7 34.2 31.1 35.6b 25.1 36.9b 37.8 
mHypoA-63 31.2 34.5 29.6 35.6b 25.3 37.3b - 
a
data for mHypoA-50 from a separate experiment (see methods); 
b
undetermined Ct value 






      
Fig. 5.1 Relative mRNA expression of target genes A) Esr1, B) Esr2, C) Gper1, D) Kiss1, E) 
Nr4a1, F) Gh, and G) Prl after 24 h 10nM E2 treatment (black bars) compared to control 
treatment (DMSO, white bars) in 4 hypothalamic cell lines, (L-R): 51 - mHypoA-51; 55 – 
mHypoA-55; 59 – mHypoA-59 and 63 – mHypoA-63. Missing bars indicate undetectable 






Fig. 5.2 Relative mRNA expression of target genes in cell lines mHypoA-55 & mHypoA-
63. A) Esr1, B) Esr2, C) Gper1, D) Nr4a1 after 24 h treatment with DMSO (white bars) 
or 10nM E2 (black bars) in 2 hypothalamic cell lines, (L-R): 55 – mHypoA-55; 63 – mHypoA-
63. Three independent experiments represented (mean +/- S.E.M.).  * represents a 
































































































































Code Gene Name 
Gene ID 
(NCBI) Assay ID 
Esr1 Estrogen receptor 1 13982 Mm00433149_m1 
Esr2 Estrogen receptor 2 13983 Mm00599821_m1 
Gper1 G-protein coupled estrogen receptor 76854 Mm02620446_s1 
Kiss1 Kisspeptin 280287 Mm03058560_m1 
Nr4a1 Nuclear receptor, subfamily 4, group A, 
member 1 
15370 Mm01300401_m1 
Gh Growth hormone 14599 Mm00433590_g1 









SUMMARY AND FUTURE CONSIDERATIONS 
 
General Summary 
The main goals of the experiments discussed in this dissertation were to answer the 
following questions: 
1) Do glyceollins (Glys) oppose the 17-β estradiol (E2) effects on gene expression in 
the whole brain, i.e., do Glys act anti-estrogenically in the female mouse brain? 
2) Are there any brain-region specific effects of Gly on gene expression, specifically 
in the hypothalamus, hippocampus and cortex? 
3) Are there any differences between acute vs. chronic Gly dosing on gene 
expression in the hypothalamus, hippocampus and cortex? 
4) Can we use immortalized neuronal cell lines derived from adult female mice to 
evaluate if Gly affects gene expression through direct action at the neuron?  
The experiments described in this dissertation are a first attempt at evaluating the 
effects of Gly in the female mouse brain. We focused our experiments on gene 
expression as a means of understanding Gly’s overall effects, if any, on brain-related 
pathways and processes. As initial research on Gly was focused on its anti-estrogenic 
effects, suppressing estrogen-responsive tumors both in vitro in cancer cell lines and in 





hypothesis was that Gly would oppose the E2 effect on gene expression in the brain. To 
test this hypothesis, we first performed a whole brain microarray analysis to determine 
the effects of E2 alone, Gly alone and in combination (E2+Gly) on gene expression in the 
female mouse brain (Chapter 2). The results from the microarray experiment provided 
some evidence for Gly opposition of the effects of E2 on expression of a few genes but 
interestingly also showed E2 opposition of Gly effects on gene expression, with Gly 
exhibiting a gene expression pattern distinct from both E2 groups (Bamji et al. 2015). 
Moreover, Gly by itself significantly upregulated the expression of genes involved in 
basic cell division, immune responses and neurogenesis while downregulating the 
expression of a gene that promotes neurodegeneration. Thus, this experiment provided 
the first indication of Gly’s potential neuroprotective effects in the female mouse brain.  
As estrogen receptors (ERs), growth hormone (Gh) and prolactin (Prl) have a 
moderate to low basal expression in the brain, our microarray experiment failed to detect 
differences between treatments on the expression of these genes of interest. Previous 
research showed that the strongest anti-estrogenic effect of Gly (which includes Gly 
isomers I, II and III), was exhibited by the Gly I isomer, through action at estrogen 
receptor (ER) alpha (ERα) (Zimmermann et al. 2010). We were interested in evaluating 
Gly’s effects on expression of Gh and Prl, as they are expressed throughout the brain, 
regulated by E2 and are often found to be co-expressed with ERα, especially in 
hypothalamic neurons (Addison and Rissman 2012; Brown et al. 2010; Donahue et al. 
2006; Furigo et al. 2014). Further, Gh and Prl regulate important physiological responses. 
Gh plays a role in food intake, memory formation, learning and mood (Abba et al. 2005; 





2015; Sun et al.) and Prl regulates neurogenesis, maternal behavior, food intake and 
stress (Marano and Ben-Jonathan 2014; Torner et al. 2004). Therefore, our next 
experiment, described in Chapter 3, was an RNA-sequencing (RNA-Seq) analysis which 
not only gave us a broader picture of Gly’s gene expression pattern in relation to E2, but 
also enabled the detection of differential expression of Gh and Prl. The RNA-Seq data 
confirmed some of the results of our microarray experiment, with Gly and E2 regulating 
similar genes/pathways in both experiments and no significant E2 or Gly effects on ER 
expression. As we examined a much larger set of transcripts in the RNA-Seq experiment, 
we also found evidence for Gly regulation of genes that was similar to E2 (for example, if 
E2 upregulated a gene, Gly also upregulated the gene, but the magnitude of the effect 
may differ), which we did not observe in the microarray experiment. Overall, the results 
from both Chapters 2 and 3 provided evidence that Gly may not act as a pure anti-
estrogen in the female mouse brain, but may act as a selective estrogen-receptor 
modulator (SERM) and ER-independent effects on gene expression, as well.   
Although the whole brain studies provided useful information, they did not take into 
account the heterogeneity of the brain. Distinct brain regions have highly specific 
functions and can differ greatly in terms of gene expression. Thus, in Chapter 4, using 
quantitative real-time polymerase chain reaction (qPCR), we evaluated brain region-
specific effects of Gly on expression of select gene targets (Esr1, Gper1 (hypothalamus 
only), Nr4a1, Gh and Prl) in three brain regions — the hypothalamus, hippocampus and 
cortex. In addition, as the whole brain experiments involved an 11-day chronic treatment 
with Gly, we tested the effects of acute (single dose of Glys followed by tissue harvest at 





exposure on gene expression. Our results showed that neither an acute nor a chronic dose 
of Gly had any effect on the expression of ERs or Nr4a1 in any of the brain regions 
tested. The lack of a Gly effect on ER expression was consistent in all experiments 
conducted in this dissertation. This is not totally surprising as ER expression varies 
between different brain regions, and within each brain region (Merchenthaler et al. 2004). 
Thus, our use of grossly dissected whole hypothalamic, hippocampal and cortical brain 
regions may be the reason for the lack of an observed Gly effect on ERs. Nr4a1, on the 
other hand was highly upregulated by Gly, but not E2, compared to control, whereas E2 
suppressed that Gly upregulation in the E2+Gly treatment in the microarray study. 
However, no Gly upregulation of Nr4a1 was observed in the RNA-Seq or in the qPCR 
experiments in Chapter 4. Moreover, we observed an effect of acute Gly dosing (2hr and 
24hr) on the expression of Gh in all three brain regions and Prl in the hypothalamus and 
cortex. Both Gly treatments (Gly and E2+Gly) upregulated the expression of Gh and Prl 
compared to non-Gly treatments (control and E2). Therefore, the results from Chapter 4 
indicate that a single, acute dose of Gly can potentially influence the regulation of 
feeding, neurogenesis, stress and cognition, through its action on Gh and Prl expression.   
Lastly, all the experiments conducted in Chapters 2-4 involved a peripheral 
administration of Gly, through intraperitoneal (i.p.) injections. We were interested in 
determining an in vitro neuronal system to test if the observed Gly effects on gene 
expression in our previous experiments were through direct action at the neuron or 
through some indirect peripheral mechanism of action. To examine this question, we 
tested five immortalized adult hypothalamic cell lines (mHypoA-50, -51, -55, -59 and -





evaluated their E2-responsiveness in order to select a line(s) that may be useful in 
studying the action of estrogens and SERMs like Gly in the female hypothalamus 
(Chapter 5). Based on relatively reliable expression of our genes of interest and E2-
responsivity, we were able to select two lines (mHypoA-55 and -63) which may be useful 
in future experiments to evaluate direct Gly effects at the neuron on gene expression. 
Biomedical significance  
 The brain-related health benefits of estrogens in women are well known, with 
decreasing levels of estrogen in postmenopausal women being associated with cognitive 
decline. Hormone replacement therapy (HRT, estrogen + progesterone) and estrogen 
replacement therapy (ERT), prior to the release of the WHI report in 2003 (Chlebowski et 
al. 2003), were increasingly popular means to alleviate cognitive decline and were shown 
to improve working memory (Duff and Hampson 2000) and alleviate symptoms of 
depression (Whooley et al. 2000) in postmenopausal women. However, HRT also 
increased the risk of estrogen-responsive breast, ovarian and uterine tumors, leading to an 
interest in soy plant products genistein and daidzein, estrogenic compounds potentially 
possessing the neuroprotective effects of estrogens while reducing the risk for estrogen-
responsive tumors. Indeed, both genistein and daidzein exhibit several neuroprotective 
effects (Liu et al. 2008; Malinowska et al. 2010; Pan et al. 2012; Wang et al. 2014), but  
also induce neurotoxicity in primary neuronal cultures at high concentrations (Jin et al. 
2007). Additionally, genistein and daidzein were found to possess some anti-tumor 
effects (Barnes 1995; Zhang et al. 2016), but  also acted estrogenically in the periphery 
on reproductive tissues, e.g., the uterus and mammary gland (Gaete et al. 2012; Santell et 





limiting their use as ERT alternatives. Thus, gaining knowledge of the effects of these 
compounds in the brain, if any, is vital to fully understand the health benefits of these soy 
compounds. Gly possesses multiple anti-tumor, anti-microbial, and antioxidant properties 
in addition to its ability to regulate glucose and lipid metabolism (Chapter 1). Research 
on Gly gained momentum due to the fact that, in addition to all the health-promoting 
benefits of soy, unlike genistein and daidzein, Gly acted as an anti-estrogen in the 
periphery (Salvo et al. 2006). To determine Gly’s potential as not only an anticancer 
therapeutic but as a HRT dietary supplement, it is important to evaluate its effects in the 
brain. The experiments conducted in this dissertation are the first of their kind to 
determine Gly’s actions in the female mouse brain, with hypothesis-generating 
microarray and RNA-Seq analyses that can serve as a foundation for future studies. 
Future Considerations for Gly effects in the mouse brain    
 Our data indicate that Gly may act through both ER-mediated and potentially non 
ER-mediated mechanisms; but this finding needs to be empirically tested. Initial studies 
testing the effects of soy isoflavone supplements (containing genistein and daidzein) 
reported that the soy supplement acted anti-estrogenically by affecting both ERα and ERβ 
in the rat hypothalamus. The soy supplement suppressed the ERα-mediated, E2-
dependent upregulation of oxytocin receptor expression in the ventromedial nucleus of 
the hypothalamus (Patisaul et al. 2001) and increased ERβ mRNA expression in the 
paraventricular hypothalamic nucleus, unlike E2 which decreased ERβ expression 
(Patisaul et al. 2001). However, in a subsequent study, the same group found that 
genistein alone had no effect on ERα- mediated oxytocin receptor expression, but unlike 





(Patisaul et al. 2002). The results from these two studies highlight the need for evaluating 
the effects of individual components in soy isoflavonoid supplements. Given the known 
functions mediated by ERs in the brain, it is necessary to understand if Gly affects gene 
expression through ERs, if so, which ERs may be involved and if it translates to effects 
on cognitive and reproductive behaviors. Hence, future research on Gly should focus on 
using selective ER knockout models to determine whether the effects of Glys on gene 
expression are ER-mediated and if so, which ERs are involved in Gly’s mechanism of 
action. Also, as mentioned in Chapter 1, most studies used a mixture of Gly isomers (Gly 
I, II and III) and different Gly isomers can have estrogenic or SERM-like effects at 
different ERs (van de Schans et al. 2016). Thus research focused on the independent 
effects of individual Gly isomers on gene expression in the brain, instead of using a Gly 
mixture, may be useful in the development of disease-specific therapeutic interventions. 
Two immortalized adult hypothalamic cell lines selected in Chapter 5 (mHypoA-55 and 
mHypoA-63) can be used to evaluate the direct vs. indirect effects of Gly on gene 
expression in the brain. Other neuronal cell lines including immortalized adult 
hippocampal cell lines have also recently become commercially available and can be 
used for similar studies. Importantly, as mentioned earlier, compounds like genistein and 
daidzein eventually become neurotoxic at higher concentrations, so evaluating a dose-
response curve for Gly on neuronal action would be useful in determining an appropriate 
dose of Gly in food supplements. Lastly, when we initially started working with Gly, we 
noticed that animals that were injected with Gly for just a few days were difficult to 
handle, jumpy and seemingly anxious. Our open-field anxiety trials (not included in this 





indication of possible defensive aggression towards the mouse handler. In order to 
develop Gly as a nutritional supplement, it will be key to evaluate its effects on various 
reproductive, cognitive as well as mood-related behaviors such as anxiety and aggression. 
Researchers must test various Gly doses on gene expression and behavior in animals, 
determine the underlying molecular mechanisms of Gly action through in vivo and in 
vitro studies, and perform appropriate studies in other animal models and ultimately in 
human subjects to realize the potential of Gly as a therapeutic agent for metabolic and 
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